



US 20250257340A1

(19) **United States**

(12) **Patent Application Publication**
CRADICK et al.

(10) **Pub. No.: US 2025/0257340 A1**
(43) **Pub. Date:** **Aug. 14, 2025**

(54) **GUIDE NUCLEIC ACID IDENTIFICATION
AND METHODS OF USE**

filed on Feb. 23, 2022, provisional application No. 63/313,037, filed on Feb. 23, 2022.

(71) Applicant: **Excision BioTherapeutics Inc**, San Francisco, CA (US)

Publication Classification

(51) **Int. Cl.**

CI2N 9/22 (2006.01)

CI2N 15/11 (2006.01)

(52) **U.S. Cl.**

CPC *CI2N 9/22* (2013.01); *CI2N 15/11* (2013.01); *CI2N 2310/20* (2017.05); *CI2N 2800/80* (2013.01)

(72) Inventors: **Thomas James CRADICK**, Belmont, MA (US); **Ethan Yixun XU**, Winchester, MA (US); **Xinting YAO**, Revere, MA (US)

(21) Appl. No.: **18/172,946**

(57)

ABSTRACT


(22) Filed: **Feb. 22, 2023**

Related U.S. Application Data

(60) Provisional application No. 63/313,033, filed on Feb. 23, 2022, provisional application No. 63/313,059,

Provided herein are gene editing compositions, systems, vectors, and methods that effectively modulate and/or edit a Hepatitis B virus genome.

Specification includes a Sequence Listing.






FIG. 1




FIG. 2

GUIDE NUCLEIC ACID IDENTIFICATION AND METHODS OF USE

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63/313,033, filed Feb. 23, 2022; U.S. Provisional Application No. 63/313,059, filed Feb. 23, 2022; and U.S. Provisional Application No. 63/313,037, filed Feb. 23, 2022, which applications are incorporated herein by reference.

SEQUENCE LISTING

[0002] The instant application contains a sequence listing which has been submitted electronically in xml format and is hereby incorporated by reference in its entirety. The xml copy, created on Feb. 20, 2022, is named 56852785201_SL.xml and is 501,136 bytes in size.

BACKGROUND

[0003] Hepatitis B virus (HBV) is a cause of liver diseases and disorders including acute hepatitis that can lead to fulminate hepatic failure as well as chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). There are several challenges associated with hepatitis B virus (HBV) therapy, including: Viral persistence (HBV can persist in the liver and continue to cause damage even after antiviral therapy), drug resistance (some patients may develop resistance to antiviral drugs, which can limit the effectiveness of treatment), and overall limited treatment. Accordingly, HBV can infection millions of people worldwide. Improved therapies are needed for targeting HBV.

SUMMARY

[0004] Described herein, in certain embodiments, are compositions comprising: (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272 or a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof. In some embodiments, a gRNA comprises a region that hybridizes to a target nucleic acid sequence within a HBV genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof. In some embodiments, the target nucleic acid sequence is located within a C, X, P, or S region. In some embodiments, the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, the HBV is HBV-C genotype.

lease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, the HBV is HBV-C genotype. In some embodiments, the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype. In some embodiments, the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype. In some embodiments, the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype. In some embodiments, the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype. In some embodiments, the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype. In some embodiments, the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.

[0005] Described herein, in certain embodiments, are CRISPR-Cas systems comprising: (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.

[0006] Described herein, in certain embodiments, are nucleic acids encoding the CRISPR-Cas systems described herein.

[0007] Described herein, in certain embodiments, are vectors comprising a nucleic acid encoding: (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272 or a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof. In some embodiments, a gRNA comprises a region that hybridizes to a target nucleic acid sequence within a HBV genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof. In some embodiments, the target nucleic acid sequence is located within a C, X, P, or S region. In some embodiments, the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, the HBV is HBV-C genotype.

some embodiments, the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype. In some embodiments, the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype. In some embodiments, the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype. In some embodiments, the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype. In some embodiments, the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype. In some embodiments, the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype. In some embodiments, the nucleic acid further comprises a promoter. In some embodiments, the promoter is a ubiquitous promoter. In some embodiments, the promoter is a tissue-specific promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a human cytomegalovirus promoter. In some embodiments, the nucleic acid further comprises an enhancer element. In some embodiments, the enhancer element is a human cytomegalovirus enhancer element. In some embodiments, the nucleic acid further comprises a 5' ITR element and 3' ITR element. In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the adeno-associated virus (AAV) vector is AAV2, AAV5, AAV6, AAV7, AAV8, or AAV9. In some embodiments, the vector is an AAV6 vector or an AAV9 vector.

[0008] Described herein, in certain embodiments, are methods of excising part or all of a Hepatitis B Virus (HBV) sequence from a cell, the method comprising providing to the cell the compositions described herein, the CRISPR-Cas systems described herein, or the vector described herein. Described herein, in certain embodiments, are methods of inhibiting or reducing Hepatitis B Virus (HBV) replication in a cell, the method comprising providing to the cell the compositions described herein, the CRISPR-Cas systems described herein, or the vectors described herein. In some embodiments, the cell is in a subject. In some embodiments, the subject is a human.

INCORPORATION BY REFERENCE

[0009] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0011] FIG. 1 shows an exemplary flowchart of a method for selecting a guide RNA.

[0012] FIG. 2 schematically illustrates a computer system that is programmed or otherwise configured to implement methods provided herein.

DETAILED DESCRIPTION

[0013] Provided herein are gene editing systems (e.g. CRISPR-Cas9, CRISPR-CasX) useful for inhibiting, reducing, or ameliorating Hepatitis B virus (HBV) infection. For instance, provided herein are methods of for inhibiting, reducing, or ameliorating HBV infection by the gene editing systems that effectively edit the HBV genome. Provided herein are programmable nucleases that target the HBV viral genomic DNA that is either integrated into a host cell's genome or maintained extrachromosomally (e.g. not integrated into the genome of a host cell). For example, in some instances, targeting specific genes or elements of the HBV genome leads to the depletion of infectious viral genomes and/or excision of regions within the viral genome at coding sequences or regulatory regions to inactivate viral replication. Provided herein, in certain embodiments, are compositions and methods that result in producing fewer off-target effects by targeting sequences in the HBV genome but not in the host genome.

[0014] Programmable nucleases enable precise genome editing by, in some instances, introducing DNA double-strand breaks (DSBs) at specific genomic loci, thereby initiating gene editing. Generally, as embodied herein, a variety of gene editing systems can be employed to target the HBV genes, elements, or regions described herein. In some embodiments, the gene editing system comprises a CRISPR-Cas system. In some embodiments, the gene editing system comprises meganucleases. In some embodiments, the gene editing system comprises zinc finger nucleases (ZFNs). In some embodiments, the gene editing system comprises transcription activator-like effector nucleases (TALENs). These gene editing systems can be broadly classified into two categories based on their mode of DNA recognition: ZFNs, TALENs and meganucleases achieve specific DNA binding via protein-DNA interactions, whereas CRISPR-Cas systems are targeted to specific DNA sequences by a short RNA guide molecule that base-pairs directly with the target DNA and by protein-DNA interactions. Accordingly, protein targeting or nucleic acid targeting can be employed to target the HBV DNA loci described herein.

[0015] For example, described and provided herein are CRISPR-Cas compositions and methods useful for reducing or inhibiting HBV replication within a cell. By way of further example, the described and provided CRISPR-Cas compositions are useful for modulating (e.g. altering, removing, etc.) and/or editing (e.g. excising) genomic HBV DNA in a cell, thereby inhibiting HBV replication. Inhibiting HBV by modulating and/or editing HBV DNA in a cell yields an incompetent and/or deficient HBV genome structure that does not allow for replication of the HBV virus. As such, the CRISPR-Cas compositions and methods described herein can be used to effectively modulate and/or edit a HBV genome in a cell. In some embodiments, the cells already comprise a HBV infection. In some embodiments, the CRISPR systems provided herein eliminate or reduce a latently infected cell. In some embodiments, the CRISPR systems provided herein modulate and/or edit HBV DNA in a latently infected cell. In some embodiments, the CRISPR systems provided herein prevent HBV infection.

[0016] Provided and described herein are systems (e.g., computer-implemented systems) for selecting, evaluating, or prioritizing a guide RNA candidate comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: (a) a data storage system

comprising a target sequence (e.g., consensus sequence); and (b) one or more modules communicatively coupled to the data storage system, wherein the one or more modules are configured to: (i) identify one or more targeting sites in the target sequence; (ii) identify one or more guide target sequences in proximity to the one or more targeting sites; and (iii) calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences, wherein the guide RNA candidate is selected based on the one or more criteria of step (b) (iii). In some embodiments, the one or more targeting sites are adjacent or proximal to (e.g., within 10 bp) protospacer adjacent motifs (PAMs).

[0017] Provided and described herein are systems (e.g., computer-implemented systems) for selecting, evaluating, or prioritizing a guide RNA candidate comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: (a) a data storage system comprising a target sequence (e.g., consensus sequence); and (b) one or more modules communicatively coupled to the data storage system, wherein the one or more modules are configured to: (i) identify one or more protospacer adjacent motifs (PAMs) in the target sequence; (ii) identify one or more guide target sequences in proximity to the one or more PAMs; and (iii) calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences, wherein the guide RNA candidate is selected based on the one or more criteria of step (b) (iii).

[0018] Also provided and described herein are systems for selecting, evaluating, or prioritizing a guide RNA candidate comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: (a) a data storage system comprising a target sequence (e.g., consensus sequence); (b) a targeting site identifier configured to identify one or more targeting sites in the target sequence; (c) a proximity identifier configured to identify one or more guide target sequences in proximity to the one or more targeting sites; and (d) a criteria analysis module configured to calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences, wherein the guide RNA candidate is selected based on the one or more criteria of step (d). In some embodiments, the one or more targeting sites are adjacent or proximal to (e.g., within 10 bp) protospacer adjacent motifs (PAMs).

[0019] Also provided and described herein are systems for selecting, evaluating, or prioritizing a guide RNA candidate comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: (a) a data storage system comprising a target sequence (e.g., consensus sequence); (b) a protospacer adjacent motif (PAM) identifier configured to identify one or more PAMs in the target sequence; (c) a proximity identifier configured to identify one or more guide target sequences in proximity to the one or more PAMs; and (d) a criteria analysis module configured to calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences, wherein the guide RNA candidate is selected based on the one or more criteria of step (d).

[0020] Further provided herein are methods for selecting, evaluating, or prioritizing a guide RNA candidate, comprising: (a) providing a target sequence (e.g., consensus

sequence); (b) identifying one or more targeting sites in the target sequence; (c) identifying one or more guide target sequences in proximity to the one or more targeting sites; (d) calculating one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences; and (e) selecting the guide RNA candidate based on the one or more criteria of step (d). In some embodiments, the one or more targeting sites are adjacent or proximal to (e.g., within 10 bp) protospacer adjacent motifs (PAMs).

[0021] Further provided herein are methods for selecting, evaluating, or prioritizing a guide RNA candidate, comprising: (a) providing a target sequence (e.g., consensus sequence); (b) identifying one or more PAMs in the target sequence; (c) identifying one or more guide target sequences in proximity to the one or more PAMs; (d) calculating one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences; and (e) selecting the guide RNA candidate based on the one or more criteria of step (d).

[0022] Further provided herein are computer-implemented systems to select, evaluate, or prioritize a targeting site, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: a) a data storage system comprising a target sequence (e.g., consensus sequence) comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5; b) a criteria analysis module configured to calculate one or more criteria of the targeting site; and c) a target identifier for selecting the target site based on the one or more criteria of step (b). In some embodiments, the one or more criteria is based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a targeting site (e.g., a PAM site), or combinations thereof. Provided herein are computer-implemented systems to select, evaluate, or prioritize a targeting site, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising: a) a data storage system comprising a target sequence (e.g., consensus sequence); and b) a criteria analysis module configured to calculate one or more criteria of the targeting site, wherein the one or more criteria is based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a targeting site (e.g., a PAM site), or combinations thereof; and c) a target identifier for selecting the target site based on the one or more criteria of step (b). In some embodiments, the targeting site is recognized by a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a CRISPR-associated protein (e.g., Cas).

Cas Nucleases

[0023] Engineered CRISPR systems generally contain two components: a guide RNA (gRNA or sgRNA) and a CRISPR-associated endonuclease (Cas protein). In nature, CRISPR/CRISPR-associated (Cas) systems provide bacteria and archaea with adaptive immunity against viruses and plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. The CRISPR-Cas is a RNA-mediated adaptive defense system that relies on small

RNA molecules for sequence-specific detection and silencing of foreign nucleic acids. CRISPR/Cas systems are composed of cas genes organized in operon(s) and CRISPR array(s) consisting of genome-targeting sequences (called spacers). Provided herein are engineered CRISPR systems that detect and silence HBV DNA in a cell.

[0024] As described herein, CRISPR-Cas systems generally refer to an enzyme system that includes a guide RNA sequence that contains a nucleotide sequence complementary or substantially complementary to a region of a target polynucleotide (e.g. HBV genomic DNA), and a protein with nuclease activity. CRISPR-Cas systems include Type I CRISPR-Cas system, Type II CRISPR-Cas system, Type III CRISPR-Cas system, and derivatives thereof. CRISPR-Cas systems include engineered and/or programmed nuclease systems derived from naturally accruing CRISPR-Cas systems. In certain embodiments, CRISPR-Cas systems contain engineered and/or mutated Cas proteins. In some embodiments, nucleases generally refer to enzymes capable of cleaving the phosphodiester bonds between the nucleotide subunits of nucleic acids. In some embodiments, endonucleases are generally capable of cleaving the phosphodiester bond within a polynucleotide chain. Nickases refer to endonucleases that cleave only a single strand of a DNA duplex.

[0025] In some embodiments, CRISPR-Cas systems further comprise transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. In certain embodiments, a target sequence comprises any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell.

[0026] In some embodiments, the CRISPR/Cas system used herein can be a type I, a type II, or a type III system. Non-limiting examples of suitable CRISPR/Cas proteins include Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, CasX, CasΦ, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966. By way of further example, in some embodiments, the CRISPR-Cas protein is a Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, CasH, Cas7, Cas8, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966.

By way of further example, in some embodiments, the CRISPR-Cas protein is a Cas12 (e.g., Cas12a, Cas12b, Cas12c, Cas12d, Cas12k, Cas12j/CasΦ, Cas12L etc.), Cas13 (e.g., Cas13a, Cas13b (such as Cas13b-t1, Cas13b-t2, Cas13b-t3), Cas13c, Cas13d, etc.), Cas14, CasX, CasY, or an engineered form of the Cas protein. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas9. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas12. In certain embodiments, the Cas12 polypeptide is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas12L or Cas12J. In some embodiments, the CRISPR/Cas protein or endonuclease is CasX. In some embodiments, the CRISPR/Cas protein or endonuclease is CasY. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas.

[0027] In some embodiments, the Cas9 protein can be from or derived from: *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus* sp., *Nocardiopsis dasonvilliei*, *Streptomyces pristinaespiralis*, *Streptomyces viridochromogenes*, *Streptomyces viridochromogenes*, *Streptosporangium roseum*, *Alicyclobacillus acidocaldarius*, *Bacillus pseudomycoides*, *Bacillus selenitireducens*, *Exiguobacterium sibiricum*, *Lactobacillus delbrueckii*, *Lactobacillus salivarius*, *Microscilla marina*, *Burkholderiales bacterium*, *Polaromonas naphthalenivorans*, *Polaromonas* sp., *Crocospaera watsonii*, *Cyanothecace* sp., *Microcystis aeruginosa*, *Synechococcus* sp., *Acetohalobium arabaticum*, *Ammonifex degensii*, *Caldicelulosiruptor beccsii*, *Candidatus Desulfurales*, *Clostridium botulinum*, *Clostridium difficile*, *Fine goldia magna*, *Natranaerobius thermophilus*, *Pelotomaculum thermopropionicum*, *Acidithiobacillus caldus*, *Acidithiobacillus ferrooxidans*, *Allochromatium vinosum*, *Marinobacter* sp., *Nitrosococcus halophilus*, *Nitrosococcus watsoni*, *Pseudoalteromonas haloplanktis*, *Ktedonobacter racemifer*, *Methanohalobium evestigatum*, *Anabaena variabilis*, *Nodularia spumigena*, *Nostoc* sp., *Arthrobacteria maxima*, *Arthrobacteria platensis*, *Arthrobacteria* sp., *Lyngbya* sp., *Microcoleus chthonoplastes*, *Oscillatoria* sp., *Petrotoga mobilis*, *Thermosiphon africanus*, or *Acaryochloris marina*.

[0028] In some embodiments, the composition comprises a CRISPR-associated (Cas) protein, or functional fragment or derivative thereof. In some embodiments, the Cas protein is an endonuclease, including but not limited to the CasX endonuclease. In some embodiments, the CasX protein comprises an amino acid sequence identical to the wild delta-proteobacteria or planctomycetes CasX amino acid sequence. In some embodiments, the Cas protein comprises the amino acid sequence of delta-proteobacteria CasX amino acid sequence. In some embodiments, the Cas protein comprises the amino acid sequence of planctomycetes CasX amino acid sequence.

[0029] In some embodiments, the composition comprises a CRISPR-associated (Cas) protein, or functional fragment or derivative thereof. In some embodiments, the Cas protein is an endonuclease, including but not limited to the Cas9 endonuclease. In some embodiments, the Cas9 protein comprises an amino acid sequence identical to the wild type *Streptococcus pyogenes* or *Staphylococcus aureus* Cas9 amino acid sequence. In some embodiments, the Cas protein comprises the amino acid sequence of a Cas protein from other species, for example other *Streptococcus* species, such as *thermophilus*; *Pseudomonas aeruginosa*, *Escherichia coli*, or other sequenced bacteria genomes and archaea, or other prokaryotic microorganisms. Other Cas proteins, use-

ful for the present disclosure, known or can be identified, using methods known in the art (see e.g., Esvelt et al., 2013, *Nature Methods*, 10:1116-1121). In some embodiments, the Cas protein comprises a modified amino acid sequence, as compared to its natural source.

[0030] CRISPR/Cas proteins comprise at least one RNA recognition and/or RNA binding domain. RNA recognition and/or RNA binding domains interact with guide RNAs (gRNAs). CRISPR/Cas proteins can also comprise nuclease domains (i.e., DNase or RNase domains), DNA binding domains, helicase domains, RNase domains, protein-protein interaction domains, dimerization domains, as well as other domains.

[0031] The CRISPR/Cas-like protein can be a wild type CRISPR/Cas protein, a modified CRISPR/Cas protein, or a fragment of a wild type or modified CRISPR/Cas protein. The CRISPR/Cas-like protein can be modified to increase nucleic acid binding affinity and/or specificity, alter an enzymatic activity, and/or change another property of the protein. For example, nuclease (i.e., DNase, RNase) domains of the CRISPR/Cas-like protein can be modified, deleted, or inactivated. Alternatively, the CRISPR/Cas-like protein can be truncated to remove domains that are not essential for the function of the Cas protein. The CRISPR/Cas-like protein can also be truncated or modified to optimize the activity of the effector domain of the Cas protein.

[0032] In some embodiments, the CRISPR/Cas-like protein can be derived from a wild type Cas protein or fragment thereof. In some embodiments, the CRISPR/Cas-like protein is a modified Cas9 protein. For example, the amino acid sequence of the Cas9 protein can be modified to alter one or more properties (e.g., nuclease activity, affinity, stability, etc.) of the protein relative to wild-type or another Cas protein. Alternatively, domains of the Cas9 protein not involved in RNA-guided cleavage can be eliminated from the protein such that the modified Cas9 protein is smaller than the wild-type Cas9 protein.

[0033] The disclosed CRISPR-Cas compositions should also be construed to include any form of a protein having substantial homology to a Cas protein (e.g., Cas9, saCas9, Cas9 protein) disclosed herein. In some embodiments, a protein which is “substantially homologous” is about 50% homologous, about 70% homologous, about 80% homologous, about 90% homologous, about 95% homologous, or about 99% homologous to amino acid sequence of a Cas protein disclosed herein.

[0034] In some embodiments, the CRISPR/Cas-like protein can be derived from a wild type Cas protein or fragment thereof. In some embodiments, the CRISPR/Cas-like protein is a modified CasX protein. For example, the amino acid sequence of the CasX protein can be modified to alter one or more properties (e.g., nuclease activity, affinity, stability, etc.) of the protein relative to wild-type or another Cas protein. Alternatively, domains of the CasX protein not involved in RNA-guided cleavage can be eliminated from the protein such that the modified CasX protein is smaller than the wild-type CasX protein.

[0035] The disclosed CRISPR-Cas compositions should also be construed to include any form of a protein having substantial homology to a Cas protein (e.g., CasX, saCasX, CasX protein) disclosed herein. In some embodiments, a protein which is “substantially homologous” is about 50% homologous, about 70% homologous, about 80% homolo-

gous, about 90% homologous, about 95% homologous, or about 99% homologous to amino acid sequence of a Cas protein disclosed herein.

HBV Targeting

[0036] The CRISPR-Cas systems described herein achieve, in some embodiments, the effective modulation and/or editing of a HBV genome through use of gRNA targets. CRISPR-Cas systems, in some embodiments, are designed to target a nucleic acid sequence in a HBV genome.

[0037] In some embodiments, the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof. In some embodiments, the target nucleic acid sequence is located within a C, X, P, or S region.

[0038] In some embodiments, the target nucleic acid sequence is a naturally occurring sequence. In other embodiments, the target nucleic acid sequence is a non-naturally occurring sequence.

[0039] In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, HBV-C genotype. In some embodiments, the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype. In some embodiments, the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype. In some embodiments, the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype. In some embodiments, the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype. In some embodiments, the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype. In some embodiments, the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.

[0040] Described herein, in some embodiments, are compositions comprising (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises at least about 70%, 75%, 80%, 85%, 90%, or 95% identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprising at least about 80%, 85%, 90%, 91%, 92%, 93%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5.

[0041] SEQ ID NOs: 2-5 are non-naturally occurring consensus sequences generated by aligning different HBV strains, e.g., strains within the same HBV genotype or strains from different HBV genotypes. For example, SEQ ID NO: 2 is a consensus sequence of Clustal-Omega HBV Genotype A strains; SEQ ID NO: 3 is a consensus sequence of Clustal-Omega HBV Genotype B strains; SEQ ID NO: 4 is a consensus sequence of Clustal-Omega HBV Genotype C strains; and SEQ ID NO: 5 is a consensus sequence of Clustal-Omega HBV Genotypes B and C strains.

TABLE 1

Sequences

SEQ ID NO.	Sequence
1	ATTCCACAACTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCGTGATTTCCCTGGT GGTGGCTCCAGTCAGGAACAGTAAACCCCTGTCAGACTACTGCCTCTCCCTATCGTAATC TTCTCGAGGATTGGGGACCCCTGCGCTGAACATGGAGAACATCACATCAGGATTCCTAGGACC CTTCTCGTGTTCAGGGGGGTTTTCTTGTGACAAGAAATCCTCACAAATACCGCAGAGTCTA GACTCGTGGTGGACTCTCTCAATTTCAGGGGAACTACCGTGTGCTTGCCAAAATTG CAGTCCCCAACCTCCAACTCACTCACCAACCTCTGTCCTCCAACTTGTCTGGTTATCGTGG ATGTGTCTGCGCGTTTATCATCTCCCTTCATCCTGCTGCTATGCCCTATCTCTGGT GTCTCTGGATAACAGGTGTTGCCCCGTTTGTCTTAATTCCAGGATCCCTCAACAACC AGCACGGGACCATGCCGGACCTGCGATGACTACTGCTCAAGGAACCTATGTATCCCTCTGT TCTGTGACCCAACCTGGACGGAAATTGACCTGTTATTCCCATCCATCATCTGGGCTTC GGAAAATTCTATGGGAGTGGGCTCAGGCCGTTCTCTGGCTCAGTTACTAGTGCAATT GTCAGTGGGCTGAGGGCTTCCCCACTGTTGGCTTCAAGTTATGATGATGTTGTT TGGGGGCAAGTCTGAGCATCTTGAGTCCCTTTTACCGCTGTTACCAATTTCCTTGT CTTGGGTATACTTAAACCTTAACAAAACAAAGAGATGGGTTACTCTTAATTTTATGG GTTATGTCATTGGATGTTATGGGCTCTGGCCAAGAACATCATACAAAAAATCAAAGAAT GTTTAGAAAACCTCTTAAACAGGCCATTGATGGAAAGTATGTCACGAATTGTTGGGTC TTTGGGATGTCATTGGGCTTACAGGAACTCTGGCTGTTGCTGCTGTTGCTGACGCAA TTATGGGACTGATAACTCTGTCCTATCCCAAATATACATGTTTCCATGGCTGCTAG GCTGTGTCGCAACTGGATCTGGGGGGACGCTCTTGTTCAGTCCCGTGGCGCTGAATC CTCGGGACGACCTTCTGGGGTCGTTGGGACTCTCTCGTCCCTCTCGTCTGCGCTTC GACCGGACACGGGGCAGCCTCTGGGGACTCTGGGACTCCGGCTGTGCTTCTCATCTGG ACCGTGTGCACTCGCTCACCTGCACTGCGCATGGAGACCAACCGTGAACGCCAACAA ATTGCCAAGGCTTACATAAGAGGACTCTGGACTCTCACGAATGTCACGACGCCATTGA GGCATACTTCAAAGACTGTTTAAAGACTGGGAGGAGTGGGGAGGAGATTAGGTTAA GTCCTTGTGACTAGGACTGAGCTAGGCATAATGTTGCTGGGACCCAGCACCTGCAACTTTT CACCTCTGCCATACTCATCTTGTCTGTCATGTTACTGTTCAAGCCTCAAGCTGTGCGCTTGG TGGCTTGGGACATGGACATGCCACCTTAAAGAATTGGAGCTACTGTTGAGTTACTCTG TTTGCGCTTCTGACTCTTCTCTGACTAGAGATCTTAGATAACCGCCTCAGCTCTGAT CGGAGCCATTAGGCTCTGAGCATCTGACCTCACCATACTGCACTCAGGCAAGCAATT CTTGTGCTGGGGGAACTAATGACTCTAGGACTCTGGGTTGGGTTAATTGGAGATCCAGCG CTAGAGACCTAGTGTGAGCTACACTAATGGGCTAAAGTTGAGGACTCTTGG TGGGTCACATTCTGTCCTACTTGGAGAGAACAGTTAGAGTATTGGTGTCTTC GGAGTGGGATGCGACTCCCTCAGGTTAGGACCCAAATGCCCTATCCCTATCAACACTT CCGGAGACACTCTGGTGTGAGGAGCTCCCTAGAGGAACTCCCTGCCCTCC AGACGAGGCTCAATGCCCGTCCAGAGAATCTCAATCTGGGAATCTCAATGTTAGTAT TCCTGGACTCATAGGTTGAGGAAACTTACTGGGTTATTCTTACTGTACCTGTTTAA TCCTCTGGGAAACACCATTTCTCTAAATACATTACCCAAAGACATTATCAAATGG TGAACAGTTGAGGCCACTCAGGTTAGAGAAAAGAATGCAATTGATTGATTGCTG CAGGTTTATCAAAGGTTACAAAATTACCATGGATAAGGGTATTAACCTTATTATCC AGAACATCTAGTTAATCATTACTTCAAATAGACACTATTACACACTCTATGGAGGCC TATATTATATAAGAGGAAACACACATAGGCCCTCATTTGGGGTCACCATATTCTGGG ACAAGATCTACAGCATGGGGCAATTTCCACAGCACTCTGGGATTCTTCCCGACC ACCAAGTGGGATCAGGCCACTCAGGAAACACGGCAATCTCAGGATGGGACTTCAATCCAAACA AGGACACCTGGGAGCAGCCAAAGGTAGGGCTGGAGCATCGGGCTGGGTTACCC CCACGGAGGCCCTGGGGTGGAGGCCCTAGGGCTCAGGGCATACTACAAACTTGGCAGCAA ATCCGCTCTGCCCTCCACCATGCCAGCAGGAGCTGGAGCATGGCCCTACCCGCTGCTCCACCT TGAGAAACTCATCTCCAGGCGATGAGTGG 2 TTCCACTGCCTTACCAAGCTCTGCAAGGATCCCAGAGTCAGGGCTGTATTTCTGCTGG TGGCTCAGTCAGGAACAGTAAACCTGCTCCGAAATATTGCTCTCACATCTGCTCAATCTC CGCGAGGACTGGGACCTGTCAGCACACATGGAGAACATCACATCAGGATTCAGGACCCCT GCTCGTGTACAGGGGGTTTTCTTGTGACAAGAACCTCCTCACAAATACCGCAGAGTCTAGA CTCGTGGGACTCTCTCAATTCTCTAGGGGATCACCCCTGTTGCTTGGCCTAAATTGCA GTCCCCAACCTCCAACTACTCACCAACCTCTGCTCCAAATTGCTCTGGTTATCGCTGGAT GTGCTGCGGGCTTATCATATTCTCTCATCTG CTGCTATGCCCTATCTTATGGTCTTCTGGATTATCAAGGTATGTTGCCGTTGCT CTAATTCCAGGATCAACAACACAGTACGGGACCATGCAAACACCTGCACGACTCTGCTCAA GGCAACTCTATGTTCTCTCATGTTGCTGTCAGGAAACCTACGGATGGAAATTGACCTGTATT CCCCATCCCATCTGCTGGCTTTCGCAAACCTACCTATGGAGTGGGCTCAGTCGTTCT TGGCTCAGTTACTAGTGTGCAATTGTTGCTAGTGGCTGTTGCTAGGGCTTCCCCACTTGGCT TCAGCTATGGATGATGTTGAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CCGCTGTTACCAATTCTTCTTGTCTCTGGGATACATTAAACCTTAACAAAACAAAAAGAT GGGGTTATTCTCAAACCTACGGGTTACATAATTGGAGTGGGGAAATTGCCACAGGATC ATATTGTCACAAAGACACTGTTAGAGAAAACCTCTGTTACAGGCTTACAGGCTTACG AGTATGTCACAAAGAATTGTTGAGTGGGCTTGGGCTTGTGCTCCTACACAAATGTTG CTGCCCTAATGCTTGTATGCTGTCATGAACTAACAGCTAAACAGGCTTCACTTCTGCCAACTT ACAAGGCCCTTCTAAGTAAACAGTACATGAACTTACCCGCTGGCTCGGCAACGCCGGTC TGTGCCAAGTGGTGGCTGACGCCACCCCCACTGGCTGGGGTGGGCTAGGCCATAGGCCATCAGCGCA

TABLE 1-continued

		Sequences
SEQ ID NO.	Sequence	
	TGCCTGGAACCTTGTGGCTCTCGCATCTGGAACTCCTAGCCGTTTTG CTCGCAGCGGTCTGGAGCAAGCTATCGAACTGACAATTCTGTCGCTCTCGCGAAAT ATACATCGTTCCATGGCTAGGCTACTGCCAAGTGATCCTCGCGGGACGTCCTTG TTACGTCCTCGGGCTGAATCCGGGAGACCCCCTCGGGGCGCTGGGACTCTC GTCCCCCTCTCGCTCGGCTTCAGCGAACACGGGCGCACCTCTTAACGGGTCTCC CGCTGTGCTCTCATCTGGGTCTGCACTCGCTCACCTCTGACCGTTGATGGA GACCACCGTGAACG----- CCCATCAGATCTGGCCAAGGCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTAACGA CCGACCTTGAGGCTACTAAAGACTGTGTTAAAGACTGGGAGCTGGGAGGAGCTGGGGAGGAGA TTAGGTTAAAGGCTTTGT----- ATTAGGAGGCTTAGGCATAAATTGGTCTGCCACCAGCACCATGCAACTTTCACCTCTGC CTAATCATCTGTACATGCCACTGTTCAAGCCTCAAGCTGCTGCCCTGGGCTTTGG GCATGGACATTGACCCCTATAAAGAATTGGAGCTACTGTTGAGTTACTCTCGCTTTGCT TCTGACTCTCTCGTCAAGAGATCTCTAGAACCGCCTGACTCTGATCGGGAAAGCC TTAGAGTCTCTGAGCATGCTCACCTCACCATACTGCACTCAGGCAAGCATTCTGCTGG GGGAAGATGAGACTCTAGGCTACCTGGGTAAATAATTGGAAGATCCAGCATCCAGGGAT CTAGTAGTCATATGTTAAAGATCAGGCAACTATTGTTGTTTCA ATATCTGCCCTACTTTGGAAAGAGAGACTGACTTGAATATTGCTCTTGGAGTGTGG ATTGCACTCTCAGCCTATAGACCACCAATGCCCTATCTTATCAACACTCCGGAAACT ACTGTTGTTAGCGACGGGACCC----- GAGGAGGCTCCCTAGAAGAAGAACTCCCTCGCCCTCGCAGACGCGAGATCTCAATGCCGCGTC CGAGAAGATCTCAATCTGGGAACTCTCAATGTTAGTATTCTTGACTCATAGTGGAAAC TTACTGGCTTATTCTCTACAGTACCTATCTTAATCTGAAATGGAAACTCTCTCTT CTTAAGATTACAAGAGGACATTAAATAGGTGTCACAAATTGTTGGCCCTCTCACT GTAATGAAAAGAGAAGAAATTAAATTGCTGCTAGATTCTATCCTACCCACACTAAA TATTGCCCCATAGACAAGGAAATTAAACCTTATTCAGATCAGGTAGTTAATCATTACTC CAAACAGACATTACACCTTTGGAAAGGCTGGTATTCTATATAAGAGGAAACAC CGTAGCGCATCTTGCGGTACCATATTCTGGAAACAAGAGCTACAGCATGGGAGGTTG GTGATGAAAATCTCGGAAAGGAGATCTCTGCTCCAAACCTCTGGGATCTT TCCGATCATCTGGGACCTGGGCGCAACTCAAAATCCAGATTTGGAGCTTCAA CCCCATCAAGGACACTGGCAGCAGCAACAGTAGGAGTGGGAGCATGGGCAAGGGT CACCCCTCACGGCGTGGGGGGGGGCTCAGGCTCAGGCAATTGACCACAGT GTCACAAATTCTCCCTGCCCCAACATGGCAGTCAGGAAGGCAGCTACTCCATCTC TCCACCTTAAGAGACAGTCATCTCAGGCCATGCACTGGAA----- 3 CTCCACCACTTCCACCAAACCTTCAGATCCAGAGTCAGGGCCCTGACTTTCTGCTGG TGGCTCCAGTCTAGGAGACAGTCAGGAGACTCTCTCTGCAATATCGTCAATCTT ATCGAAGACTGGGACCTGTCAGAACATGGAGAACATCGCATCAGGACTCTAGGACCC GCTCGTGTACAGCGGGGTTTCTGTTGACAAAAATCTCACAATACACAGAGCTAGA CTCGTGGGACTCTCTCAATTCTAGGGGAACACCCGTGTCCTGGCAAATTCGCA GTCCTAAATCTCAGCACTTACCAACCTGTTGCTCTGGCTAGTTACTGTCGAT GTGTCCTGGCGCTTTATCATCTCTGCTCATCTGCTGTCATGCTTCTGTTG TCTCTGACTATCAAGGTATGTTGCCGTTGCTCTCATCTCAGGATCATCAACACAG CACCGGACATGCAAACACTCTGCTCAAGGAACCTCTATGTTCCCTCATGTT CTGTAACAAAATCTAGGAGCAGACCTGCACTCTCCATCATCTGGCTTCTGC AAAATACCTATGGGAGTGGGCTCTGGCTCAGTCTGGCTCTGGCTAGTTACTGTC TCACTGTTGTTGGGCTTCTCCCACTGTCGGCTTCAAGTATATGGATGATGTTG GGGCAAGTCTGACAACATCTGAGTCCTTATGCCGCTGTTACCAATTCTTGTCT TTGGGTTACATTTAACCTCACAAAACAAAAGATGGGGATATTCCCTTAACCTCATGGA TATGTAATTGGGAGTGGGCAACATTGCCACAGGAACATATTGTCACAAAATCAAAATGTT TTAGGAAACTCTCTGAAACAGGCTATTGTTGAAAGTATGTCACAGAATTGTTGGCT TTGGGTTGCCGCCCCCTTCACGCAATGTTGATCTGCTTAAATGCCCTATATGCT ATACAAGCAAACAGGCTTACTCTCGCAACTTACAAGGCCCTTCAAGTAAACAGTAT CTGAACTTACCCGGCTGGCTGGCATAGGCCATCAGCGCATCGCTGGGAAAC CCCACTGTTGGGCTGGCATAGGCCATCAGCGCATCGCTGGGAACTTGTGCTCTCTG CCGATCCATACTCGGAACCTCTAGCCGCTGTTGCTCGCAGCAGGCTGGGCAAAC ATCGGGAACGCAATTCTGTCGTCCTCCGCAAGTATACATCTTCCATGGCTGCTAGGC TGTGTCCTGCCAACGGATCTGGATCTGGCTCTGGCTCTGGCTGGCTGAATCCC GGGACGACCCCTCCGGGGCGCTGGGGCTCACGCCGCTCTCCGCTGTTGACCGA CCGACCAAGGGCGCACCTCTTACGCGACTCCCGCTGTCCTCTCATGCCGAC CGTGTGCACTGCTCACCTCTGCACTGGAGACCACTGAAACGCCACCGAAC -----CTGC----- CCAGGTCTGCAAGAGGACTCTGGACTTCAGCAATGTCAGCACGCCATTGAGGCA ACTTCAAAGACTGTGTTACTGAGTGGGAGGAGTGGGGAGGAGATTAGGTTAAAGGCT ---TTGTAATTGGGAGGCTGAGGCTAAATTGGTGTGTTACAGCACCATGCAACTT TT----- CACCTCTGCCATATCATCTGTTGTCATGTCCTACTGTTCAAGCCTCAAGCTGTC TGGCTTGGGCTGAT----- GACATTGACCCCTATAAAGAATTGGAGCTCTGTCAGGACTCTCTCTCTCTCT TTTGCTCTGACTCTCTCTTCTTCTTCTATTGAGATCTCTGACACCCGCTCTGCTCTG GGGAGGCTTAGAGTCTCGGAACATTGTTACCTCACCATACGGCACTCAGGCAAGCTATT TGTGTTGGGGTGAAGTGAATCTAGGCCACCTGGGAGGAGTAATTGGAAGATCCAGC ----- 	

TABLE 1-continued

		Sequences
SEQ ID NO.	Sequence	
	CCAGGGAAATTAGTAGTCAGCTATGTCACCGTTAATATGGGCCAAAAATCAGACAACTATTGT GTTTCAACATTCTCTGCTTACTTTGGGAGAGAAACTGTTCTGAATATTGGTGTCTTTG GAGTGGAATTGCACCTCTCCCTGCATATAGACCACCAATGCCCTATCTAACACTTC CGAAACTACTGTGTTAGACGAA----- AGGCAGGCCCCCTAGAAGAGAACTCCCTCGCCTCGCAGACGAAGGTCTCAATGCCCGTCG CGAAAGATCTCAATCTGGGAA--- TCTCAATGTTAGTATCCTGGACACAATAAGGGGAAACTTACGGGCTTATTCTTCTAC GTACCTTGCTTAATCTCAAATGGCAAACCTCTTCTTCTGACATTCTTGAGGAGGA CATGTTGATAGATGTAAGCAATTGTTGGGCCCCCTACAGTAAATGAAAACAGGAGACTAA ATTAAATTATGCTGCTAGGTTTATCCAAATGTTACTAAATTTGCCCTAGATAAGGGAT CAAACGTTTACAGAGCATGTTAATCATTACTTCAGACGAGACATTATTCACAC CTCTTGGAGGGGGTCTTATATAAAAGAGAGTCCACAGTAGCGGCCTCATTTGCCGGTC ACCATTCTGGGAAAGACTACAGGAGTGGGGTTGGGCTTCCAAACCTCGAAAAGGCA TGGGACAATCTCTGCCCCATCCCTGGGATTCTTCCCAGTATCAGTTGGACCTG CATTCAAAGCAACTCAGAAATCCAGATTGGGACCTCAACCGCACAGAACACTGCCGG ACGCCAACAAAGGTGGGAGTGGGAGATTGGGGCAAGGGTTTACCCCTCCCATGGGGACTGT TGGGGTGGAGGCTCAGGGCTAGGGCATACTCACAACGTGCGCAGCTCTCCTGCC CACCACATCGGAGTCAGGAGCACCCACTCCCTTATCTCACCTCTAAGGGACACTCATC CTCAGGCGATGCAGTGAA	
4	CTCCACAAACATTCCACCAAGCTCTGCTAGATCCCAGAGTGAGGGGCCTATACTTTCTGCTG TGCTCAGCTGGGACAGTAACCTGTTGCGACTACTCCTCACCCATATGTCATCT CTCGAGGACTGGGACCTGCAACGAACTGGAGAACACACATCAGGATTCTAGGACCC GTCGTGTTACAGGGGGTTCTTCTGTTGACAAGAATCTCACAATACACAGAGTCTAGA CTCGTGTGGACTCTTCTCAATTCTAGGGGAGCAGCCACGTTGCTCTGGCAAAATTCGA GTCTCCAACCTCTTCTGCTCTGGCTTATGCTGCTATCAGCTGGAT GTGCTGCGGCTTATCTGCTTCTTCTGCTCTGCTATCAGCTGCTATCTTGTGGT TCTCTGAGTACAAAGGTATGCGCCGTTGGCTACTCTGCTTCTGCTGCTGCTGCT ACCGACGGGACATGCAAGACCTGCACGATTCTGCTCAAGGAACCTATGTTCCCT TGGCTGTACAAAACCTCGGAGGAAACTGCACTTGATTTCCATCCATCATCTGGCT TCGCAAGATTCTATGGGAGTGGGCTCAGTCCGTTCTCTGGCTCAGTTACTAGTGCA TTGTGTCAGTGTCTAGGGCTTCCCTCCACTGTTGGCTACTGTTATATGGATGATGTG TATTGGGAGGCAACTCTGACAATCTTGACCTTTCATCTGAGCCCTTTACCTTACCAATT TGTCTTGGGATACATTGAAACCTTAAAAAACCAACAGTGGGCTACTCCTTAACCTCA TGGGATGTAATTGGAAGTGGGGACTTTACACAGGAACATTGACTAAAAATCAAGC ATGTGTTCTGAAACTCTGCTTAATGACCTATTGAGGAAAGTATGTCAAAGAATTGTG GTCTTTGGGCTTGTCTGCCCCCTTACACATGTCATCTGCTTAATGCTTATATG CATGATACAACTCTAAGCGCTTTCACCTTCGCAACTTACAGGCCCTTGTGAAAC AATATCTGAACCTTACCCGTGCGGGCACGGTCAGGTCTCTGCAAGTGTGCTGAC CAACCCGGAACGGATGGGCTGGGACATGGGCACTGGGCTGGAACCTTGTGCTC CTCGCCGATCCACTCGGAAACTCTGAGCCTGGCTTGTGCTCGCAGCGGGTCTGGAGC ACTTATCGGAAACCGACAACCTGTTGCTCTCGGAAATACACCTCTTCCATGGCTG TAGGGTGTGCTGCCAAGTGGATCCTGCGGGACGTCCTTGTCTACGTCCGTGGCGTGA ATCCCGGGGAGGACCCGCTCGGGGCGTTGGGACTCTACCGTCCCTCTCATCTGCCGT TCCGGGCGAACCCGGCACCTCTTACGGGCTCTCTGGGCTCTGTGCCCCCTCATCTGC CGGACCGTGTGACTTCGCTCACCTGCACTGGAGACCCGTGAACGCCAACCA GGTCT---CC-A---AGGT-TTGC----- CCAGGGCTTACATAAGAGGAACCTGGACTCTGCACTGCAAGGCCCTGAGGGCAT ACTTCAAAGACTTTGTTAAAGACTGGGAGGAGTGGGGAGGAGATTGGTAAATGATCT ---TTGACTAGGGACTGAGGCATAATGGCTGTTACACGACCATGCAA----- ----- CTTTTACACCTGCTTAATCATCTCATGTTCTACTGTTCAAGCTCCAAGCTGTGC CTGGGCTGCTTGGGGCATGGACATTGACCCGATAAAAGAATTGGAGCTCTGTGGAGTT CTCTCTT--- TTTGCTCTGACTCTTCCCTTATTCGAGATCTCTGCAACGCCCTGCTCTGATC GGAGGCTTAAAGCTCCGGAACATTGTTACCTCACCATACGCAACTCAGGAAAGCTATT TGTGTGGGGTGGAGTGTGATCTGGGACCTGGGAGGAAATTTGGAGACCCAGCAT CAGGGAAATTAGTCAGCTATGTCATGTTAATATGGGCTTAAACAGACAACTATTGT GGTTTCACATTCTGCTTACTTTGGAGAGAAACTGTTCTGAGTATTTGGTGTCTTG GAGTGTTGGGACTGGCACTCTCCCGTACAGACCCACCAATGCCCTATCTAACACTTC CGGAAACTACTGTTAGA----- CAACGAGGGAGGCTCCCTAGAGAAAGCACTCCCTGCCCTGCCAGACGAAGGTCTCAATGCC CGTCGAGAAGATCTCAATCTGGGAACATTCAATGTTAGTATCCCTGGACTCATAAAGTGG AAACTCTACTGGCTTATTCTCTACTGTACTCTGCTTTAACTCTGAGTGGCAACTCC CTTCTCTCACATTCTGAGGAGGACATTAAATAGATGTCACAAACTATGTTGGGCCCT TACAGTTAATGAAAAGGAGATTAAAATTAAATTGCTCTAGGTTCTATCCCTAACCTAC CAAAATTTGCCCTGGACAAAGGCAATTAAACCTTATTATCTGACATGCAAGTAACTATT CTCTCAAACCTAGGCATTATTACATACTCTGAGGCTGCATTCTATATAAGAGGAAAC TACACGCAGGCCCTATTGAGGCTCACCATATTCTGGAGAGACGAGCTACAGCATGGGAG GTGGTCTCCAAACCTGACAAGGATGGGAGCAATTCTCTGTGCCCCCTCTGGGAT TCTTCCGATCACCAGTGGGACCCCTGCCGTTGGAGGCCACTCAAACAATCCAGATTGGGACT	

TABLE 1-continued

		Sequences
SEQ ID NO.	Sequence	
	TCAACCCCAACAAAGGATCACTGGCCAGAGGAAATCAGGTAGGAGCGGGAGCATTGGGCCAG GGTTCACCCACCCACACGGCG----- GTCTTTGGGGTGGAGCCCTCAGGCTCAGGGCATATTGACAACA----- ----- GTGCCAGCAGCACCTCCCTGCCTCCACCAATCGGAGTCAGGAAGACAGCCTACTCCCATC TCTCCACCTCTAACAGACAGTCATCCTCAGGCCATGCAGTGAA	
5	----- CTCCACCACATTCACCAAGGCTCTGCTAGATCCCAGAGTGAAGGGCTATACTTTCTGCTGG TGCTCCAGTTCGGAACAGTAACACCTGTTCGACTACTGCCTCTCCCATATCGCAATCT CTCGAGGACTGGGGACCTGCGACCGAACATGGAGAACACCACATCAGGATTCTAGGACCCCT GTCGIGTTACAGGGGGGTTTTCTTGTTGACAAGAATCCTCACAAATACACAGAGCTAGA CTCGTGGGGACTCTCTCAATTCTAGGGGAGCACCACGTGTCCTGGCAAAATTTCGCA GTCCCCAACCTCAAATCACTCACCAACCTCTGCTCTCCAAATTGTCCTGGTTATCGCTGGAT GTGTCTGGCGGTTTATCATCTCCTCTCATCTGCTGCTATGCCCATCTCTGGTGGT TCTCTGAGACTACCAAGGTATGTTGCCGTTGCTCTACTTCAGGAACATCAAC-ACC-- ----- CAGCACGGGACCATGCAAGACCTGCACTGACTCTGCTCAAGGAACCTTATGTTCCCTT TTGCTGTACAAAACCTCGGAGCGGAAATGCACTTGTATTCCCATCCATCATCTGGCTTT CCCAAGATTCTATGGGAGTGGCCTCAGTCGGTTCTCTGGCTCAGTTACTAGTGCCTT TGTCAGTGGTGTAGGGCTTCTCTGTTACGGGCTTTCAGTTATGATGATGTGGTA TTGGGGGCAAGTCTGTACAACATCTGAGTCTCTTACCGCTATTACCAATTTCCTT TCTTGGGTATACATTAAACCTAATAAAACAAACGTTGGGCTACTCCCTAACCTCATG GGATATGTAATTGGAGTTGGGACTTTACACAGGAACATATTGTAACAAAATCAAACAA TGTGTTGGGAAACTCTGTAATAGACCTATTGATGGAAAGTATGTCAAAGAATTGTGGGT CTTGGGGCTTGTGCTGCCCTTACACATGTCCTATCTGCTTTAATGCTTTATGCA TGTATACAAGCTAAGCAGGCTTCACCTCTGCCAACATTACAAGGCCTTCTGTGTAACAA TATCTGAACCTTACCCGTTGCTCGGCAACGGTCAGGTCTGTGCAAGTGTGCTGACGA ACCCCACTGTTGGGCTTGGGCACTAGGCCATCAGCGCATGCGTGGAAACCTTTGTCCT CTGCCGATCCATACTGGGAACTCCTAGCAGCTTGTGTCCTCGCAGCCGCTCGAGCAAA CTTATCGGACTGACAACCTCTGTTGTCCTCTCGGAAATACACCTCTTCACTGGCTGCTA GGCTGTGCTGCCAACCTGGATCTGCGCGGGAGCTTGTCTACGTCCCCTCGCGCTGAAT CCCGCGGACGACCGCTCGGGCGTTGGGCTTACCGCCCTTCTCGTGTGCGTTC CGGGCGAACCGGGCGCACCTCTTTACGGGTCTCCCGCTGTGCTTCTCATCTGCC GACCGTGTGCACTTCGCTTACCTGCGCATGGAGACCCAGGTGACGCCAACCGGA ACA---CC---CTGGT- CAAGGCTTACATAAGGAGCTTGGACTTCAGCAATGTCACGACCGACCTGAGGCATA CTTCAAAGACTGTTGTTAATGACTGGAGGAGTTGGGGAGGAGATTGGTTAAAG- CTTCTTGTACTAGGAGGCTGAGGATAAAATTGGCTGTTCACCGACACCAGCAACTTTT- ----- TCACCTCTGCCATAATCATCTCATGTTCATGTCCTACTGTTCAAGCCTCAAGCTGTGCCCTGG GTGGCTTGGGG----- CATGGACATTGCCGTATAAAGAATTGGAGCTCTGTGGAGTTACTCTCTT----- TTTGCTCTCTGACTCTTCCCTTCTATTGAGATCTCTGACACCGCCTCTGCTCTGATC GGGAGGCTTAAGACTCCGGAACATTGTCACCTCACCACACGCACTCAGGCAAGCTATT TGTGTTGGGTGAGTTGATGAACTCTGCCACCTGGTGGAGTAATTGGAGACCCAGCAT CCAGGAATTACTAGTCAGGTATGTAATATGGGCTAAACATGAGACAACATTG GGTTGCACTTCTGTTACTTTGGAGAGAACTGTTCTGAGTATTGGTGTCTT GAGTGTGGATTGCACTCTCTGCTTACAGACCCACAAATGCCCTATCTTACACACTTC CGGAAACTACTGTTAGGAGC----- ACGAGGCAGGTCCCCTAGAAGAGAACTCCCTGCCCTCGCAGACAGAAGGTCTAACGCCCG TCCGAGAAGATCTCAATCTCGGA- ATCTCAATGTTGACTCTGACTCATAAAGTGGAAACTTACTGGCTTTATTCTCTA CTGTAACCTGTCCTTAATCTGAGTGGCAAACCTCCCTTCTCCTCACATTGCAAGGAG ACATTAAATTAAGATGTCACAAATATGTCGGCCCTTCTACAGTTAATGAAAAAGGAGATTAA ATTAATTATGCCCTGCTAGGTTCTACCTAACCTAACAAATATTGCCCTAGATAAAGCA TTAACCTTATATCTGAACTGAGTTAACCTACTTCCAAACTAGGCATTATTACATA CTCTGGAAGCGGGCATTTATATAAGAGGAAACACTACAGCGAGCGCTCATTTGTGGGT CACCATATTCTGGGAAGAGCTACAGCTGGAGGTTGGCTTCCAAACCTCGACAAGGC ATGGGGACAAACTCTTCTGTCCTCCAAAGGCTACAGCTGGAGGTTCAACCCCAACAGGATCACTGGCCA GAGGCAACCCAGGTAGGAGTGGAGCATTGCCAGGGTTCAACCCACACGGCGG----- ----- GTGCCAGCAGCTCTCCCTGCCCTCCACCAATCGGAGTCAGGAAGACAGCCTACTCCCATC TCTCCACCTCTAACAGACAGTCATCCTCAGGCCATGCAGTGAA	
6	CACCAAACCTCTCAAGATCC	
7	CAGGAACAGTGAGCCCTGCT	

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
8	ACCCCTGCTCGTGTACAGG
9	CAAAAATCCTCACAAATACCA
10	CCAATTGTCCTGGTTATCG
11	GCCC GTT GT CCT CTA ATT C
12	GGCTT TCG CAA AAT ACCT AT
13	ACT GT CT GG CTT CAG TT AT
14	GGCC AAG TCT GT ACA ACAT C
15	TT ACCA A T T T C T T T G T C T
16	CCCT CAC AAA A CAAAAA AGAT
17	GGG AT AT CC CTT A ACT TCA
18	A CTT C AT GGG AT AT GT A ATT
19	AT TG AT TGG AA AGT AT GT CA
20	GGAA AGT AT GT CA AC GA ATT
21	TCA AC GA AT TGT GGG GT CTT
22	TGCC GCCC CTT CAC GCA AT
23	CTG CTAG GCT GT GCT GCC A A
24	TTG TTT AC GT CCC GT CGG CG
25	CTT CAA AGA CT GT GT GT TTA
26	CT GT GT GT TTA CT GAG T GGG
27	TCA AGC CT CC AAG CT GT G CC
28	TAA AGA A T TGG AG CTT CTG
29	TG CT CT GT AT CGG GAG GC CT
30	TCAG GCA AGC TATT CT GT GT
31	TT CT GT GT TGG GT GAG TT G
32	GAG TT GAT GA AT C TAG CC AC
33	TTT GGA AGA TCC AGC ATCCA
34	TTT GGG AGAG A AACT GT TC
35	CTT GA AT AT TGG GT CTT
36	TAT TGG GT CTT GG AGT
37	AA A T A T TGC CTT AGA TAA
38	AT TT A C A C A C T CTT GG AAG
39	GGC GGG TAT CTT ATATA AAAA
40	CAC ACG TAG CGC CT CATT TT
41	TCT TT CT GT CCCC AAT CCCC
42	TGG CCG GACGCC AACA AGGT
43	GGG AGT TGG AGC ATT CGGG C

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
44	CCCTCCCCATGGGGGACTGT
45	GCCCTGACTCTGGGATCTTG
46	AAAGTACAGGGCCCTGACTC
47	GATGTTCTCCATGTTCGGTA
48	GTAACACGAGCAGGGTCCT
49	ACCCCGCCTGTAACACGAGC
50	TCTAGACTCTGTGGTATTGT
51	AAAATTGAGAGAAGTCCACC
52	GCGAATTGGCCAAGACAC
53	GTGACTGGAGATTGGGACT
54	AATTGGAGGACAACAGGTTG
55	AAGAAGATGAGGCATAGCAG
56	GTGCTGGTTGTTGATGATCC
57	AACATAGAGGTTCCCTTGAGC
58	AAAGCCCAAGATGATGGGAT
59	TTTGCAGAAAGCCCAAGATGA
60	TCCCCATTTTGTGTTGT
61	TACATATCCCAGTGAAGTTAA
62	TGCATATAAAGGCATTAAG
63	ACCAGGCCGTTGCCGAGCAA
64	ATGGCCAAGCCCCAACAGT
65	GCGGCTAGGAGTTCCGCAGT
66	TGCGAGCAAAACAAGCGGCT
67	CGACAGAATTGTCAGTCCCG
68	ATACTTGCAGGAGAGCACGA
69	TAAACAAAGGACGTCCCGCG
70	GCCCCGGGAGGGGTCGTCCG
71	GAGCCCCAAGCGGCCCCGGG
72	CAGATGAGAAGGCACAGACG
73	GTTGACATTGCTGAAAGTCC
74	AGAAGCTCCAATTCTTTAT
75	GAGGCAGGTGTCGAGGAGATC
76	CCCAACACAGAATAGCTTGC
77	TTCATCAACTCACCCCAACA
78	GACTACTAATTCCCTGGATG
79	CATAGCTGACTACTAATTCC

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
80	GGTCTATATGCAGGAGGAGT
81	TTTGGTGGTCTATATGCAGG
82	GACCTTCGTCTGCGAGGCAG
83	TTTCCCACCTTATGTGTCCA
84	ATTAAAGCAAGGTACCGTAG
85	AAAAGAAGGAGTTGCCATT
86	AAATGAATGTCAGGAAAAGA
87	TCAACAATGTCCCTCGCAA
88	GGGCAAATATTAGTAACAT
89	GTAATGATTAACTACATGCT
90	TATAAGATAACCGCCTTCCA
91	ATGCTGTAGATCTTGTCCCC
92	ATGATCGGGGAAGAACATCCA
93	GGTCCAAC TGATGATCGGGG
94	TTCTGAGTTGGCTTGATG
95	CTGGATTTCTGAGTTGGCT
96	GAGGTCCCAATCTGGATTT
97	GTGCGGGTTGAGGTCCCAAT
98	GTCCGGCCAGTTGTCCTTGT
99	GGGGAGGGGTGAACCCCTGGC
100	CCCAACAGTCCCCATGGGG
101	GAGGAGCTGCTGGCACAGTT
102	TCCCTTAGAGGTGGAGATAA
103	CACCAAGCTCTGCTAGATCC
104	GAACATGGAGAACACAACAT
105	GCGGGGTTTTCTTGTGAC
106	CAAGAACCTCACAAATACCA
107	CCAATTGTCCTGGCTATCG
108	AACCTCGACAAGGCATGGGG
109	GGCTTTCGCAAGATTCTAT
110	ACTGTTGGCTTCAGTTAT
111	GGGCTACTCCCTTAACCTCA
112	TGGGATATGTAATTGGAAGT
113	GGAAAGTATGTCAAAGAATT
114	GTTCGCTGACGCAACCCCCA
115	CACCTCCTTCATGGCTGC

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
116	CTGCTAGGGTGTGCTGCCAA
117	TTGTCTACGTCCCGTCGGCG
118	CTGTTTGTAAAGACTGGG
119	CATGGACATTGACCCGTATA
120	GAGTTGATGAATCTGGCAC
121	TTTGGAAAGACCCAGCATCCA
122	TTTGGAAAGAGAAACTGTTC
123	CTTGAGTATTTGGTGTCTTT
124	TCGCAGAAGATCTCAATCTC
125	TACTGTACCTGTCTTAATC
126	TACACGCAGCCTCATTTT
127	TCTTCTGTTCCAATCCTC
128	ATTGGGACTTCAACCCCAAC
129	AGGAGCGGGAGCATTGGGC
130	TGGGATCTAGCAGAGCTTGG
131	AAAGTATAGGCCCTCACTC
132	GGGTGAGGCAGTAGTCGGAA
133	TCCTCGAGAAGATTGACGAT
134	TGTGTTCTCCATGTTGGTG
135	GCGAATTGGCCAGGACAC
136	GTGATTGGAGGTTGGGACT
137	AATTGGAGGACAAGAGGTTG
138	GGCATAGCAGCAGGATGAAG
139	AAAGCCCAGGATGATGGGAT
140	CTTGCAGGCCAGGATGA
141	ATAGGAATCTTGCAGGCC
142	GGACTGAGGCCACTCCAT
143	GCCCCAACGTTGGTTTAT
144	TGCATATAAAGGCATTAAGG
145	ACCTGACCGTTGCCGGCAA
146	ATGGCCAAGCCCCATCCAGT
147	GCTGCTAGGAGTCCCGAGT
148	TGCGAGCAAAACAAGCTGCT
149	GTATTTCCGAGAGAGGACAA
150	TAGACAAAGGACGTCCCGCG
151	GCCCCGAGACGGGTGTCGTCG

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
152	GAGTCCCAAACGGCCCCGAG
153	GCAGATGAAGAAGGGGACGG
154	GTTGACATTGCTGAGAGTCC
155	GGTCGGTCGTTGACATTGCT
156	GGTCTGTAAGCGGGAGGAGT
157	TTTGGTGGTCTGTAAGCGGG
158	GTGGAGTTGGCTCCGAACG
159	TTTCCCACCTTATGAGTCCA
160	CCAGTAAAGTTCCCACCTT
161	ATTAAGACAGGTACAGTAG
162	AAAGGAGGGAGTTGCCACT
163	AAATGAATGTGAGGAAAGGA
164	TTAATAATGTCCCTGTAA
165	GGGCAAATATTTGGTAAGGT
166	GTAATGATTAACTGCATGTT
167	TATAGAATGCCAGCCTTCCA
168	CGTGTAGTTCTCTCTTATA
169	ATGCTGTAGCTTTGTTCCC
170	GTGATCGGGAAAGAACCTCA
171	GGTCCAACCTGGTGATCGGG
172	GAAGTCCCAATCTGGATTGT
173	GTTGGGGTTGAAGTCCCAAT
174	CTCTGGCCAGTGATCCTTGT
175	GTGGTGGGGTGAACCCCTGGC
176	TCTCTTAGAGGTGGAGAGAT
177	CTGCCTTCCACCAAGCTCTG
178	CACCAAGCTCTGCAGGATCC
179	CTCTGCAGGATCCCAGAGTC
180	CAGGAACAGTAAACCCTGCT
181	GAACATGGAGAACATCACAT
182	GAAGTTGGGGAACATTGCCA
183	CAAGAACCTCACAATACCG
184	GACTTCTCTCAATTCTAG
185	TCATCTTCTTATTGGTTCTT
186	AACCTCGCAAAGGCATGGGG
187	CATGTTGCTGTACAAAACCT

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
188	ACTGTTGGCTTCAGCTAT
189	GCCCAAGTCTGTACAGCATC
190	ACCCTAACAAAAACAAAAAGA
191	GGGGTTATTCCCTAAACTTC
192	TGCTGCTCCATTACACAAT
193	CTGCTAGGCTGTACTGCCAA
194	CATGGACATTGACCCTTATA
195	TAAAGAATTGGAGCTACTG
196	AGCTCTGTATCGGAAGCCT
197	GCAAGCCATTCTTGCTGGG
198	GAATTGATGACTCTAGCTAC
199	ATTTGGAAGATCCAGCATCC
200	TCAATTATGTTAATACTAAC
201	TTTGGAGAGAGACTGTAC
202	CTTGAATATTGGTCTCTTT
203	TATTGGTCTCTTCGGAGT
204	TACAGTACCTATCTTAATC
205	AAATATTGCCCTTAGACAA
206	CACACGTAGCGCATCATTT
207	TCTTCTGTTCCAACCTC
208	TGGCCAGCAGCCAACCAGGT
209	AGGAGTGGAGCATTGGGC
210	CCCTCACACGGCGGTGTT
211	AAAATACAGACCCCTGACTC
212	GTGAGAGGCAATTGGAG
213	GATGTTCTCCATGTTGTCA
214	TCTAGACTCTGGGTATTGT
215	AATTGGAGGACAGGGAGTTG
216	GTACTGGTTGTTGATCC
217	AACATAGAGTTGCCCTGAGC
218	ACAGCAACATGAGGGAAACA
219	GTTTGAGTTGGCTCCGAATG
220	AAAGCCCAGGACGATGGGAT
221	TTTGCAGAAGCCCAGGACGA
222	ACCCCATTTTGTGTTGT
223	TATGTAACCCATGAAGTTA

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
224	TGCATACAAAGGCATTAAGG
225	ATGGCCAAGCCCCAGCCAGT
226	ATATTTCCGCGAGAGGACGA
227	GCCCCGAGAGGGTCGTCCG
228	GAGTCCCAAGCGGCCCCGAG
229	GCAGACGGAGAAGGGGACGA
230	TCTAAGGGCAAATATTAGT
231	CTCTTATGTAAGACCTTGGG
232	GTTGACATTGCTGGGAGTCC
233	AGTAGCTCCAATTCTTTAT
234	AGAAGTCAGAAGGCAAAAAC
235	CCCAGCAGAGAATGGCTTGC
236	GTCATCAATTCCCCCAGCA
237	TTATTACCCACCCAGGTAGC
238	GACTACTAGATCCCTGGATG
239	CATAATTGACTACTAGATCC
240	GGTCTATAGGCTGGAGGAGT
241	TTTGGTGGTCTATAGGCTGG
242	GATCTGCGTCTGGAGGCCA
243	ATTAAAGATAGGTACTGTAG
244	AAAGGAAGGAGTTGCCATT
245	AAATGAATCTTAGGAAAGGA
246	TTAATAATGTCCCTTGTA
247	AATATTTAGTGTGGGTAGGA
248	GTAATGATTAACCTACCTGAT
249	TATAGAATACCAGCCTTCCA
250	CGTGTGGTTCCCTCTTATA
251	ATGATCGGGAAAGAACCCCA
252	GGTCCAACGTGATCGGGAA
253	CTGGATTGTTGAGTTGGCT
254	GATGGGGTTGAAGTCCTTCA
255	TGCTGGCCAGTGGTCCTTGA
256	GTGGAGGGGTGAACCTGGC
257	CCCAAAACACCGCCGTGTGG
258	CGATTGGTGGAGGCAGGAGG
259	GAACATGGAGAACACCACAT

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
260	CTGTGTGTTAATGACTGGG
261	TGGCCAGAGGCAAACCAGGT
262	GGGAGAGGCAGTAGTCGGAA
263	GGTGTCTCCATGTTCGGTG
264	CTTGCAGAACGCCAAGATGA
265	ACCTGACCGTTGCCGAGCAA
266	GAGCCCCAACGGCCCCGAG
267	GGTCTGTAAGCAGGAGGAGT
268	TTTGGTGGTCTGTAAGCAGG
269	AAAAGAGGGAGTTGCCACT
270	AAATGAATGTGAGGAAAAGA
271	TTAATAATGTCCTCCTGCAA
272	TATAAAATGCCCGCCTCCA
273	CCTCTGCACGTGCATGGAGAC
274	CCCACTGTCTGGCTTCAGTTA
275	GAGTTGGCTTGAAATGCAGGGT
276	CCATGTTGGTACAGGGTCCCC
277	GATACTGTTACTTAGAAAGGC
278	CATTCCTGTCTTACTTTGGG
279	TGTTGACAAAAATCCTCACAAAT
280	CATCTGCCGGACCGTGTGCACT
281	TCTGGACTATCAAGGTATGTTG
282	CATCCCACATCTGGGTTTC
283	GCAATGTCAACGACCGACCTTG
284	GCAGTATGGATGGCAGAGGAG
285	TGTGGCAATGTGCCCAACTCC
286	CAGTCCCAAATCTCCAGTCACT
287	CACTCCTCCTGCATATAGACCA
288	TGTTGGTTCTTCTGGACTATCA
289	CACCTTATGTGTCAGGAATA
290	TCTGCGAGGCGAGGGAGTTCTT
291	GCGCCGACGGGACGTAAACAAA
292	CACCCAGGTGGCTAGATTCATC
293	TCTGCATCCTGCTGCTATGCCT
294	TCTACGGTACCTTGCTTTAATC
295	CAAAATACCTATGGGAGTGGGC

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
296	ATTCGAGATCTCCTCGACACCG
297	GGAACAGTGAGCCCTGCTCAGA
298	GCGACGCGGCATTGAGACCTT
299	TGTCTTACTTTGGGAGAGAAA
300	CCCCCTCCCCATGGGGACTGTT
301	CCCTAGAAAATTGAGAGAAAGTC
302	CTTAACTTCATGGGATATGTAA
303	CTTCACCTCTGCACGTCGCATG
304	TGCTGGTGGCTCCAGTTCAAGGA
305	CTCCCAAAAGTAAGACAGGAAA
306	CTCATGTTGCTGTACAAAACCT
307	CTTGGCTCAGTTACTAGTGCC
308	CTCAATTCTAGGGGAACAC
309	TGACTGCCGATTGGTGGAGGCA
310	CGGTGGTCTCCATGCGACGTGC
311	TGGGAACAAGATCTACAGCATG
312	TTTGTCTTGGGTATACTTTA
313	CGCCAACTTACAAGGCCTTCT
314	CGCAATGTGGATATCCTGCTTT
315	TGGGATATGTAATTGGGAGTTG
316	TGACATTCAATTGCAGGAGGAC
317	TGTAAACAGGCCTATTGATTGG
318	CGAGATTGAGATCTCTGCGAC
319	TGAATATTGGGTCTTTGGA
320	TGAACCTGGAGCCACCAGCAGGA
321	GACTTCTTCCTTCTATTGAG
322	TCAACTCACCCAACACAGAAT
323	CCTCACCATACGGCACTCAGGC
324	GAGCAGGGCTCACTGTTCTGA
325	TGTCCTACTGTTCAAGCCTCCA
326	CCGCCTGTTGACCGACCGACC
327	ATGGCTGCTAGGCTGTGCTGCC
328	GGAAGTGGTGTAAAGATAGGGG
329	CAAGAATATGGTGACCCGCAA
330	GTCCGTAGGTTGTACAGCAA
331	ACGCATGCGCTGATGGCCTATG

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
332	TTGGACACATAAGGTGGGAAAC
333	GTCCCCAATCCCTGGGATTCT
334	GGAGACTCTAAGGCCTCCGAT
335	ACCAAACTCTTCAAGATCCCAG
336	GTCGTGCTCTCCGCAAGTATA
337	GTGGTTCGTAGGGCTTTCCCCC
338	GTGTTGGGTGAGTTGATGAAT
339	AATCAATAGGCCTGTTACAGG
340	AAGTAAACAGTATCTGAACCTT
341	GTACAGGGTCCCCAGTCTTCGA
342	GTTATATGGATGATGTGGTTT
343	TCCCCGATCATCAGTTGGACCC
344	AAGACTGTGTGTTACTGAGTG
345	TTTACTGTAAGGGCCCCACAA
346	TTTCCTGACATTCAATTGCAGG
347	AAATTACTCCCACCCAGGTGG
348	AAAGAGTGTGAAATAATGTCT
349	TTTGCAGGAGGACATTGTTGAT
350	TAAAACACATTTGATTTTG
351	AAACCTCGAAAAGGCATGGGA
352	TAGGGCTTCCCCACTGTCTG
353	AAGCCAACTCAGAAAATCCAGA
354	ACTGCATGGCCTGAGGATGAGT
355	CTGGATGCTGGATCTCCAAAT
356	AGGTTTGGAAAGACCAACCTCCC
357	TCTAACACAGTAGTTCCGGA
358	TTCCCTCTATTGAGATCTCCT
359	TTGACATACTTCCAATCAATA
360	AGCCTCCAAGCTGTGCCTGGG
361	TTCTATTGAGATCTCTCGAC
362	GGTGGGC GTTACGGTGGTCTC
363	AGGATCATCAACAACCAGCACC
364	TTGAGCAGGAGTTGTGCAGGTT
365	AGATCTCCTCGACACCGCCTCT
366	AGATCCCAGAGTCAGGGCCCTG
367	ATAAGATTGACGATATGGCAGA

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
368	AGACGAGACATTATTTACACAC
369	AGAACAGTTCTCTCCAAAAG
370	G GCCAGGGTTCACCCCTCCCCA
371	AGGGGGAACACCCGTGTCTT
372	GGAACAGTAAACCTGTTCCGA
373	TAGGACCCCTGCTCGTGTTACA
374	CTTCCAAAAGTAAGACAGGAAA
375	G GCCAGGGTTCACCCACCACA
376	GGATAATAAGGTTAACGCCTT
377	TAGGGCTTCCCCACTGTTTG
378	TGAGTATTTGGTGTCTTTGGA
379	TCCCCATGCCCTGTCGAGGTTT
380	TATGGGAGTGGGCCTCAGTCG
381	TCATCTGCCGTTCCGGCGACC
382	CTTTCTGCCAACTTACAAGGC
383	CTGGATGCTGGGTCTTCAAAT
384	GATATTGTTACACAGAAAGGC
385	TCTACTGTACCTGTCTTAATC
386	TCCTGCTGCTATGCCCATCTT
387	GATAAGTTCGCTCCAGACCGG
388	GTCCGAAGGTTTGTACAGCAA
389	GAGCCAACCTAAACAATCCAGA
390	TCTTCATCCTGCTGCTATGCCT
391	GTGCAGGGTCCCCAGTCCTCGA
392	GTTCCAATCCTCTGGGATTCT
393	TCTGGACTACCAAGGTATGTTG
394	GAGAGAGGACACAGAGTTGTC
395	GTTATATGGATGATGTGGTATT
396	GGCCGACCACGGGGCGCACCTC
397	GACTACTGCCAACCCATATCG
398	GCGCCGACGGGACGTAGACAAA
399	GACGGAAACTGCACTGTATTTC
400	GTGTAAACAATATCTGAACCTT
401	GGAACACTGGAGGCCACCAGCAGGA
402	TTTGTCTTGTTGGGTATACATTG
403	CTCTTGTTGCTGTACAAAACCT

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
404	CAATCCTCTGGGATTCTTCCC
405	CAAGATTCCATGGGAGTGGGC
406	CAAGAATATGGTGACCCACAAA
407	TGCTCAAGGAACCTCTATGTTT
408	TTATACGGGTCAATGTCCATGC
409	TTCCCGATCACCAAGTGGACCC
410	ATCCTAACCTTACCAAATATTT
411	ATATAAGAGAGAAACTACACGC
412	AGGGGGAGCACCCACGTGTCCT
413	TTGAGCAGGAATCGTGCAGGTC
414	ACTGCATGGCCTGAGGATGACT
415	ACGCATGCGCCGATGGCTATG
416	ACCCCAACAAGGATCACTGGCC
417	ACCAAGCTCTGCTAGATCCCAG
418	ACAGAGTATGTAATAATGCCT
419	AATTACATATCCCATGAAGTTA
420	AATGTATAACCAAAGACAAAAG
421	AATCAATAGGTCTATTACAGG
422	TTTACAGGAGGACATTATTAAT
423	AAGACTGTTGTTAAAGACTG
424	AAACTAGGCATTATTTACATAC
425	AAACCTCGACAAGGCATGGGA
426	AAAAGTAAGACAGGAAATGTGA
427	AAAACTGCCTGTAATAGACCT
428	AAAACATTGCTTGATTTTAGT
429	CACCCAGGTGCCAGATTCAATC
430	TTAACTGTAAGAGGGCCACAT
431	ATGGCTGCTAGGGTGTGCTGCC
432	CACTCCTCCCGCTTACAGACCA
433	CTCTTATATAGAATGCCAGCCT
434	TGCTGGTGGCTCCAGTTCCGGA
435	CTCCAGACCGGCTGCGAGCAA
436	TGGAAGTAGAGGACAAACGGGC
437	CTCAATTCTAGGGGGAGCAC
438	TGGGAACAAGAGCTACAGCATG
439	TGGGATATGTAATTGGAAGTTG

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
440	CGATCACCAGTTGGACCCCTGCG
441	CGAGGACTGGGACCCCTGCACC
442	CCTGGCTCAGTTACTAGTGCC
443	CACCTTATGAGCCAAGGGATA
444	CCTCTGCCTAATCATCTCATGT
445	TGTCAACAAGAAAAACCCGCC
446	CCTCACCCATACAGCACTCAGGC
447	TGTCTTACTTTGGAAGAGAAA
448	TCACATTCAATTACAGGAGGAC
449	TGTTGGTTCTCTGGACTACCA
450	CAGTCCCCAACCTCCAATCACT
451	CATCCCATCATCCTGGGCTTTC
452	TGTGGTAAAGTACCCCAACTTC
453	TGTTGACAAGAACCTCACAAT
454	CCATGTTGGTGCAGGGTCCCC
455	CCCACTGTTGGCTTCAGTTA
456	CATTTCTGTCTTACTTTGGA
457	TCTGGATTATCAAGGTATGTTG
458	TTTGTCTCTGGTATACTTTA
459	TTTGTCTAAGGGCAAATATTAA
460	TCCCCATGCCTTGCAGGT
461	TTATAAGGGTCAATGTCCATGC
462	TTTCCTAAGATTCAACAG
463	TTTACAGTGAGAGGGCCCACAA
464	TGGGTTACATAATTGGAAGTTG
465	TTCCCGATCATCAGTTGGACCC
466	TTTACAAGAGGACATTATTAAAT
467	TCCTCCTGCCTCCACCAATCGG
468	TTGGACTCATAAGGTGGAAAC
469	TCTACAGTACCTATTTAATC
470	TTCCGTCAGAGATCTCCTAGAC
471	TTCCCTCCGTCAAGAGATCTCCT
472	TGTTAACAGGCCTATTGATTGG
473	TGTACTGTTACTTAGAAAGGC
474	AAAACAGTGTTGATTTTGT
475	CCGTCTGCCGTTCCAGCCGACC

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
476	AAGACTGTGTGTTAACGGACTG
477	CCTCTGCCTAATCATCTCTTGT
478	CCTCTGCACGTTGCATGGAGAC
479	TCACAGGGTCCCCAGTCCTCGC
480	CCCCTCCACACGGCGGTGTTT
481	CCCCAGCAGAGAATGGCTTGCC
482	CCCACTGTTGGCTTCAGCTA
483	CCATGTTCGTCACAGGGTCCCC
484	CCAACCTCCAATTATGTAACCC
485	CATCTGCCGGTCCGTGTGCACT
486	CATCCCATCGTCCCTGGGCTTTC
487	CACTCCTCCAGCCTATAGACCA
488	CACCTTATGAGTCCAAGGAATA
489	CAACCCCTCTGGGATTCTTCCC
490	ATGGCTGCTAGGCTGTACTGCC
491	ATCTTCTCTTCATTACAGT
492	ATCCTACCCACACTAAATATT
493	ATCCGTAGGTTTGTACAGCAA
494	ATATAAGAGGAAACCACACGT
495	AGTACAGTCTCTTCCAAAAG
496	AGGGGGATCACCCGTGTCTT
497	AGGATCAACAACAACCAAGTACG
498	AGCCGACCACGGGGCGCACCTC
499	AAGTAAACAGTACATGAACCTT
500	ACTGCCTTCCACCAAGCTCTGC
501	ACCCCATCAAGGACCACTGGCC
502	ACCAAGCTCTGCAGGATCCCAG
503	CGATACAGAGCTGAGGCAGGTGT
504	AATCAATAGGCCTGTTAACAGG
505	AAATTATTACCCACCCAGGTAG
506	CGGGACGTCTTGTACGTC
507	TATTGGTTCTTCTGGATTATCA
508	TATATCTTGCCTTACTTTGGA
509	TAAGATTCAATTACAAGAGGAC
510	GTTCCCAACCCCTGAGGATTCT
511	GTCGTCTCTCGCGGAAATATA

TABLE 1-continued

Sequences	
SEQ ID NO.	Sequence
512	GTCAGAGATCTCCTAGACACCG
513	AAAAGTAAGGCAAGATATATGA
514	GGCCAGGGTTCACCCCTCCACA
515	GGATTAAAGATAGGTACTGTAG
516	GGAACAGTAAACCTGCTCCGA
517	GGAAACTACTGTTGTTAGACGA
518	GCTATATGGATGATGTGGTATT
519	GCGAGAGGACGACAGAATTGTC
520	GCGACGCGCGATTGAGATCTG
521	GATGAGCTTGCTCCAGACCGG
522	GAGTGTGGATTCGCACTCCTCC
23	GAGCAGGGTTTACTGTTCCGTGA
524	GACTTCTTCCTTCAGTCAGAG
525	AAACCAGACATTATTTACATAC
526	AAAGAGTATGTAATAATGTCT
527	CTTTTCATTTACAGTGAGAGGG
528	CTTCACCTCTGCACGTTGCATG
529	CTGCTGGGGGAATTGATGACT
530	CTCTTATATAGAATACCAGCCT
531	CTCAATTCTAGGGGGATCAC
532	CTAAACTTCATGGTTACATAA
533	CGGTGGTCTCCATGCAACGTGC
534	CGATCATCAGTTGGACCTGCA
535	AATTATGTAACCCATGAAGTTT
536	AAGACTGTGTGTTAACGACTG
537	TTTGCAGGAGGACATTATTAAT
538	TCACATTCAATTGCAGGAGGAC
539	TTGAGCAGGAGTCGTGCAGGTC
540	CACTCCTCTGCTTACAGACCA
541	TGTAAATAGACCTATTGATTGG
542	CGATCACCAAGTTGGACCTGCA
543	CTCTTATATAAAATGCCCGCCT
544	GAAACTCCTGTAATAGACCT
545	GACTACTGCCTCTCCCATATCG
546	TCGTCTGCCGTTCCGGCCGACC
547	TTGTACTAGGAGGCTGTAGGCA

[0045] The gRNA is a short RNA nucleotide spacer that defines the genomic target to be modified. As used herein, the term guide RNA (gRNA or sgRNA) refers to a RNA containing a sequence that corresponds and/or hybridizes to a target HBV sequence. The guide RNA sequence can be a sense or anti-sense sequence. A guide RNA can, in some embodiments, include nucleotide sequences other than the region complementary or substantially complementary to a region of a target DNA sequence. For example, in some instances, a guide RNA is part or considered part of a crRNA or an included in a crRNA, e.g., a crRNA: tracrRNA chimera. As used herein, a term target nucleic acid is intended to mean a nucleic acid that is the object of an action (e.g. editing or modulation).

[0046] In some embodiments, the gRNA is a synthetic oligonucleotide. In some embodiments, the synthetic nucleotide comprises a modified nucleotide. Modification of the inter-nucleoside linker (i.e. backbone) can be utilized to increase stability or pharmacodynamic properties. For example, inter-nucleoside linker modifications prevent or reduce degradation by cellular nucleases, thus increasing the pharmacokinetics and bioavailability of the gRNA. Generally, a modified inter-nucleoside linker includes any linker other than other than phosphodiester (PO) linkers, that covalently couples two nucleosides together. In some embodiments, the modified inter-nucleoside linker increases the nuclease resistance of the gRNA compared to a phosphodiester linker. For naturally occurring oligonucleotides, the inter-nucleoside linker includes phosphate groups creating a phosphodiester bond between adjacent nucleosides. In some embodiments, the gRNA comprises one or more inter-nucleoside linkers modified from the natural phosphodiester. In some embodiments, all of the inter-nucleoside linkers of the gRNA, or contiguous nucleotide sequence thereof, are modified. For example, in some embodiments the inter-nucleoside linkage comprises Sulphur (S), such as a phosphorothioate inter-nucleoside linkage.

[0047] Modifications to the ribose sugar or nucleobase can also be utilized herein. Generally, a modified nucleoside includes the introduction of one or more modifications of the sugar moiety or the nucleobase moiety. In some embodiments, the gRNAs, as described, comprise one or more nucleosides comprising a modified sugar moiety, wherein the modified sugar moiety is a modification of the sugar moiety when compared to the ribose sugar moiety found in deoxyribose nucleic acid (DNA) and RNA. Numerous nucleosides with modification of the ribose sugar moiety can be utilized, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or stability. Such modifications include those where the ribose ring structure is modified. These modifications include replacement with a hexose ring (HNA), a bicyclic ring having a biradical bridge between the C2 and C4 carbons on the ribose ring (e.g. locked nucleic acids (LNA)), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids or tricyclic nucleic acids. Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.

[0048] Sugar modifications also include modifications made by altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2'-OH group naturally

found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2', 3', 4' or 5' positions. Nucleosides with modified sugar moieties also include 2' modified nucleosides, such as 2' substituted nucleosides. Indeed, much focus has been spent on developing 2' substituted nucleosides, and numerous 2' substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity. A 2' sugar modified nucleoside is a nucleoside that has a substituent other than H or —OH at the 2' position (2' substituted nucleoside) or comprises a 2' linked biradicle, and includes 2' substituted nucleosides and LNA (2'-4' biradicle bridged) nucleosides. Examples of 2' substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-Fluoro-RNA, and 2'-F-ANA nucleoside. By way of further example, in some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).

[0049] In some embodiments, the gRNA comprises one or more modified sugars. In some embodiments, the gRNA comprises only modified sugars. In certain embodiments, the gRNA comprises greater than 10%, 25%, 50%, 75%, or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar comprises a 2'-O-methoxyethyl group. In some embodiments, the gRNA comprises both inter-nucleoside linker modifications and nucleoside modifications.

[0050] Target specificity can be used in reference to a guide RNA, or a crRNA specific to a target polynucleotide sequence or region and further includes a sequence of nucleotides capable of selectively annealing/hybridizing to a target (sequence or region) of a target polynucleotide (e.g. corresponding to a target), e.g., a target DNA. In some embodiments, a crRNA or the derivative thereof contains a target-specific nucleotide region complementary to a region of the target DNA sequence. In some embodiments, a crRNA or the derivative thereof contains other nucleotide sequences besides a target-specific nucleotide region. In some embodiments, the other nucleotide sequences are from a tracrRNA sequence.

[0051] gRNAs are generally supported by a scaffold, wherein a scaffold refers to the portions of gRNA or crRNA molecules comprising sequences which are substantially identical or are highly conserved across natural biological species (e.g. not conferring target specificity). Scaffolds include the tracrRNA segment and the portion of the crRNA segment other than the polynucleotide-targeting guide sequence at or near 5' end of the crRNA segment, excluding any unnatural portions comprising sequences not conserved in native crRNAs and tracrRNAs. In some embodiments, the crRNA or tracrRNA comprises a modified sequence. In certain embodiments, the crRNA or tracrRNA comprises at least 1, 2, 3, 4, 5, 10, or 15 modified bases (e.g. a modified native base sequence).

[0052] "Complementary," as used herein, generally refers to a polynucleotide that includes a nucleotide sequence capable of selectively annealing to an identifying region of a target polynucleotide under certain conditions. As used herein, the term "substantially complementary" and gram-

matical equivalents is intended to mean a polynucleotide that includes a nucleotide sequence capable of specifically annealing to an identifying region of a target polynucleotide under certain conditions. Annealing refers to the nucleotide base-pairing interaction of one nucleic acid with another nucleic acid that results in the formation of a duplex, triplex, or other higher-ordered structure. The primary interaction is typically nucleotide base specific, e.g., A:T, A:U, and G:C, by Watson-Crick and Hoogsteen-type hydrogen bonding. In some embodiments, base-stacking and hydrophobic interactions can also contribute to duplex stability. Conditions under which a polynucleotide anneals to complementary or substantially complementary regions of target nucleic acids are well known in the art, e.g., as described in Nucleic Acid Hybridization, A Practical Approach, Hames and Higgins, eds., IRL Press, Washington, D.C. (1985) and Wetmur and Davidson, Mol. Biol. 31:349 (1968). Annealing conditions will depend upon the particular application and can be routinely determined by persons skilled in the art, without undue experimentation. Hybridization generally refers to process in which two single-stranded polynucleotides bind non-covalently to form a stable double-stranded polynucleotide. A resulting double-stranded polynucleotide is a "hybrid" or "duplex." In certain instances, 100% sequence identity is not required for hybridization and, in certain embodiments, hybridization occurs at about greater than 70%, 75%, 80%, 85%, 90%, or 95% sequence identity. In certain embodiments, sequence identity includes in addition to non-identical nucleobases, sequences comprising insertions and/or deletions.

[0053] In some embodiments, the gRNA comprises a CRISPR RNA (crRNA): trans activating crRNA (tracrRNA) duplex. In some embodiments, the gRNA comprises a stem-loop that mimics the natural duplex between the crRNA and tracrRNA. In some embodiments, the stem-loop comprises a nucleotide sequence comprising AGAAAU. For example, in some embodiments, the composition comprises a synthetic or chimeric guide RNA comprising a crRNA, stem, and tracrRNA. In some embodiments, the composition comprises an isolated crRNA and/or an isolated tracrRNA which hybridize to form a natural duplex. For example, in some embodiments, the gRNA comprises a crRNA or crRNA precursor (pre-crRNA) comprising a targeting sequence.

[0054] In some embodiments, the gRNA comprises about 15 nucleotides to about 28 nucleotides. In some embodiments, the gRNA comprises at least about 15 nucleotides. In some embodiments, the gRNA comprises at most about 28 nucleotides. In some embodiments, the gRNA comprises about 15 nucleotides to about 16 nucleotides, about 15 nucleotides to about 17 nucleotides, about 15 nucleotides to about 18 nucleotides, about 15 nucleotides to about 19 nucleotides, about 15 nucleotides to about 20 nucleotides, about 15 nucleotides to about 21 nucleotides, about 15 nucleotides to about 22 nucleotides, about 15 nucleotides to about 23 nucleotides, about 15 nucleotides to about 24 nucleotides, about 15 nucleotides to about 25 nucleotides, about 15 nucleotides to about 28 nucleotides, about 16 nucleotides to about 17 nucleotides, about 16 nucleotides to about 18 nucleotides, about 16 nucleotides to about 19 nucleotides, about 16 nucleotides to about 20 nucleotides, about 16 nucleotides to about 21 nucleotides, about 16 nucleotides to about 22 nucleotides, about 16 nucleotides to about 23 nucleotides, about 16 nucleotides to about 24 nucleotides, about 16 nucleotides to about 25 nucleotides, about 16 nucleotides to about 28 nucleotides, or about 25 nucleotides to about 28 nucleotides. In some embodiments, the gRNA comprises about 15 nucleotides, about 17 nucleotides, about 18 nucleotides, about 19 nucleotides, about 20 nucleotides, about 21 nucleotides, about 22 nucleotides, about 23 nucleotides, about 24 nucleotides, about 25 nucleotides, about 26 nucleotides, about 27 nucleotides, or about 28 nucleotides.

nucleotides, about 16 nucleotides to about 25 nucleotides, about 16 nucleotides to about 28 nucleotides, about 17 nucleotides to about 18 nucleotides, about 17 nucleotides to about 19 nucleotides, about 17 nucleotides to about 20 nucleotides, about 17 nucleotides to about 21 nucleotides, about 17 nucleotides to about 22 nucleotides, about 17 nucleotides to about 23 nucleotides, about 17 nucleotides to about 24 nucleotides, about 17 nucleotides to about 25 nucleotides, about 17 nucleotides to about 26 nucleotides, about 17 nucleotides to about 27 nucleotides, about 17 nucleotides to about 28 nucleotides, about 18 nucleotides to about 19 nucleotides, about 18 nucleotides to about 20 nucleotides, about 18 nucleotides to about 21 nucleotides, about 18 nucleotides to about 22 nucleotides, about 18 nucleotides to about 23 nucleotides, about 18 nucleotides to about 24 nucleotides, about 18 nucleotides to about 25 nucleotides, about 18 nucleotides to about 26 nucleotides, about 18 nucleotides to about 27 nucleotides, about 18 nucleotides to about 28 nucleotides, about 19 nucleotides to about 20 nucleotides, about 19 nucleotides to about 21 nucleotides, about 19 nucleotides to about 22 nucleotides, about 19 nucleotides to about 23 nucleotides, about 19 nucleotides to about 24 nucleotides, about 19 nucleotides to about 25 nucleotides, about 19 nucleotides to about 26 nucleotides, about 19 nucleotides to about 27 nucleotides, about 19 nucleotides to about 28 nucleotides, about 20 nucleotides to about 21 nucleotides, about 20 nucleotides to about 22 nucleotides, about 20 nucleotides to about 23 nucleotides, about 20 nucleotides to about 24 nucleotides, about 20 nucleotides to about 25 nucleotides, about 20 nucleotides to about 26 nucleotides, about 20 nucleotides to about 27 nucleotides, about 20 nucleotides to about 28 nucleotides, about 21 nucleotides to about 22 nucleotides, about 21 nucleotides to about 23 nucleotides, about 21 nucleotides to about 24 nucleotides, about 21 nucleotides to about 25 nucleotides, about 21 nucleotides to about 26 nucleotides, about 21 nucleotides to about 27 nucleotides, about 21 nucleotides to about 28 nucleotides, about 22 nucleotides to about 23 nucleotides, about 22 nucleotides to about 24 nucleotides, about 22 nucleotides to about 25 nucleotides, about 22 nucleotides to about 26 nucleotides, about 22 nucleotides to about 27 nucleotides, about 22 nucleotides to about 28 nucleotides, about 23 nucleotides to about 24 nucleotides, about 23 nucleotides to about 25 nucleotides, about 23 nucleotides to about 26 nucleotides, about 23 nucleotides to about 27 nucleotides, about 23 nucleotides to about 28 nucleotides, about 24 nucleotides to about 25 nucleotides, about 24 nucleotides to about 26 nucleotides, about 24 nucleotides to about 27 nucleotides, about 24 nucleotides to about 28 nucleotides, or about 25 nucleotides to about 28 nucleotides. In some embodiments, the gRNA comprises about 15 nucleotides, about 16 nucleotides, about 17 nucleotides, about 18 nucleotides, about 19 nucleotides, about 20 nucleotides, about 21 nucleotides, about 22 nucleotides, about 23 nucleotides, about 24 nucleotides, about 25 nucleotides, or about 26 nucleotides.

[0055] Described herein are gRNAs targeting (e.g. hybridizing or annealing to) a region within a HBV genome. In some embodiments, a gRNA is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof.

[0056] Described herein are gRNAs targeting (e.g. hybridizing or annealing to) a region within a HBV genome. In some embodiments, a gRNA is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In

some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof.

[0057] Described herein are gRNAs targeting (e.g. hybridizing or annealing to) a region within a HBV genome. In some embodiments, a gRNA is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 273-548. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA is encoded by a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof.

[0058] The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.

[0059] The term “homology” or “similarity” between two proteins is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one protein sequence to the second protein sequence. Similarity can be determined by procedures which are well-known in the art, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information).

[0060] In some embodiments, the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease. In other embodiments, the CRISPR-associated endonuclease is Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Case, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, CasX, CasΦ, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966. By way of further example, in some embodiments, the CRISPR-Cas protein is a Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, CasH, Cas7, Cas8, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, Cas9, Cas12 (e.g., Cas12a, Cas12b, Cas12c, Cas12d, Cas12k, Cas12j/CasΦ, Cas12L etc.), Cas13 (e.g., Cas13a, Cas13b (such as Cas13b-t1, Cas13b-t2, Cas13b-t3), Cas13c, Cas13d, etc.), Cas14, CasX, CasY, or an engineered form of the Cas protein. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas9. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas12. In certain embodiments, the Cas12 polypeptide is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas12L or Cas12J. In some embodiments, the CRISPR/Cas protein or endonuclease is CasX. In some embodiments, the CRISPR/Cas protein or endonuclease is CasY. In some embodiments, the CRISPR/Cas protein or endonuclease is CasΦ. In other embodiments, the CRISPR-associated endo-

nuclease is a Cas9 endonuclease. In other embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In other embodiments, the Cas9 endonuclease is a *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus* sp., *Nocardiopsis dassonvillei*, *Streptomyces pristinaespiralis*, *Streptomyces viridochromogenes*, *Streptomyces viridochromogenes*, *Streptosporangium roseum*, *Alicyclobacillus acidocaldarius*, *Bacillus pseudomycoides*, *Bacillus selenitireducens*, *Exiguobacterium sibiricum*, *Lactobacillus delbrueckii*, *Lactobacillus salivarius*, *Microscilla marina*, *Burkholderiales bacterium*, *Polaromonas naphthalenivorans*, *Polaromonas* sp., *Crocospaera watsonii*, *Cyanothece* sp., *Microcystis aeruginosa*, *Synechococcus* sp., *Acetohalobium arabaticum*, *Ammonifex degensii*, *Caldicellulosiruptor beccsii*, *Candidatus Desulfurobacter*, *Clostridium botulinum*, *Clostridium difficile*, *Finegoldia magna*, *Natrananerobius thermophilus*, *Pelotomaculum thermopropionicum*, *Acidithiobacillus caldus*, *Acidithiobacillus ferrooxidans*, *Allochromatium vinosum*, *Marinobacter* sp., *Nitrosococcus halophilus*, *Nitrosococcus watsoni*, *Pseudalteromonas haloplankis*, *Ktedonobacter racemifer*, *Methanohalobium evestigatum*, *Anabaena variabilis*, *Nodularia spumigena*, *Nostoc* sp., *Arthrobacteria maxima*, *Arthrobacteria platensis*, *Arthrobacteria* sp., *Lynghya* sp., *Microcoleus chthonoplastes*, *Oscillatoria* sp., *Petrotoga mobilis*, *Thermosiphon africanus*, or *Acaryochloris marina* Cas9 endonuclease. In some embodiments, the CRISPR-associated endonuclease is a CasX endonuclease. In some embodiments, the CasX endonuclease is a delta proteobacteria CasX or a planctomycetes Cas X endonuclease. In some embodiments, the CasX endonuclease is a delta proteobacteria CasX. In some embodiments, the CasX endonuclease is a planctomycetes Cas X endonuclease.

[0061] Provided herein is a nucleic acid encoding the CRISPR-Cas systems described herein. In some embodiments, the nucleic acid further comprises a 5' ITR element and 3' ITR element. In some embodiments, the nucleic acid is configured to be packaged into an adeno-associated virus (AAV) vector. In some embodiments, the adeno-associated virus (AAV) vector is AAV2, AAV5, AAV6, AAV7, AAV8, or AAV9. In some embodiments, the adeno-associated virus (AAV) vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAVDJ, or AAVDJ/8.

[0062] Further provided are adeno-associated virus (AAV) vectors comprising a nucleic acid described herein. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In some embodiments, the CRISPR-associated endonuclease is a CasX endonuclease. In some embodiments, the CasX endonuclease is a delta proteobacteria CasX or a planctomycetes Cas X endonuclease. In some embodiments, the CasX endonuclease is a delta proteobacteria CasX. In some embodiments, the CasX endonuclease is a planctomycetes Cas X endonuclease. In some embodiments, the AAV vector is an AAV6 vector or an AAV9 vector. In some embodiments, the adeno-associated virus (AAV) vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAVDJ, or AAVDJ/8.

Vectors

[0063] The present disclosure includes a vector comprising one or more cassettes for expression of CRISPR components such as one or more gRNAs and a Cas endonuclease. Described herein, in some embodiments, are vectors comprising a nucleic acid encoding: (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-549 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 273-578. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 273-548. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 273-548 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof. In some embodiments, the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof. In some embodiments, the target nucleic acid sequence is located within a C, X, P, or S region.

[0064] In some embodiments, the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease. In some embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In some embodiments, the CRISPR-associated endonuclease is a CasX endonuclease. In some embodiments, the CasX endonuclease is a *delta proteobacteria* CasX or a *planctomycetes* Cas X endonuclease. In some embodiments, the CasX endonuclease is a *delta proteobacteria* CasX. In some embodiments, the CasX endonuclease is a *planctomycetes* Cas X endonuclease.

[0065] In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, the HBV is HBV-C genotype. In

some embodiments, the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype. In some embodiments, the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype. In some embodiments, the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype. In some embodiments, the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype. In some embodiments, the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype. In some embodiments, the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.

[0066] In some embodiments, the nucleic acid further comprises a promoter. In some embodiments, the promoter is a ubiquitous promoter. In some embodiments, the promoter is a tissue-specific promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a human cytomegalovirus promoter.

[0067] In some embodiments, the nucleic acid further comprises an enhancer element. In some embodiments, the enhancer element is a human cytomegalovirus enhancer element.

[0068] In some embodiments, the nucleic acid further comprises a 5' ITR element and 3' ITR element.

[0069] In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the adeno-associated virus (AAV) vector is AAV2, AAV5, AAV6, AAV7, AAV8, or AAV9. In some embodiments, the vector is an AAV6 vector or an AAV9 vector.

[0070] The vector can be any vector that is known in the art and is suitable for expressing the desired expression cassette. A number of vectors are known or can be designed to be capable of mediating transfer of gene products to mammalian cells, as is known in the art and described herein. In certain aspects, a vector refers to a nucleic acid polynucleotide to be delivered to a host cell, either *in vitro* or *in vivo*. In certain embodiments, the polynucleotide to be delivered comprises a coding sequence of interest in gene therapy (e.g. a Cas protein and gRNA). In some embodiments, a gene editing system are provided on a single vector. In some embodiments, a gene editing system are provided on a two or more vectors. In some embodiments, gene editing systems are provided by one or more vectors comprising an isolated nucleic acid encoding one or more elements of a gene editing system. In some embodiments, the CRISPR-Cas or SAM editing systems are provided by one or more vectors comprising an isolated nucleic acid encoding one or more elements of a CRISPR-Cas or SAM editing system. For example, in some embodiments, the composition comprises an isolated nucleic acid encoding a Cas protein and at least one guide nucleic acid (e.g., gRNA). In some embodiments, the composition comprises an isolated nucleic acid encoding a Cas9 protein, or functional fragment or derivative thereof. In some embodiments, the composition comprises at least one isolated nucleic acid encoding a Cas9 protein described elsewhere herein, or a functional fragment or derivative thereof. In some embodiments, the composition comprises at least one isolated nucleic acid encoding a Cas9 protein having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence homology with a Cas9 protein described elsewhere herein. In some embodiments, the composition comprises an isolated nucleic acid encoding a CasX protein, or functional fragment or derivative thereof. In some embodiments, the composition comprises at least one isolated nucleic acid

encoding a CasX protein described elsewhere herein, or a functional fragment or derivative thereof. In some embodiments, the composition comprises at least one isolated nucleic acid encoding a CasX protein having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence homology with a CasX protein described elsewhere herein. In certain embodiments, the isolated nucleic acid comprises any type of nucleic acid, including, but not limited to DNA and RNA. For example, in some embodiments, the composition comprises an isolated DNA molecule, including for example, an isolated cDNA molecule, encoding a gRNA or protein of the described CRISPR-Cas systems or compositions, or functional fragment thereof. In some embodiments, the composition comprises an isolated RNA molecule encoding a protein of the described CRISPR-Cas systems or compositions, or a functional fragment thereof. In certain embodiments, the isolated nucleic acids are synthesized using any method known in the art.

[0071] In some instances, the expression of natural or synthetic nucleic acids encoding a RNA and/or peptide is typically achieved by operably linking a nucleic acid encoding the RNA and/or peptide or portions thereof to a promoter and incorporating the construct into an expression vector. The vectors to be used are suitable for replication and, optionally, integration in eukaryotic cells. Typical vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.

[0072] In some embodiments, the vectors of the present disclosure are also used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. In another embodiment, the disclosure provides a gene therapy vector.

[0073] The isolated nucleic acid of the disclosed can be cloned into a number of types of vectors. For example, the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

[0074] Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. In some embodiments, the vector also includes conventional control elements which are operably linked to the transgene in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector or infected with the virus comprising a nucleic acid comprising the described CRISPR-Cas systems or compositions. As used herein, "operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. A great number of expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and can be utilized.

[0075] Typically, promoter elements (e.g., enhancers) are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.

[0076] The selection of appropriate promoters can readily be accomplished. In certain aspects, one would use a high expression promoter. One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. In certain embodiments, the Rous sarcoma virus (RSV) and MMT promoters are also be used. Certain proteins can be expressed using their native promoter. Other elements that can enhance expression can also be included such as an enhancer or a system that results in high levels of expression such as a tat gene and tar element. This cassette can then be inserted into a vector, e.g., a plasmid vector such as, pUC19, pUC118, pBR322, or other known plasmid vectors, that includes, for example, an *E. coli* origin of replication.

[0077] Another example of a suitable promoter is Elongation Growth Factor-1 α (EF-1 α). However, in some embodiments, other constitutive promoter sequences are used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the disclosed should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the disclosed. The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

[0078] Enhancer sequences found on a vector also regulates expression of the gene contained therein. Typically, enhancers are bound with protein factors to enhance the transcription of a gene. In some instances, enhancers are located upstream or downstream of the gene it regulates. In some instances, enhancers are also tissue-specific to enhance transcription in a specific cell or tissue type. In some embodiments, the vector of the present disclosure comprises one or more enhancers to boost transcription of the gene present within the vector. In some instances, the expression of the nucleic acid and/or protein, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identi-

fication and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other embodiments, the selectable marker is carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes can be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like.

[0079] Provided herein, in certain embodiments, are nucleic acids that encode any of the CRISPR-Cas systems described herein. For example, provided are vectors comprising a nucleic acid encoding: (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the target nucleic acid sequence comprises a sequence, the sequence comprising at least about 70%, 80%, 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-549 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 273-548. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 273-548. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 273-548 comprising 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof.

[0080] In some embodiments, the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease. In other embodiments, the CRISPR-associated endonuclease is Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, CasΦf, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, CasX, CasΦ, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966. By way of further example, in some embodiments, the CRISPR-Cas protein is a Cas1, Cas1B, Cas2, Cas3,

Cas4, Cas5, Cash, Cas7, Cas8, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, Cas9, Cas12 (e.g., Cas12a, Cas12b, Cas12c, Cas12d, Cas12k, Cas12j/CasΦ, Cas12L etc.), Cas13 (e.g., Cas13a, Cas13b (such as Cas13b-t1, Cas13b-t2, Cas13b-t3), Cas13c, Cas13d, etc.), Cas14, CasX, CasY, or an engineered form of the Cas protein. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas9. In some embodiments, the CRISPR/Cas protein or endonuclease is Cas12. In certain embodiments, the Cas12 polypeptide is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas12L or Cas12J. In some embodiments, the CRISPR/Cas protein or endonuclease is CasX. In some embodiments, the CRISPR/Cas protein or endonuclease is CasY. In some embodiments, the CRISPR/Cas protein or endonuclease is CasΦ. In other embodiments, the CRISPR-associated endonuclease is a Cas9 endonuclease. In other embodiments, the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease. In other embodiments, the Cas9 endonuclease is a *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus* sp., *Nocardiopsis dassonvillei*, *Streptomyces pristinaespiralis*, *Streptomyces viridochromogenes*, *Streptomyces viridochromogenes*, *Streptosporangium roseum*, *Alicyclobacillus acidocaldarius*, *Bacillus pseudomiyceoides*, *Bacillus selenitireducens*, *Exiguobacterium sibiricum*, *Lactobacillus delbrueckii*, *Lactobacillus salivarius*, *Microscilla marina*, *Burkholderiales bacterium*, *Polaromonas naphthalenivorans*, *Polaromonas* sp., *Crocospaera watsonii*, *Cyanothecae* sp., *Microcystis aeruginosa*, *Synechococcus* sp., *Acetohalobium arabaticum*, *Ammonifex degensii*, *Caldicelulosiruptor beccsii*, *Candidatus Desulforudis*, *Clostridium botulinum*, *Clostridium difficile*, *Fine goldia magna*, *Natranaerobius thermophilus*, *Pelotomaculum thermopropionicum*, *Acidithiobacillus caldus*, *Acidithiobacillus ferrooxidans*, *Allochromatium vinosum*, *Marinobacter* sp., *Nitrosococcus halophilus*, *Nitrosococcus watsoni*, *Pseudoalteromonas haloplanktis*, *Ktedonobacter racemifer*, *Methanohalobium evestigatum*, *Anabaena variabilis*, *Nodularia spumigena*, *Nostoc* sp., *Arthospira maxima*, *Arthospira platensis*, *Arthospira* sp., *Lyngbya* sp., *Microcoleus chthonoplastes*, *Oscillatoria* sp., *Petrotoga mobilis*, *Thermosiphon africanus*, or *Acaryochloris marina* Cas9 endonuclease. In some embodiments, the CRISPR-associated endonuclease is a CasX endonuclease. In some embodiments, the CasX endonuclease is a delta-proteobacteria CasX or a planctomycetes Cas X endonuclease. In some embodiments, the CasX endonuclease is a delta-proteobacteria CasX. In some embodiments, the CasX endonuclease is a planctomycetes Cas X endonuclease.

[0081] In some embodiments, the nucleic acid further comprises a promoter. In some embodiments, the promoter is a ubiquitous promoter. In some embodiments, the promoter is a tissue-specific promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a human cytomegalovirus promoter. In some embodiments, the nucleic acid further comprises an enhancer element. In some embodiments, the enhancer element is a human cytomegalovirus enhancer element. In some embodiments, the nucleic acid further comprises a 5' ITR element and 3' ITR element.

[0082] In some embodiments, the adeno-associated virus (AAV) vector comprises an AAV2, AAV5, AAV6, AAV7,

AAV8, or AAV9 capsid protein. In some embodiments, the adeno-associated virus (AAV) vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAVDJ, or AAVDJ/8 capsid protein. In some embodiments, the nucleic acid comprising at least about 80, 85, 90, or 95% sequence identity to SEQ ID NO: 14. In some embodiments, the AAV vector is an AAV6 vector or an AAV9 vector.

[0083] Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means.

[0084] Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art (see, for example, Sambrook et al. (2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection.

[0085] Regardless of the method used to introduce exogenous nucleic acids into a host cell, in order to confirm the presence of the recombinant nucleic acid sequence in the host cell, a variety of assays can be performed. Such assays include, for example, “molecular biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular protein, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the disclosure.

[0086] In some embodiments, a vector is provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, include but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. As described herein, a suitable vector generally contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers.

[0087] Viral methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, are useful for inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged in retroviral vectors using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either *in vivo* or *ex vivo*. A number of retroviral systems are known in the art. In some embodiments, adenovirus vectors are used. A number of adenovirus vectors are known in the

art. In some embodiments, lentivirus vectors are used. In another embodiment, non-AAV vectors are used, including integrating viruses, e.g., herpesvirus or lentivirus, although other viruses are selected. Suitably, where one of these other vectors is generated, it is produced as a replication-defective viral vector. In certain instances, replication-defective virus or viral vector refers to a synthetic or artificial viral particle in which an expression cassette containing a gene of interest is packaged in a viral capsid or envelope, where any viral genomic sequences also packaged within the viral capsid or envelope are replication-deficient; i.e., they cannot generate progeny virions but retain the ability to infect target cells. In some embodiments, the genome of the viral vector does not include genes encoding the enzymes required to replicate (the genome can be engineered to be “gutless”—containing only the transgene of interest flanked by the signals required for amplification and packaging of the artificial genome), but these genes can be supplied during production.

[0088] For example, vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity.

[0089] Further provided are nucleic acids encoding the CRISPR-Cas systems described herein. Provided herein are adeno-associated virus (AAV) vectors comprising nucleic acids encoding the CRISPR-Cas systems described herein. In certain instances, an AAV vector includes to any vector that comprises or derives from components of AAV and is suitable to infect mammalian cells, including human cells, of any of a number of tissue types, such as brain, heart, lung, skeletal muscle, liver, kidney, spleen, or pancreas, whether *in vitro* or *in vivo*. In certain instances, an AAV vector includes an AAV type viral particle (or virion) comprising a nucleic acid encoding a protein of interest (e.g. CRISPR-Cas systems described herein). In some embodiments, as further described herein, the AAVs disclosed herein are be derived from various serotypes, including combinations of serotypes (e.g., “pseudotyped” AAV) or from various genomes (e.g., single-stranded or self-complementary). In some embodiments, the AAV vector is a human serotype AAV vector. In such embodiments, a human serotype AAV is derived from any known serotype, e.g., from AAV1, AAV2, AAV4, AAV6, or AAV9. In some embodiments, the serotype is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAVDJ, or AAVDJ/8.

[0090] In some embodiments, the composition includes a vector derived from an adeno-associated virus (AAV). AAV vectors possess a number of features that render them ideally suited for gene therapy, including a lack of pathogenicity, minimal immunogenicity, and the ability to transduce post-mitotic cells in a stable and efficient manner. Expression of a particular gene contained within an AAV vector can be specifically targeted to one or more types of cells by choosing the appropriate combination of AAV serotype, promoter, and delivery method.

[0091] A variety of different AAV capsids have been described and can be used, although AAV which preferentially target the liver and/or deliver genes with high efficiency are particularly desired. The sequences of the AAV8

are available from a variety of databases. While the examples utilize AAV vectors having the same capsid, the capsid of the gene editing vector and the AAV targeting vector are the same AAV capsid. Another suitable AAV is, e.g., rh10 (WO 2003/042397). Still other AAV sources include, e.g., AAV9 (see, for example, U.S. Pat. No. 7,906,111; US 2011-0236353-A1), and/or hu37 (see, e.g., U.S. Pat. No. 7,906,111; US 2011-0236353-A1), AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV7, AAV8, (U.S. Pat. Nos. 7,790,449; 7,282,199, WO 2003/042397; WO 2005/033321, WO 2006/110689; U.S. Pat. Nos. 7,790,449; 7,282,199; 7,588,772). Still other AAV can be selected, optionally taking into consideration tissue preferences of the selected AAV capsid.

[0092] In some embodiments, AAV vectors disclosed herein include a nucleic acid encoding a CRISPR-Cas systems described herein. In some embodiments, the nucleic acid also includes one or more regulatory sequences allowing expression and, in some embodiments, secretion of the protein of interest, such as e.g., a promoter, enhancer, polyadenylation signal, an internal ribosome entry site ("IRES"), a sequence encoding a protein transduction domain ("PTD"), and the like. Thus, in some embodiments, the nucleic acid comprises a promoter region operably linked to the coding sequence to cause or improve expression of the protein of interest in infected cells. Such a promoter can be ubiquitous, cell- or tissue-specific, strong, weak, regulated, chimeric, etc., for example, to allow efficient and stable production of the protein in the infected tissue. In certain embodiments, the promoter is homologous to the encoded protein, or heterologous, although generally promoters of use in the disclosed methods are functional in human cells. Examples of regulated promoters include, without limitation, Tet on/off element-containing promoters, rapamycin-inducible promoters, tamoxifen-inducible promoters, and metallothionein promoters. In certain embodiments, other promoters used include promoters that are tissue specific for tissues such as kidney, spleen, and pancreas. Examples of ubiquitous promoters include viral promoters, particularly the CMV promoter, the RSV promoter, the SV40 promoter, etc., and cellular promoters such as the phosphoglycerate kinase (PGK) promoter and the b-actin promoter.

[0093] In some embodiments, the recombinant AAV vector comprises packaged within an AAV capsid, a nucleic acid, generally containing a 5' AAV ITR, the expression cassettes described herein and a 3' AAV ITR. As described herein, in some embodiments, an expression cassette contains regulatory elements for an open reading frame(s) within each expression cassette and the nucleic acid optionally contains additional regulatory elements. The AAV vector, in some embodiments, comprises a full-length AAV 5' inverted terminal repeat (ITR) and a full-length 3' ITR. A shortened version of 5' ITR, termed ΔITR, has been described in which the D-sequence and terminal resolution site (trs) are deleted. The abbreviation "sc" refers to self-complementary. "Self-complementary AAV" refers a construct in which a coding region carried by a recombinant AAV nucleic acid sequence has been designed to form an intra-molecular double-stranded DNA template. Upon infection, rather than waiting for cell mediated synthesis of the second strand, the two complementary halves of scAAV will associate to form one double stranded DNA (dsDNA) unit that is ready for immediate replication and transcription (see,

for example, D M McCarty et al, "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis", Gene Therapy, (August 2001); see also, for example, U.S. Pat. Nos. 6,596,535; 7,125,717; and 7,456,683). Where a pseudotyped AAV is to be produced, the ITRs are selected from a source which differs from the AAV source of the capsid. For example, in some embodiments, AAV2 ITRs are selected for use with an AAV capsid having a particular efficiency for a selected cellular receptor, target tissue or viral target. In some embodiments, the ITR sequences from AAV2, or the deleted version thereof (ΔITR), are used for convenience and to accelerate regulatory approval (i.e. pseudotyped). In some embodiments, a single-stranded AAV viral vector is used.

[0094] Methods for generating and isolating AAV viral vectors suitable for delivery to a subject are known in the art (see, for example, U.S. Pat. Nos. 7,790,449; 7,282,199; WO 2003/042397; WO 2005/033321, WO 2006/110689; and U.S. Pat. No. 7,588,772 B2, U.S. Pat. Nos. 5,139,941; 5,741,683; 6,057,152; 6,204,059; 6,268,213; 6,491,907; 6,660,514; 6,951,753; 7,094,604; 7,172,893; 7,201,898; 7,229,823; and 7,439,065). In one system, a producer cell line is transiently transfected with a construct that encodes the transgene flanked by ITRs and a construct(s) that encodes rep and cap. In a second system, a packaging cell line that stably supplies rep and cap is transfected (transiently or stably) with a construct encoding the transgene flanked by ITRs. In each of these systems, AAV virions are produced in response to infection with helper adenovirus or herpesvirus, requiring the separation of the rAAVs from contaminating virus. More recently, systems have been developed that do not require infection with helper virus to recover the AAV—the required helper functions (i.e., adenovirus E1, E2a, VA, and E4 or herpesvirus UL5, UL8, UL52, and UL29, and herpesvirus polymerase) are also supplied, in trans, by the system. In these newer systems, the helper functions can be supplied by transient transfection of the cells with constructs that encode the required helper functions, or the cells can be engineered to stably contain genes encoding the helper functions, the expression of which can be controlled at the transcriptional or posttranscriptional level. In yet another system, the transgene flanked by ITRs and rep/cap genes are introduced into insect cells by infection with baculovirus-based vectors.

[0095] The CRISPR-Cas systems, for instance a Cas9 or CasX, and/or any of the present RNAs, for instance a guide RNA, can be delivered using adeno associated virus (AAV), lentivirus, adenovirus or other viral vector types, or combinations thereof. Cas9 or CasX and one or more guide RNAs can be packaged into one or more viral vectors. In some embodiments, the viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while other times the viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery can be either via a single dose, or multiple doses. One skilled in the art understands that the actual dosage to be delivered herein can vary greatly depending upon a variety of factors, such as the vector chose, the target cell, organism, or tissue, the general condition of the subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transformation/modification sought, etc.

[0096] Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, nanoparticles, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

[0097] In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo). In another aspect, the nucleic acid can be associated with a lipid. The nucleic acid associated with a lipid is can be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they can be present in a bilayer structure, as micelles, or with a "collapsed" structure. They can also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which can be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

[0098] The compositions described herein are suitable for use in a variety of vector systems described above. Additionally, in order to enhance the in vivo serum half-life of the administered compound, the compositions can be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques can be employed which provide an extended serum half-life of the compositions (see, for example, Szoka, et al., U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028). Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma, St. Louis, Mo.; dicetyl phosphate ("DCP") can be obtained from K & K Laboratories (Plainview, N.Y.); cholesterol ("Choi") can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol ("DMPG") and other lipids can be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20° C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. "Liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes

between the lipid bilayers (Ghosh et al., 1991 *Glycobiology* 5: 505-10). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids can assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.

Methods of Treatment

[0099] The gene editing systems provided herein are useful for methods of modifying and/or editing a HBV genome in the genome of a cell (e.g. host cell). In some embodiments, the gene editing systems (e.g., CRISPR-Cas) are designed to target a nucleic acid sequence in a HBV genome. In some embodiments, the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof. In some embodiments, the target nucleic acid sequence is located within a C, X, P, or S region.

[0100] In some embodiments, the HBV is HBV-A genotype. In some embodiments, the HBV is HBV-B genotype. In some embodiments, HBV-C genotype. In some embodiments, the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype. In some embodiments, the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype. In some embodiments, the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype. In some embodiments, the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype. In some embodiments, the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype. In some embodiments, the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.

[0101] Described herein, in some embodiments, are methods of modifying and/or editing a HBV genome in the genome of a cell (e.g. host cell) comprising administering compositions comprising (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5. In some embodiments, the target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 70%, 75%, 80%, 85%, 90%, or 95% identity to any one of SEQ ID NOs: 2-5. In some embodiments, the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-549. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-549 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 6-272. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272. In some embodiments, a

gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOS: 6-272 comprising 1, 2, or 3 modifications. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOS: 273-548. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOS: 273-548. In some embodiments, a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOS: 273-548sing 1, 2, or 3 modifications. In some embodiments, the modification is a substitution, deletion, insertion, or a combination thereof.

[0102] Provided herein, in certain embodiments, are methods of modifying and/or editing a HBV genome in the genome of a cell (e.g. host cell) using the CRISPR-Cas systems or compositions described herein. Generally, of modifying and/or editing a HBV DNA molecule (e.g. the HBV genome) in the genome of a cell (e.g. host cell) comprises contacting a cell, or providing to the cell, a CRISPR-Cas system or composition comprising one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOS: 2-5. In certain instances, modulating or editing a HBV genome comprises removing and/or excising a polynucleotide sequence and/or region of the genome. In certain instances, modulating and editing comprises removing and/or excising a polynucleotide sequence and/or region sufficient to ablate or prevent the HBV genome from yielding a functional HBV gene product and/or a competent HBV virus (e.g. a functional HBV virus capable of replication in a host cell).

[0103] In some embodiments, the CRISPR-Cas system is encoded by a nucleic acid (e.g. a vector) and the cell is provided with the nucleic acid (e.g. via infection or transfection). In some embodiments, the nucleic acid is packaged in a viral vector.

[0104] In some embodiments, the cell is in a subject. In some specific embodiments, the subject is a human. In other specific embodiments, the subject is a non-human mammal. In other specific embodiments, the subject is any host that HBV may infect. In some embodiments, the HBV sequence is integrated into the cell. In some embodiments, the HBV sequence is in cytosol of the cell.

[0105] The methods disclosed herein further encompass, in some embodiments, administering a CRISPR-Cas system or composition. In certain instances, the pharmaceutical compositions comprising a CRISPR-Cas system or composition, as described herein, is administered. In certain instances, data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compositions lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. In some embodiments, the dosage varies within this range depending upon the dosage form employed and the route of administration utilized. For any composition used in the method of the described CRISPR-Cas systems or compositions, therapeutically effective dose can be estimated initially from cell culture assays. In certain embodiments, a dose is formulated in animal models to achieve a circulating plasma concen-

tration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0106] The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, the severity of the disease, the identity (e.g., weight) of the subject or host in need of treatment, but can nevertheless be routinely determined in a manner known in the art according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, and the subject or host being treated. In certain instances, therapeutically effective amount and effective amount of a compound refer to an amount sufficient to provide a therapeutic benefit in the treatment, prevention and/or management of a disease, to delay or minimize one or more symptoms associated with the disease or disorder to be treated. In certain instances, therapeutically effective amount and effective amount encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or disorder, or enhances therapeutic efficacy of another therapeutic agent. In some embodiments, the desired dose(s) is (are) conveniently be presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.

[0107] In some embodiments, the cell is genetically modified in vivo in the subject in whom therapy is intended. In certain aspects, for in vivo, delivery the nucleic acid is injected directly into the subject. For example, In some embodiments, the nucleic acid is delivered at the site where the composition is required. In vivo nucleic acid transfer techniques include, but is not limited to, transfection with viral vectors such as adenovirus, Herpes simplex I virus, adeno-associated virus), lipid-based systems (useful lipids for lipid-mediated transfer of the gene are DOTMA, DOPE and DC-Chol, for example), naked DNA, and transposon-based expression systems. Exemplary gene therapy protocols see Anderson et al., *Science* 256:808-813 (1992). See also WO 93/25673 and the references cited therein. In some embodiments, the method comprises administering of RNA, for example mRNA, directly into the subject (see for example, Zangi et al., 2013 *Nature Biotechnology*, 31: 898-907).

[0108] For ex vivo treatment, an isolated cell is modified in an ex vivo or in vitro environment. In some embodiments, the cell is autologous to a subject to whom therapy is intended. Alternatively, the cell can be allogeneic, syngeneic, or xenogeneic with respect to the subject. The modified cells can then be administered to the subject directly.

[0109] One skilled in the art recognizes that different methods of delivery can be utilized to administer an isolated nucleic acid into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein the nucleic acid or vector is complexed to another entity, such as a liposome, aggregated protein or transporter molecule.

[0110] The amount of vector to be added per cell will likely vary with the length and stability of therapeutic gene inserted in the vector, as well as also the nature of the

sequence, and is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present disclosure (for instance, the cost associated with synthesis). One skilled in the art can easily make any necessary adjustments in accordance with the exigencies of the particular situation.

Methods for Guide Identification

[0111] Referring to FIG. 1 is an exemplary flowchart of a method for selecting a guide RNA comprising a target sequence 105. In some embodiments, a target sequence comprises a nucleotide sequence for selecting a guide RNA. In some cases, the target sequence comprises at least 5, 10, 15, 20, 25, 30, 35, or 40 nucleotides. In some cases, the target sequence comprises about 5, 10, 15, 20, 25, 30, 35, or 40 nucleotides. In some embodiments, the target sequences comprise a reference sequence. In some embodiments, the target sequence comprises a single natural or computed sequence. In some embodiments, the target sequence is a single natural sequence. In some embodiments, the target sequence is a single computed sequence. In some embodiments, the target sequence is generated by aligning a plurality of sequences. In some cases, the plurality of sequences comprises at least 5, 20, 50, 80, 100, 200, 400, 500, 800, or 1000 sequences. In some cases, the plurality of sequences comprises about 5, 20, 50, 80, 100, 200, 400, 500, 800, or 1000 sequences. In some embodiments, the consensus sequence generated from the plurality of sequences is a non-naturally occurring sequence. In some embodiments, the consensus sequence comprises ambiguity (e.g., different nucleotides at each position). In some embodiments, the consensus sequence comprises at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more than 60% ambiguity. In some embodiments, the consensus sequence comprises less than about 5%, 10%, 15%, 20%, 25%, 30%, or more than 30% difference as compared to the naturally occurring sequence.

[0112] In some embodiments, the target sequence (e.g., a reference sequence or a plurality of sequences) is found in a data storage system (e.g., database), such as those described herein. In some embodiments, the data storage system comprises a centralized system. In some embodiments, the data storage system comprises a decentralized system. In some embodiments, the data storage system comprises a cloud-based storage system (e.g., iCloud, AWS, Dropbox, Google Drive, OneDrive, etc.). In some cases, the cloud-based storage system is a private cloud storage, a public cloud storage, a hybrid cloud storage, or a community cloud storage system.

[0113] In some cases, the target sequence is generated by aligning a plurality of sequences. In some cases, the plurality of sequence is aligned through a computer program (e.g., Clustal Omega). In some instances, the target sequence is a consensus sequence determined by aligning the plurality of sequences. In some examples, the consensus sequence is determined by aligning sequences with common geographies, pathologies, other attributes, or combinations thereof. In some cases, the consensus is determined by comparing nucleotides at each position of the plurality of sequences and selecting a nucleotide at each position that appears at a frequency higher than other nucleotides. In some embodiments, the target sequence is a consensus sequence generated by a module configured to align the plurality of sequences. In some cases, the module is further configured

to compare nucleotides at each position of the plurality of sequences; and select a nucleotide at each position that appears at a frequency higher than other nucleotides. In some examples, any one of A, T, G, and C appear at a higher frequency than the other three nucleotides at a given position in the plurality of sequences.

[0114] In some embodiments, the plurality of sequences aligned to generate the target sequence is a plurality of viral sequences. In some cases, the plurality of viral sequences are sequences from a single virus. In some cases, the plurality of viral sequences are sequences from different viruses. In some instances, the plurality of viral sequences are sequences within a same genotype of a virus. In some instances, the plurality of viral sequences are sequences within different genotypes of a virus. In some examples, the plurality of viral sequences are sequences within different subclades of a virus. In some examples, the plurality of viral sequences are sequences within a same subclade of a virus.

[0115] In some embodiments, a virus comprises Hepatitis B virus (HBV), Human Immunodeficiency virus (HIV), JC virus (JCV), herpes simplex virus (HSV), or SARS-CoV-2. In some cases, the virus is Hepatitis B virus (HBV) and the genotype is HBV-A. In some cases, the virus is Hepatitis B virus (HBV) and the genotype is HBV-B. In some cases, the virus is Hepatitis B virus (HBV) and the genotype is HBV-C. In some cases, the virus is Hepatitis B virus (HBV) and the different genotypes comprise HBV-A, HBV-B, HBV-C, or combinations thereof. In some cases, the virus is Hepatitis B virus (HBV) and different genotypes comprise HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof. In some cases, the virus is Hepatitis B virus (HBV) and various subclades within HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof.

[0116] In some instances, the subclade within HBV-A comprises HBV-A1, HBV-A2, HBV-QS-A3, HBV-A4, or combinations thereof. In some instances, the subclade within HBV-B comprises HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, HBV-B5, or combinations thereof. In some instances, the subclade within HBV-C comprises HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, HBV-C6-C15, or combinations thereof. In some instances, the subclade within HBV-D comprises HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, HBV-D6, or combinations thereof. In some instances, the subclade within HBV-F comprises HBV-F1, HBV-F2, HBV-F3, HBV-F4, or combinations thereof.

[0117] In some embodiments, HBV genotypes and subgenotypes/subclades in populations differ between geographic regions. As an example, the subclades in North America include HBV-A2, HBV-D2, HBV-B5, HBV-B4, and HBV-G. As an example, the subclades in Central America include HBV-A2, HBV-F1, HBV-H, HBV-G, HBV-B2, HBV-F3, HBV-C1, and HBV-F4. As an example, the subclades in Caribbean include HBV-A1, HBV-QS-A3, HBV-D4, HBV-A2, and HBV-D3. As an example, the subclades in South America include HBV-F1, HBV-F4, HBV-D3, HBV-F3, HBV-F2, HBV-A1, HBV-A2, and HBV-D2. As an example, the subclades in Northern Europe include HBV-D2, HBV-A2, HBV-D3, and HBV-E. As an example, the subclades in Southern Europe include HBV-D3, HBV-D2, HBV-D1, and HBV-A2. As an example, the subclades in Western Europe include HBV-A2, HBV-D1, HBV-D2, HBV-D3, and HBV-E. As an example, the subclades in Eastern Europe include HBV-D2, HBV-A2, HBV-D1, and

HBV-D3. As an example, the subclades in Northern Africa include HBV-D1, HBV-E, HBV-D6, HBV-D2, and HBV-D3. As an example, the subclades in Western Africa include HBV-E and HBV-A2. As an example, the subclades in Middle Africa include HBV-E, and HBV-QS-A3. As an example, the subclades in Eastern Africa include HBV-A1, HBV-D2, and HBV-E. As an example, the subclades in Southern Africa include HBV-A1, HBV-D3, HBV-E, and HBV-A2. As an example, the subclades in Western Asia include HBV-D1 and HBV-D2. As an example, the subclades in Southern Asia include HBV-D1, HBV-D3, HBV-D2, HBV-A1, HBV-C1, and HBV-D5. As an example, the subclades in Central Asia include HBV-D1, HBV-D2, HBV-QS-C2, and HBV-A2. As an example, the subclades in Eastern Asia include HBV-QS-C2, HBV-B2, HBV-C1, HBV-QS-B3, and HBV-C6-C15. As an example, the subclades in Southeastern Asia include HBV-C1, HBV-B2, HBV-QS-B3, HBV-B4, and HBV-QS-C2. As an example, the subclades in Melanesia include HBV-D2, HBV-C3, and HBV-C6-C15. As an example, the subclades in Polynesia include HBV-C3. As an example, the subclades in Australia and New Zealand include HBV-D1, HBV-C4, HBV-C3, and HBV-D4. In some embodiments, the most frequently observed subclades for various geographic regions, in decreasing order, comprise, for North America: HBV-A2>HBV-D2>HBV-B5>HBV-B4>HBV-G; for Central America: HBV-A2>HBV-F1>HBV-H>HBV-G>HBV-B2>HBV-F3>HBV-C1>HBV-F4; for Caribbean: HBV-A1>HBV-QS-A3>HBV-D4>HBV-A2>D3; for South America: HBV-F1>HBV-F4>HBV-D3>HBV-F3>HBV-F2>HBV-A1>HBV-A2>HBV-D2; for Northern Europe: HBV-D2>HBV-A2>HBV-D3>HBV-E; for Southern Europe: HBV-D3>HBV-D2>HBV-D1>HBV-A2; for Western Europe: HBV-A2>HBV-D1>HBV-D2>HBV-D3>HBV-E; for Eastern Europe: HBV-D2>HBV-A2>HBV-D1>HBV-D3; for Northern Africa: HBV-D1>HBV-E>HBV-D6>HBV-D2>HBV-D3; for Western Africa: HBV-E>HBV-A2; for Middle Africa: HBV-E>HBV-QS-A3; for Eastern Africa: HBV-A1>HBV-D2>HBV-E; for Southern Africa: HBV-A1>HBV-D3>HBV-E>HBV-A2, for Western Asia: HBV-D1>HBV-D2, for Southern Asia: HBV-D1>HBV-D3>HBV-D2>HBV-A1>HBV-C1>HBV-D5; for Central Asia: HBV-D1>HBV-D2>HBV-QS-C2>HBV-A2; for Eastern Asia: HBV-QS-C2>HBV-B2>HBV-C1>HBV-QS-B3>HBV-C6-C15; Southeastern Asia: HBV-C1>HBV-B2>HBV-QS-B3>B4>HBV-QS-C2; Melanesia: HBV-D2>HBV-C3>HBV-C6-C15; Polynesia: HBV-C3; and for Australia and New Zealand: HBV-D1>HBV-C4>HBV-C3>HBV-D4.

Identifying a Targeting Site

[0118] In some embodiments, a target sequence (e.g., consensus sequence) is provided and one or more targeting sites that can be recognized by a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a CRISPR-associated protein (e.g., targeting site adjacent or proximal to PAMs) are determined within the target sequence **110**. In some embodiments, the presence of a targeting site (e.g., targeting site adjacent or proximal to PAMs) is indicative of a cut prediction by a nuclease (e.g., zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a CRISPR-associated protein) within the target sequence. In some cases, the targeting site (e.g., targeting site adjacent or proximal to PAMs) is approximately 5, 10, 15, 20, 25, or 30

nucleotides downstream of a sequence targeted by a guide RNA. In some cases, the targeting site is approximately 2, 3, 4, 5, or 6 nucleotides downstream of a sequence targeted by a guide RNA (e.g., PAM). In some cases, the targeting site is approximately 5, 10, 15, 20, 25, or 30 nucleotides upstream of a sequence targeted by a guide RNA (e.g., PAM). In some cases, the targeting site is approximately 2, 3, 4, 5, or 6 nucleotides upstream of where the target sequence is cut by a nuclease. In some instances, the nuclease comprises a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a CRISPR-associated protein (e.g., Cas). In some instances, the nuclease comprises a CRISPR-associated protein (e.g., Cas). In some embodiments, the one or more target sites are determined with one or more modules (e.g., a target site identifier). In some embodiments, the one or more PAMs are determined with one or more modules (e.g., a PAM identifier). In some cases, the one or more modules are communicably coupled to a data storage system (e.g., a database) comprising a target sequence, such as those described herein.

[0119] In some embodiments, the targeting site is a site in the target sequence to which a programmable DNA-binding domain (pDBD) binds. In some embodiments, the one or more targeting sites comprise one or more pDBD binding sites in the target sequence. In some embodiments, such one or more pDBD binding sites are located at different positions and orientations relative to the nuclease target site (e.g., targeting site adjacent or proximal to PAMs). In some embodiments, the one or more targeting sites comprise one or more pDBD binding sites and one or more PAMs. As an example, for a given genotype, a corresponding target sequence (e.g., a consensus sequence) is scanned through to compile all candidate guide RNAs that include a PAM sequence (e.g., SaCas9 PAM sequence). In some embodiments, to compile guide RNAs targeting the (+) strand of the cccDNA, 30-basepair (bp) DNA sequences composed of a 24-bp protospacer and 5'-NNGRRT-3' PAM sequences are selected. In some further embodiments, to compile guide RNAs targeting the (-) strand of the cccDNA, 30-bp DNA sequences composed of 5'-AYYCNN-3' PAM sequence and a 24-bp protospacer are selected. In some instances, candidate guide RNAs with '-' in protospacer is eliminated for downstream analysis afterwards.

[0120] In some instances, during a PAM finding step, the protospacers and PAM sequence are selected based on a downstream analysis. As an example, a 24-bp protospacer with 6-bp PAM sequence is selected if the downstream analysis comprises an on-target knockout scoring with Azimuth 2.0 algorithm, which requires a 30-bp input sequence. In some examples, downstream in silico evaluation processes are measuring only the 20-bp protospacer of interest with a 6-bp PAM sequence.

[0121] In some embodiments, one or more guide target sequences are identified that are in proximity to the one or more target sites (e.g., targeting site adjacent or proximal to PAMs) **115**. In some cases, the one or more modules are further configured to identify the one or more guide target sequences in proximity to the one or more target sites (e.g., targeting site adjacent or proximal to PAMs). In some instances, the one or more modules comprises a proximity identifier. In some cases, the one or more guide target sequences comprises a guide RNA candidate.

[0122] As used herein, “proximity” or “proximal” refers to a distance within 5, 10, 15, 20, 25, 30, 35, or 40 nucleotides or base pairs (bps). In some embodiments, “proximity” or “proximal” refers to a distance of 5, 10, 15, 20, 25, 30, 35, or 40 nucleotides or bps upstream or downstream of a position or sequence (e.g., a targeting site). In some embodiments, “proximity” or “proximal” refers to a distance of 5, 10, 15, 20, 25, 30, 35, or 40 nucleotides or bps upstream or downstream of a targeting site. In some embodiments, “proximity” or “proximal” refers to a distance of 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides or bps upstream or downstream of a position or sequence (e.g., a targeting site). In some embodiments, “proximity” or “proximal” refers to a distance of 2, 3, 4, 5, or 6 nucleotides or bps upstream or downstream of a position or sequence (e.g., a targeting site). In some embodiments, “proximity” or “proximal” refers to a distance of 3 or 4 nucleotides or bps upstream or downstream of a position or sequence (e.g., a targeting site).

[0123] In some embodiments, in silico evaluation of a guide RNA’s likelihood of an on-target cleavage is assessed using a position-specific penalty matrix comprising mismatches across the protospacer. In some cases, protospacers proximal to the target site sequence is more deleterious than those distal to the target site (e.g., targeting site adjacent or proximal to PAMs). In some instances, penalty scores are assigned to mismatches within the PAM sequence (e.g., SaCas9 PAM sequence). An exemplary algorithm to compute a set of mismatch scores for each guide RNA comprises:

- [0124] a. for each viral sequence of a given genotype (e.g., HBV genotype), find the best match of this guide RNA (e.g., shortest Levenshtein distance);
- [0125] b. apply an additive penalty function across all guide RNA-target pairs in the ungapped sequence to compute individual guide RNA mismatch scores (e.g., score 0 indicates a perfect match);
- [0126] c. summarize the distribution of mismatch scores for each guide RNA into bins (e.g., five bins, six bins, seven bins, etc.);
- [0127] d. use the mismatch scores to eliminate candidate guide RNAs with low probabilities of target site cleavage.

[0128] In some cases, the pseudocode for in silico evaluation of a guide RNAs’ likelihood of on-target cleavage based on the algorithm above comprises:

```

1 position-specific penalty vector = [penalty1, penalty2, ..., penalty26]
2 for each guide RNA i:
3   for each viral DNA sequence j of a given genotype in a data storage system:
4     for each position k of the (RNA, DNA) pair:
5       if RNAk matches DNAk: penalty1 = 0
6       else: penalty1 = penalty vector [k]
7       calculate mismatch scoreij = penalty1 + penalty2 + ... + penalty26
8       mismatch score vector for RNA i = [mmsi,1, mmsi,2, ..., mmsi,3000+]
9       plot distribution of all mismatch scores for RNA i
10      summarize the distribution of mismatch scores for RNA i with 6 probabilities for
11      6 bins:
12      probabilities = [Pmms - 0, P0 < mms < - 1, P0 < mms < - 2, P0 < mms < - 3, P0 < mms < - 5, P0 < mms < - 10, Pmms >
13      10]
14      eliminate guide RNAs with low probabilities of target site cleavage

```

[0129] In some embodiments, the one or more guide RNA (gRNA) candidates generated from the target sequence are about 15 nucleotides to about 28 nucleotides. In some embodiments, the gRNA comprises at least about 15 nucleo-

tides. In some embodiments, the gRNA comprises at most about 28 nucleotides. In some embodiments, the gRNA comprises about 15 nucleotides to about 16 nucleotides, about 15 nucleotides to about 17 nucleotides, about 15 nucleotides to about 18 nucleotides, about 15 nucleotides to about 19 nucleotides, about 15 nucleotides to about 20 nucleotides, about 15 nucleotides to about 21 nucleotides, about 15 nucleotides to about 22 nucleotides, about 15 nucleotides to about 23 nucleotides, about 15 nucleotides to about 24 nucleotides, about 15 nucleotides to about 25 nucleotides, about 15 nucleotides to about 26 nucleotides, about 16 nucleotides to about 17 nucleotides, about 16 nucleotides to about 18 nucleotides, about 16 nucleotides to about 19 nucleotides, about 16 nucleotides to about 20 nucleotides, about 16 nucleotides to about 21 nucleotides, about 16 nucleotides to about 22 nucleotides, about 16 nucleotides to about 23 nucleotides, about 16 nucleotides to about 24 nucleotides, about 16 nucleotides to about 25 nucleotides, about 16 nucleotides to about 26 nucleotides, about 17 nucleotides to about 18 nucleotides, about 17 nucleotides to about 19 nucleotides, about 17 nucleotides to about 20 nucleotides, about 17 nucleotides to about 21 nucleotides, about 17 nucleotides to about 22 nucleotides, about 17 nucleotides to about 23 nucleotides, about 17 nucleotides to about 24 nucleotides, about 17 nucleotides to about 25 nucleotides, about 17 nucleotides to about 26 nucleotides, about 18 nucleotides to about 19 nucleotides, about 18 nucleotides to about 20 nucleotides, about 18 nucleotides to about 21 nucleotides, about 18 nucleotides to about 22 nucleotides, about 18 nucleotides to about 23 nucleotides, about 18 nucleotides to about 24 nucleotides, about 18 nucleotides to about 25 nucleotides, about 18 nucleotides to about 26 nucleotides, about 19 nucleotides to about 20 nucleotides, about 19 nucleotides to about 21 nucleotides, about 19 nucleotides to about 22 nucleotides, about 19 nucleotides to about 23 nucleotides, about 19 nucleotides to about 24 nucleotides, about 19 nucleotides to about 25 nucleotides, about 19 nucleotides to about 26 nucleotides, about 20 nucleotides to about 21 nucleotides, about 20 nucleotides to about 22 nucleotides, about 20 nucleotides to about 23 nucleotides, about 20 nucleotides to about 24 nucleotides, about 20 nucleotides to about 25 nucleotides, about 20 nucleotides to about 26 nucleotides, about 21 nucleotides to about 22 nucleotides, about 21 nucleotides to about 23 nucleotides, about 21 nucleotides to about 24 nucleotides, about 21 nucleotides to about 25 nucleotides, about 21 nucleotides to about 26 nucleotides, about 22 nucleotides to about 23 nucleotides, about 22 nucleotides to about 24 nucleotides, about 22 nucleotides to about 25 nucleotides, about 22 nucleotides to about 26 nucleotides, about 23 nucleotides to about 24 nucleotides, about 23 nucleotides to about 25 nucleotides, about 23 nucleotides to about 26 nucleotides, about 24 nucleotides to about 25 nucleotides, about 24 nucleotides to about 26 nucleotides, about 25 nucleotides to about 26 nucleotides, about 26 nucleotides to about 27 nucleotides, about 26 nucleotides to about 28 nucleotides, about 27 nucleotides to about 28 nucleotides, about 27 nucleotides to about 29 nucleotides, about 27 nucleotides to about 30 nucleotides, about 28 nucleotides to about 29 nucleotides, about 28 nucleotides to about 30 nucleotides, about 29 nucleotides to about 30 nucleotides.

about 24 nucleotides, about 21 nucleotides to about 25 nucleotides, about 21 nucleotides to about 28 nucleotides, about 22 nucleotides to about 23 nucleotides, about 22 nucleotides to about 24 nucleotides, about 22 nucleotides to

about 25 nucleotides, about 22 nucleotides to about 28 nucleotides, about 23 nucleotides to about 24 nucleotides, about 23 nucleotides to about 25 nucleotides, about 23 nucleotides to about 28 nucleotides, about 24 nucleotides to about 25 nucleotides, about 24 nucleotides to about 28 nucleotides, or about 25 nucleotides to about 28 nucleotides. In some embodiments, the gRNA comprises about 15 nucleotides, about 16 nucleotides, about 17 nucleotides, about 18 nucleotides, about 19 nucleotides, about 20 nucleotides, about 21 nucleotides, about 22 nucleotides, about 23 nucleotides, about 24 nucleotides, about 25 nucleotides, or about 28 nucleotides.

[0130] In some embodiments, the guide RNA candidate is compared against the consensus sequence or the plurality of sequences. In some embodiments, the guide RNA candidate is compared against a sequence of a viral strain different from the plurality of sequences. In further embodiments, the guide RNA candidate is compared against a sequence of a human genome different from the plurality of sequence.

[0131] In some cases, the guide RNA candidate hybridizes to a section of the target sequence (e.g., consensus sequence). In some cases, the guide RNA candidate is complementary sequence to a section of the target sequence. In some embodiments, the target sequence has about 2000 nucleotides to about 4200 nucleotides. In some embodiments, the gRNA comprises at least about 2000 nucleotides. In some embodiments, the gRNA comprises at most about 4000 nucleotides. In some embodiments, the gRNA comprises about 2000 nucleotides to about 2200 nucleotides, about 2000 nucleotides to about 2400 nucleotides, about 2000 nucleotides to about 2600 nucleotides, about 2000 nucleotides to about 2800 nucleotides, about 2000 nucleotides to about 3000 nucleotides, about 2000 nucleotides to about 3200 nucleotides, about 2000 nucleotides to about 3400 nucleotides, about 2000 nucleotides to about 3600 nucleotides, about 2000 nucleotides to about 3800 nucleotides, about 2000 nucleotides to about 4000 nucleotides, about 2000 nucleotides to about 4200 nucleotides, about 2200 nucleotides to about 2400 nucleotides, about 2200 nucleotides to about 2600 nucleotides, about 2200 nucleotides to about 2800 nucleotides, about 2200 nucleotides to about 3000 nucleotides, about 2200 nucleotides to about 3200 nucleotides, about 2200 nucleotides to about 3400 nucleotides, about 2200 nucleotides to about 3600 nucleotides, about 2200 nucleotides to about 3800 nucleotides, about 2200 nucleotides to about 4000 nucleotides, about 2200 nucleotides to about 4200 nucleotides, about 2400 nucleotides to about 2600 nucleotides, about 2400 nucleotides to about 2800 nucleotides, about 2400 nucleotides to about 3000 nucleotides, about 2400 nucleotides to about 3200 nucleotides, about 2400 nucleotides to about 3400 nucleotides, about 2400 nucleotides to about 3600 nucleotides, about 2400 nucleotides to about 3800 nucleotides, about 2400 nucleotides to about 4000 nucleotides, about 2400 nucleotides to about 4200 nucleotides, about 2600 nucleotides to about 2800 nucleotides, about 2600 nucleotides to about 3000 nucleotides, about 2600 nucleotides to about 3200 nucleotides, about 2600 nucleotides to about 3400 nucleotides, about 2600 nucleotides to about 3600 nucleotides, about 2600 nucleotides to about 3800 nucleotides, about 2600 nucleotides to about 4000 nucleotides, about 2600 nucleotides to about 4200 nucleotides, about 2800 nucleotides to about 3000 nucleotides, about 2800 nucleotides to about 3200 nucleotides, about 2800 nucleotides to about 3400 nucleotides, about 2800 nucleotides to about 3600 nucleotides, about 2800 nucleotides to about 3800 nucleotides, about 2800 nucleotides to about 4000 nucleotides, about 2800 nucleotides to about 4200 nucleotides, about 3000 nucleotides to about 3200 nucleotides, about 3000 nucleotides to about 3400 nucleotides, about 3000 nucleotides to about 3600 nucleotides, about 3000 nucleotides to about 3800 nucleotides, about 3000 nucleotides to about 4000 nucleotides, about 3000 nucleotides to about 4200 nucleotides, about 3200 nucleotides to about 3400 nucleotides, about 3200 nucleotides to about 3600 nucleotides, about 3200 nucleotides to about 3800 nucleotides, about 3200 nucleotides to about 4000 nucleotides, about 3200 nucleotides to about 4200 nucleotides, about 3400 nucleotides to about 3600 nucleotides, about 3400 nucleotides to about 3800 nucleotides, about 3400 nucleotides to about 4000 nucleotides, about 3400 nucleotides to about 4200 nucleotides, about 3600 nucleotides to about 3800 nucleotides, about 3600 nucleotides to about 4000 nucleotides, about 3600 nucleotides to about 4200 nucleotides, about 3800 nucleotides to about 4000 nucleotides, about 3800 nucleotides to about 4200 nucleotides, or about 4000 nucleotides to about 4200 nucleotides. In some embodiments, the gRNA comprises about 2000 nucleotides, about 2200 nucleotides, about 2400 nucleotides, about 2600 nucleotides, about 2800 nucleotides, about 3000 nucleotides, about 3200 nucleotides, about 3400 nucleotides, about 3600 nucleotides, about 3800 nucleotides, about 4000 nucleotides, or about 4200 nucleotides.

tides to about 3400 nucleotides, about 2800 nucleotides to about 3600 nucleotides, about 2800 nucleotides to about 3800 nucleotides, about 2800 nucleotides to about 4000 nucleotides, about 2800 nucleotides to about 4200 nucleotides, about 3000 nucleotides to about 3200 nucleotides, about 3000 nucleotides to about 3400 nucleotides, about 3000 nucleotides to about 3600 nucleotides, about 3000 nucleotides to about 3800 nucleotides, about 3000 nucleotides to about 4000 nucleotides, about 3000 nucleotides to about 4200 nucleotides, about 3200 nucleotides to about 3400 nucleotides, about 3200 nucleotides to about 3600 nucleotides, about 3200 nucleotides to about 3800 nucleotides, about 3200 nucleotides to about 4000 nucleotides, about 3200 nucleotides to about 4200 nucleotides, about 3400 nucleotides to about 3600 nucleotides, about 3400 nucleotides to about 3800 nucleotides, about 3400 nucleotides to about 4000 nucleotides, about 3400 nucleotides to about 4200 nucleotides, about 3600 nucleotides to about 3800 nucleotides, about 3600 nucleotides to about 4000 nucleotides, about 3600 nucleotides to about 4200 nucleotides, about 3800 nucleotides to about 4000 nucleotides, about 3800 nucleotides to about 4200 nucleotides, or about 4000 nucleotides to about 4200 nucleotides. In some embodiments, the gRNA comprises about 2000 nucleotides, about 2200 nucleotides, about 2400 nucleotides, about 2600 nucleotides, about 2800 nucleotides, about 3000 nucleotides, about 3200 nucleotides, about 3400 nucleotides, about 3600 nucleotides, about 3800 nucleotides, about 4000 nucleotides, or about 4200 nucleotides.

[0132] In some embodiments, the target sequence (e.g., consensus sequence) comprises at least about 70%, 75%, 80%, 85%, 90% or 95% sequence identity to any one of SEQ ID NOs: 2-5 of Table 1. In some embodiments, the guide RNA candidate is encoded by a sequence according to any one of SEQ ID NOs: 6-290 of Table 1. In some embodiments, the guide RNA candidate is encoded by a sequence according to any one of SEQ ID NOs: 6-14 of Table 1. In some embodiments, the guide RNA candidate is encoded by a sequence according to any one of SEQ ID NOs: 15-290 of Table 1.

Criteria for Selecting a Guide RNA

[0133] In some embodiments, one or more criteria are calculated based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequence. In some cases, the one or more criteria are used to calculate a score for the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences 120, as exemplary illustrated in FIG. 1. In some embodiments, the one or more criteria are used to select a guide sequence of interest from the one or more guide target sequences. In some embodiments, the one or more criteria are used to select a guide RNA from the candidate guide RNAs. In some embodiments, the guide RNA candidate is selected based on a score 125.

[0134] In some embodiments, the one or more criteria are user-supplied criteria. In some embodiments, the one or more criteria are based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a PAM site, or combinations thereof. In some cases, the positional entropy comprises Shannon entropy. In some instances, a

positional frequency matrix is generated from sequence alignments described herein. In some cases, the positional frequency matrix illustrates the contribution of different nucleotides or combinations (e.g., “A”, “T”, “C”, “G”, “N”, “-”, etc.) in each position of the sequence alignments. For each position, positional Shannon entropy is calculated based on the positional frequency matrix, for example, according to the equation:

$$\text{Entropy} = - \sum_{i=A,T,G,C} (p_i * \log_2(p_i))$$

$$p_i = \frac{f_i + 1}{(\sum_{i=A,T,G,C} f_i) + 1}$$

[0135] where f_i is the frequency of a given nucleotide i for a given position. In some embodiments, an average Shannon entropy is computed as a moving average of at least a 10, 15, 20, 25, or 30-nt window. In some embodiments, an average Shannon entropy is computed as a moving average of about a 10, 15, 20, 25, or 30-nt window. In some embodiments, an average Shannon entropy is computed as a moving average of a 26-nt window.

[0136] In some cases, the knockout score is an on-target knockout score. In some cases, the on-target knockout score is determined by efficiency of cleavage. In some cases, the efficiency of cleavage is based at least in part in the one or more PAMs. In some instances, the on-target knockout score is determined using an algorithm (e.g., Azimuth 2.0). In some cases, the knockout score is an off-target knockout score. In some instances, the off-target knockout score is determined using an algorithm (e.g., COSMID, python script, Cas-OFFinder). In some embodiments, the one or more modules comprise a criteria analysis module configured to calculate the one or more criteria described herein. In some cases, the criteria analysis module comprises an algorithm described herein (e.g., Azimuth 2.0, COSMID, python script, Cas-OFFinder, etc.).

[0137] In some embodiments, the one or more criteria, such as those described herein, are used to select a guide RNA. In some cases, the guide RNA is referred to as a candidate guide RNA. In some instances, the guide RNA is selected based on a score, such as those described herein. In some cases, the guide RNA candidate is selected by a user. In some cases, the guide RNA candidate is selected by a module configured to analyze the one or more criteria and select the guide RNA candidate based on the one or more criteria. In some cases, the guide RNA candidate is a clinical candidate.

Computer Systems

[0138] In an aspect, the present disclosure provides computer systems that are programmed or otherwise configured to implement methods of the disclosure, e.g., any of the subject methods for medical imaging. FIG. 2 shows a computer system 201 that is programmed or otherwise configured to implement a method for selecting a guide RNA. In some embodiments, the computer system 201 is configured to, for example, (i) identify one or more target sites (e.g., targeting site adjacent or proximal to PAMs) in the target sequence (e.g., consensus sequence), (ii) identify

one or more guide target sequences in proximity to the one or more target sites (e.g., targeting site adjacent or proximal to PAMs), and (iii) calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequence. In some embodiments, the computer system 201 is an electronic device of a user or a computer system that is remotely located with respect to the electronic device. In some embodiments, the electronic device is a mobile electronic device.

[0139] In some embodiments, the computer system 201 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 205. In some embodiments, the CPU is a single core or multi core processor, or a plurality of processors for parallel processing. In some embodiments, the computer system 201 also includes memory or memory location 210 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 215 (e.g., hard disk), communication interface 220 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 225, such as cache, other memory, data storage and/or electronic display adapters. The memory 210, storage unit 215, interface 220 and peripheral devices 225 are in communication with the CPU 205 through a communication bus (solid lines), such as a motherboard. In some embodiments, the storage unit 215 is a data storage unit (or data repository) for storing data. In some embodiments, the computer system 201 is operatively coupled to a computer network (“network”) 230 with the aid of the communication interface 220. In some embodiments, the network 230 is the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. In some embodiments, the network 230 in some cases is a telecommunication and/or data network. In some embodiments, the network 230 includes one or more computer servers, which enable distributed computing, such as cloud computing. In some embodiments, the network 230, in some cases with the aid of the computer system 201, implements a peer-to-peer network, which enables devices coupled to the computer system 201 to behave as a client or a server.

[0140] In some embodiments, the CPU 205 executes a sequence of machine-readable instructions. In some embodiments, the sequence of machine-readable instructions are embodied in a program or software. In some embodiments, the instructions are stored in a memory location, such as the memory 210. In some embodiments, the instructions are directed to the CPU 205, which subsequently program or otherwise configure the CPU 205 to implement methods of the present disclosure. Examples of operations performed by the CPU 205 include fetch, decode, execute, and writeback.

[0141] In some embodiments, the CPU 205 is part of a circuit, such as an integrated circuit. In some embodiments, one or more other components of the system 201 are included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).

[0142] In some embodiments, the storage unit 215 stores files, such as drivers, libraries and saved programs. In some embodiments, the storage unit 215 stores user data, e.g., user preferences and user programs. In some embodiments, the computer system 201 in some cases includes one or more additional data storage units that are located external to the

computer system 201 (e.g., on a remote server that is in communication with the computer system 201 through an intranet or the Internet).

[0143] In some embodiments, the computer system 201 communicates with one or more remote computer systems through the network 230. In some embodiments, the computer system 201 communicates with a remote computer system of a user (e.g., a subject, an end user, a consumer, a healthcare provider, an imaging technician, etc.). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Gala2 Tab), telephones, Smart phones (e.g., Apple® iphone, Android-enabled device, Blackberry®,) or personal digital assistants. In some embodiments, the user accesses the computer system 201 via the network 230.

[0144] In some embodiments, methods as described herein are implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 201, such as, for example, on the memory 210 or electronic storage unit 215. In some embodiments, the machine executable or machine readable code is provided in the form of software. In some embodiments, during use, the code is executed by the processor 205. In some cases, the code is retrieved from the storage unit 215 and stored on the memory 210 for ready access by the processor 205. In some situations, the electronic storage unit 215 is precluded, and machine-executable instructions are stored on memory 210.

[0145] In some embodiments, the code is pre-compiled and configured for use with a machine having a processor adapted to execute the code, or is compiled during runtime. In some embodiments, the code is supplied in a programming language that is selected to enable the code to execute in a pre-compiled or as-compiled fashion.

[0146] In some embodiments, aspects of the systems and methods provided herein, such as the computer system 201, is embodied in programming. Various aspects of the technology are thought of as "products" or "articles of manufacture" typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium. In some embodiments, machine-executable code is stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. In some embodiments, "storage" type media includes any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like. In some embodiments, the "storage" type media provides non-transitory storage at any time for the software programming. In some embodiments, all or portions of the software are at times communicated through the Internet or various other telecommunication networks. In some embodiments, such communications, for example, enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. In some embodiments, thus, another type of media that bears the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. In some embodiments, the physical elements that carry such waves, such as wired or wireless links, optical links or the like, also

are considered as media bearing the software. In some embodiments, as used herein, unless restricted to non-transitory, tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.

[0147] In some embodiments, hence, a machine readable medium, such as computer-executable code, takes many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. In some embodiments, non-volatile storage media including, for example, optical or magnetic disks, or any storage devices in any computer(s) or the like, is used to implement the databases, etc. shown in the drawings. In some embodiments, volatile storage media include dynamic memory, such as main memory of such a computer platform. In some embodiments, tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. In some embodiments, carrier-wave transmission media takes the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer reads programming code and/or data. In some embodiments, many of these forms of computer readable media are involved in carrying one or more sequences of one or more instructions to a processor for execution.

[0148] In some embodiments, the computer system 201 includes or is in communication with an electronic display 235 that comprises a user interface (UI) 240 for providing, for example, a portal for a user to view a plurality of sequences or select a guide RNA candidate. In some embodiments, the portal is provided through an application programming interface (API). In some embodiments, a user or entity also interacts with various elements in the portal via the UI. Examples of UI's include, without limitation, a graphical user interface (GUI) and web-based user interface.

[0149] In some embodiments, methods and systems of the present disclosure are implemented by way of one or more algorithms. In some embodiments, an algorithm is implemented by way of software upon execution by the central processing unit 205. In some embodiments, for example, the algorithm is configured to identify one or more PAMS in the target sequence (e.g., consensus sequence), identify one or more guide target sequences in proximity to the one or more PAMs, and/or calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequence. In some embodiments, an algorithm is also configured align a plurality of sequences, as described herein.

[0150] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the disclosure be limited by the specific examples provided

within the specification. While the disclosure has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. Furthermore, it shall be understood that all aspects of the disclosure are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is therefore contemplated that the disclosure shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

NUMBERED EMBODIMENTS

- [0151] 1. A composition comprising:
- [0152] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and
- [0153] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0154] 2. The composition of embodiment 1, wherein the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5.
- [0155] 3. The composition of embodiment 1 or 2, wherein a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272 or a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications.
- [0156] 4. The composition of embodiment 3, wherein the modification is a substitution, deletion, insertion, or a combination thereof.
- [0157] 5. The composition of any one of embodiments 1-4, wherein a gRNA comprises a region that hybridizes to a target nucleic acid sequence within the HBV genome, the HBV comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0158] 6. The composition of any one of embodiments 1-5, wherein the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof.
- [0159] 7. The composition of any one of embodiments 1-5, wherein the target nucleic acid sequence is located within a C, X, P, or S region.
- [0160] 8. The composition of any one of embodiments 1-7, wherein the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease.
- [0161] 9. The composition of any one of embodiments 1-7, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease.
- [0162] 10. The composition of any one of embodiments 1-7, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease.
- [0163] 11. The composition of embodiment 10, wherein the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease.
- [0164] 12. The composition of any one of embodiments 1-11, wherein the HBV is HBV-A genotype.
- [0165] 13. The composition of any one of embodiments 1-11, wherein the HBV is HBV-B genotype.
- [0166] 14. The composition of any one of embodiments 1-11, wherein the HBV is HBV-C genotype.
- [0167] 15. The composition of any one of embodiments 1-11, wherein the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype.
- [0168] 16. The composition of any one of embodiments 1-11, wherein the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype.
- [0169] 17. The composition of any one of embodiments 1-11, wherein the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype.
- [0170] 18. The composition of any one of embodiments 1-11, wherein the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype.
- [0171] 19. The composition of any one of embodiments 1-11, wherein the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype.
- [0172] 20. The composition of any one of embodiments 1-11, wherein the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.
- [0173] 21. A CRISPR-Cas system comprising:
- [0174] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and
- [0175] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0176] 22. A nucleic acid encoding the CRISPR-Cas system of embodiment 21.
- [0177] 23. A vector comprising a nucleic acid encoding:
- [0178] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and
- [0179] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0180] 24. The vector of embodiment 23, wherein the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5.
- [0181] 25. The vector of any one of the preceding embodiments, wherein a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 6-272 or a sequence according to any one of SEQ ID NOs: 6-272 comprising 1, 2, or 3 modifications.

- [0182] 26. The vector of embodiment 25, wherein the modification is a substitution, deletion, insertion, or a combination thereof.
- [0183] 27. The vector of any one of the preceding embodiments, wherein a gRNA comprises a region that hybridizes to a target nucleic acid sequence within the HBV genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0184] 28. The vector of any one of the preceding embodiments, wherein the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof.
- [0185] 29. The vector of any one of the preceding embodiments, wherein the target nucleic acid sequence is located within a C, X, P, or S region.
- [0186] 30. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease.
- [0187] 31. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease.
- [0188] 32. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease.
- [0189] 33. The vector of embodiment 32, wherein the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease.
- [0190] 34. The vector of any one of the preceding embodiments, wherein, wherein the HBV is HBV-A genotype.
- [0191] 35. The vector of any one of the preceding embodiments, wherein the HBV is HBV-B genotype.
- [0192] 36. The vector of any one of the preceding embodiments, wherein the HBV is HBV-C genotype.
- [0193] 37. The vector of any one of the preceding embodiments, wherein the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype.
- [0194] 38. The vector of any one of the preceding embodiments, wherein the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype.
- [0195] 39. The vector of any one of the preceding embodiments, wherein the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype.
- [0196] 40. The vector of any one of the preceding embodiments, wherein the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype.
- [0197] 41. The vector of any one of the preceding embodiments, wherein the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype.
- [0198] 42. The vector of any one of the preceding embodiments, wherein the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.
- [0199] 43. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises a promoter.
- [0200] 44. The vector of embodiment 43, wherein the promoter is a ubiquitous promoter.
- [0201] 45. The vector of embodiment 43, wherein the promoter is a tissue-specific promoter.
- [0202] 46. The vector of embodiment 43, wherein the promoter is a constitutive promoter.
- [0203] 47. The vector of embodiment 43, wherein the promoter is a human cytomegalovirus promoter.
- [0204] 48. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises an enhancer element.
- [0205] 49. The vector of embodiment 48, wherein the enhancer element is a human cytomegalovirus enhancer element.
- [0206] 50. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises a 5' ITR element and 3' ITR element.
- [0207] 51. The vector of any one of the preceding embodiments, wherein the vector is an adeno-associated virus (AAV) vector.
- [0208] 52. The vector of embodiment 51, wherein the adeno-associated virus (AAV) vector is an AAV2, AAV5, AAV6, AAV7, AAV8, or AAV9 vector.
- [0209] 53. The vector of embodiment 51, wherein the vector is an AAV6 vector or an AAV9 vector.
- [0210] 54. A method of excising part or all of a Hepatitis B Virus (HBV) sequence from a cell, the method comprising providing to the cell the composition of any one of embodiments 1-14, the CRISPR-Cas system of embodiment 21, or the vector of any one of the preceding embodiments.
- [0211] 55. A method of inhibiting or reducing Hepatitis B Virus (HBV) replication in a cell, the method comprising providing to the cell the composition of any one of embodiments 1-14, the CRISPR-Cas system of embodiment 21, or the vector of any one of the preceding embodiments.
- [0212] 56. The method of embodiment 54 or 55, wherein the cell is in a subject.
- [0213] 57. The method of embodiment 57, wherein the subject is a human.
- [0214] 58. A composition comprising:
- [0215] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and
- [0216] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0217] 59. The composition of embodiment 58, wherein the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5.
- [0218] 60. The composition of embodiment 58 or 59, wherein a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 272-548 sequence according to any one of SEQ ID NOs: 272-548 comprising 1, 2, or 3 modifications.
- [0219] 61. The composition of embodiment 60, wherein the modification is a substitution, deletion, insertion, or a combination thereof.
- [0220] 62. The composition of any one of embodiments 58-61, wherein a gRNA comprises a region that hybridizes to a target nucleic acid sequence within the HBV

- genome, the HBV comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0221] 63. The composition of any one of embodiments 58-62, wherein the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof.
- [0222] 64. The composition of any one of embodiments 58-62, wherein the target nucleic acid sequence is located within a C, X, P, or S region.
- [0223] 65. The composition of any one of embodiments 58-64, wherein the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease.
- [0224] 66. The composition of any one of embodiments 58-64, wherein the CRISPR-associated endonuclease is a CasX endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease.
- [0225] 67. The composition of any one of embodiments 58-64, wherein the CRISPR-associated endonuclease is a CasX endonuclease.
- [0226] 68. The composition of embodiment 67, wherein the CasX endonuclease is a delta-proteobacteria CasX or planctomycetes CasX endonuclease.
- [0227] 69. The composition of embodiment 68, the CasX endonuclease is a delta-proteobacteria CasX endonuclease.
- [0228] 70. The composition of embodiment 68, the CasX endonuclease is a planctomycetes CasX endonuclease.
- [0229] 71. The composition of any one of embodiments 58-70, wherein the HBV is HBV-A genotype.
- [0230] 72. The composition of any one of embodiments 58-70, wherein the HBV is HBV-B genotype.
- [0231] 73. The composition of any one of embodiments 58-70, wherein the HBV is HBV-C genotype.
- [0232] 74. The composition of any one of embodiments 58-70, wherein the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype.
- [0233] 75. The composition of any one of embodiments 58-70, wherein the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype.
- [0234] 76. The composition of any one of embodiments 58-70, wherein the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype.
- [0235] 77. The composition of any one of embodiments 58-70, wherein the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype.
- [0236] 78. The composition of any one of embodiments 58-70, wherein the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype.
- [0237] 79. The composition of any one of embodiments 58-70, wherein the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.
- [0238] 80. A CRISPR-Cas system comprising:
- [0239] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and
- [0240] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.

- [0241] 81. A nucleic acid encoding the CRISPR-Cas system of embodiment 21.
- [0242] 82. A vector comprising a nucleic acid encoding:
- [0243] (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease; and
- [0244] (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0245] 83. The vector of embodiment 82, wherein the HBV genome comprises a sequence of any one of SEQ ID NOs: 2-5.
- [0246] 84. The vector of any one of the preceding embodiments, wherein a gRNA of the one or more gRNAs is encoded by a sequence according to any one of SEQ ID NOs: 272-548 or a sequence according to any one of SEQ ID NOs: 272-548 comprising 1, 2, or 3 modifications.
- [0247] 85. The vector of embodiment 84, wherein the modification is a substitution, deletion, insertion, or a combination thereof.
- [0248] 86. The vector of any one of the preceding embodiments, wherein a gRNA comprises a region that hybridizes to a target nucleic acid sequence within the HBV genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0249] 87. The vector of any one of the preceding embodiments, wherein the target nucleic acid sequence is located within a structural gene, non-structural gene, or combinations thereof.
- [0250] 88. The vector of any one of the preceding embodiments, wherein the target nucleic acid sequence is located within a C, X, P, or S region.
- [0251] 89. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is Type I, Type II, or Type III Cas endonuclease.
- [0252] 90. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease, a Cas12 endonuclease, a CasX endonuclease, or a CasΦ endonuclease.
- [0253] 91. The vector of any one of the preceding embodiments, wherein the CRISPR-associated endonuclease is a Cas9 endonuclease.
- [0254] 92. The vector of embodiment 91, wherein the Cas9 endonuclease is a *Staphylococcus aureus* Cas9 endonuclease.
- [0255] 93. The vector of any one of the preceding embodiments, wherein the HBV is HBV-A genotype.
- [0256] 94. The vector of any one of the preceding embodiments, wherein the HBV is HBV-B genotype.
- [0257] 95. The vector of any one of the preceding embodiments, wherein the HBV is HBV-C genotype.
- [0258] 96. The vector of any one of the preceding embodiments, wherein the HBV is HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, or HBV-H genotype.

- [0259] 97. The vector of any one of the preceding embodiments, wherein the HBV is HBV-A1, HBV-A2, HBV-QS-A3, or HBV-A4 genotype.
- [0260] 98. The vector of any one of the preceding embodiments, wherein the HBV is HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, or HBV-B5 genotype.
- [0261] 99. The vector of any one of the preceding embodiments, wherein the HBV is HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, or HBV-C6-C15 genotype.
- [0262] 100. The vector of any one of the preceding embodiments, wherein the HBV is HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, or HBV-D6 genotype.
- [0263] 101. The vector of any one of the preceding embodiments, wherein the HBV is HBV-F1, HBV-F2, HBV-F3, or HBV-F4 genotype.
- [0264] 102. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises a promoter.
- [0265] 103. The vector of embodiment 102, wherein the promoter is a ubiquitous promoter.
- [0266] 104. The vector of embodiment 102, wherein the promoter is a tissue-specific promoter.
- [0267] 105. The vector of embodiment 102, wherein the promoter is a constitutive promoter.
- [0268] 106. The vector of embodiment 102, wherein the promoter is a human cytomegalovirus promoter.
- [0269] 107. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises an enhancer element.
- [0270] 108. The vector of embodiment 107, wherein the enhancer element is a human cytomegalovirus enhancer element.
- [0271] 109. The vector of any one of the preceding embodiments, wherein the nucleic acid further comprises a 5' ITR element and 3' ITR element.
- [0272] 110. The vector of any one of the preceding embodiments, wherein the vector is an adeno-associated virus (AAV) vector.
- [0273] 111. The vector of embodiment 110, wherein the adeno-associated virus (AAV) vector is an AAV2, AAV5, AAV6, AAV7, AAV8, or AAV9 vector.
- [0274] 112. The vector of embodiment 110, wherein the vector is an AAV6 vector or an AAV9 vector.
- [0275] 113. A method of excising part or all of a Hepatitis B Virus (HBV) sequence from a cell, the method comprising providing to the cell the composition of any one of embodiments 58-79, the CRISPR-Cas system of embodiment 21, or the vector of any one of the preceding embodiments.
- [0276] 114. A method of inhibiting or reducing Hepatitis B Virus (HBV) replication in a cell, the method comprising providing to the cell the composition of any one of embodiments 58-79, the CRISPR-Cas system of embodiment 21, or the vector of any one of the preceding embodiments.
- [0277] 115. The method of embodiment 113 or 114, wherein the cell is in a subject.
- [0278] 116. The method of embodiment 115, wherein the subject is a human.
- [0279] 117. A computer-implemented system to select, evaluate, or prioritize a target site and/or a guide RNA candidate, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising:
- [0280] a. a data storage system comprising a target sequence (e.g., a consensus sequence); and
- [0281] b. one or more modules communicatively coupled to the data storage system, wherein the one or more modules are configured to:
- [0282] i. identify one or more targeting sites in the target sequence;
- [0283] ii. identify one or more guide target sequences in proximity to the one or more targeting sites; and
- [0284] iii. calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences,
- [0285] wherein the guide RNA candidate is selected based on the one or more criteria of step (b) (iii).
- [0286] 118. A computer-implemented system to select, evaluate, or prioritize a target site and/or a guide RNA candidate, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising:
- [0287] a. a data storage system comprising a target sequence (e.g., consensus sequence);
- [0288] b. a targeting site identifier configured to identify one or more targeting sites in the target sequence;
- [0289] c. a proximity identifier configured to identify one or more guide target sequences in proximity to the one or more targeting sites; and
- [0290] d. a criteria analysis module configured to calculate one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequences, wherein the guide RNA candidate is selected based on the one or more criteria of step (d).
- [0291] 119. The computer-implemented system of embodiment 117 or 118, wherein the one or more targeting sites are adjacent or proximal to (e.g., within 10 bp) protospacer adjacent motifs (PAMs).
- [0292] 120. The computer-implemented system of embodiment 117 or 118, wherein the target sequence is a reference sequence.
- [0293] 121. The computer-implemented system of embodiment 117 or 118, wherein the target sequence is a single natural or computed sequence.
- [0294] 122. The computer-implemented system of embodiment 117 or 118, wherein the target sequence is a single natural sequence.
- [0295] 123. The computer-implemented system of embodiment 117 or 118, wherein the target sequence is a single computed sequence.
- [0296] 124. The computer-implemented system of embodiment 117 or 118, wherein the target sequence is generated by aligning a plurality of sequences.
- [0297] 125. The computer-implemented system of embodiment 124, wherein the target sequence is a consensus sequence generated by a module configured to (1) align the plurality of sequences.
- [0298] 126. The computer-implemented system of embodiment 125, wherein the consensus is generated

- by a module configured to (1) align the plurality of sequences with common geographies, pathologies, or combinations thereof.
- [0299] 127. The computer-implemented system of embodiment 126, wherein the module is further configured to (2) compare nucleotides at each position of the plurality of sequences; and (3) select a nucleotide at each position that appears at a frequency higher than other nucleotides.
- [0300] 128. The computer-implemented system of any one of embodiments 124-127, wherein the plurality of sequences comprises at least 5 sequences.
- [0301] 129. The computer-implemented system of any one of embodiments 124-127, wherein the plurality of sequences comprises at least 50 sequences.
- [0302] 130. The computer-implemented system of any one of embodiments 124-127, wherein the plurality of sequences comprises at least 100 sequences.
- [0303] 131. The computer-implemented system of any one of embodiments 124-127, wherein the plurality of sequences comprises at least 500 sequences.
- [0304] 132. The computer-implemented system of any one of embodiments 124-127, wherein the plurality of sequences comprises at least 1000 sequences.
- [0305] 133. The computer-implemented system of embodiment 124, wherein the guide RNA candidate is compared against at least one (e.g., a plurality) of the plurality of sequences.
- [0306] 134. The computer-implemented system of embodiment 124, wherein the guide RNA candidate is compared against a sequence of a viral strain different from the plurality of sequences.
- [0307] 135. The computer-implemented system of embodiment 134, the sequence of a viral strain different from the plurality of sequences is a viral sequence reference.
- [0308] 136. The computer-implemented system of embodiment 134, the sequence of a viral strain different from the plurality of sequences is derived from multiple genome sequences (e.g., multiple genome sequences from a library of viral genome, e.g., Virus Pathogen Database and Analysis Resource (ViPR) and/or LANL Research Library Database).
- [0309] 137. The computer-implemented system of embodiment 124, wherein the guide RNA candidate is compared against a sequence of a human genome different from the plurality of sequences.
- [0310] 138. The computer-implemented system of embodiment 137, wherein the sequence of a human genome is a human reference sequence.
- [0311] 139. The computer-implemented system of embodiment 137, wherein the sequence of a human genome is derived from multiple genome sequences (e.g., multiple genome sequences from a library of human genome, e.g., from The 100,000 Genomes Project).
- [0312] 140. The computer-implemented system of embodiment 137, wherein the sequence of a human genome comprises one or more single nucleotide polymorphisms (SNPs).
- [0313] 141. The computer-implemented system of any one of embodiments 124-140, wherein the plurality of sequences are found in the data storage system.

- [0314] 142. The computer-implemented system of any one of embodiments 124-141, wherein the plurality of sequences are a plurality of viral sequences.
- [0315] 143. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences from a single virus.
- [0316] 144. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences from different viruses.
- [0317] 145. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences within a same genotype of a virus.
- [0318] 146. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences within different genotypes of a virus.
- [0319] 147. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences within different subclades of a virus.
- [0320] 148. The computer-implemented system of embodiment 142, wherein the plurality of viral sequences are sequences within a same subclade of a virus.
- [0321] 149. The computer-implemented system of any one of embodiments 143-148, wherein the virus is Hepatitis B virus (HBV), Human Immunodeficiency virus (HIV), JC virus (JCV), herpes simplex virus (HSV), or SARS-CoV-2.
- [0322] 150. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and the genotype is HBV-A.
- [0323] 151. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and the genotype is HBV-B.
- [0324] 152. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and the genotype is HBV-C.
- [0325] 153. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and the different genotypes comprise HBV-A, HBV-B, HBV-C, or combinations thereof.
- [0326] 154. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and different genotypes comprise HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof.
- [0327] 155. The computer-implemented system of embodiment 149, wherein the virus is Hepatitis B virus (HBV) and various subclades within HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof.
- [0328] 156. The computer-implemented system of embodiment 155, wherein the subclade within HBV-A comprises HBV-A1, HBV-A2, HBV-QS-A3, HBV-A4, or combinations thereof.
- [0329] 157. The computer-implemented system of embodiment 155, wherein the subclade within HBV-B comprises HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, HBV-B5, or combinations thereof.
- [0330] 158. The computer-implemented system of embodiment 155, wherein the subclade within HBV-C

- comprises HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, HBV-C6-C15, or combinations thereof.
- [0331] 159. The computer-implemented system of embodiment 155, wherein the subclade within HBV-D comprises HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, HBV-D6, or combinations thereof.
- [0332] 160. The computer-implemented system of embodiment 155, wherein the subclade within HBV-F comprises HBV-F1, HBV-F2, HBV-F3, HBV-F4, or combinations thereof.
- [0333] 161. The computer-implemented system of any one of embodiments 117-160, wherein the one or more criteria are user-supplied criteria.
- [0334] 162. The computer-implemented system of any one of embodiments 117-160, wherein the one or more criteria are based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a targeting site (e.g., a PAM), or combinations thereof.
- [0335] 163. The computer-implemented system of embodiment 161, wherein the knockout score is an on-target knockout score.
- [0336] 164. The computer-implemented system of embodiment 163, wherein the on-target knockout score is determined by efficiency of cleavage.
- [0337] 165. The computer-implemented system of embodiment 163, wherein the on-target knockout score is determined using an algorithm (e.g., Azimuth 2.0).
- [0338] 166. The computer-implemented system of embodiment 161, wherein the knockout score is an off-target knockout score.
- [0339] 167. The computer-implemented system of embodiment 166, wherein the off-target knockout score is determined using an algorithm (e.g., COSMID, python script, Cas-OFFinder).
- [0340] 168. The computer-implemented system of any one of embodiments 117-167, wherein the guide RNA candidate is selected by a user.
- [0341] 169. The computer-implemented system of any one of embodiments 117-167, wherein the guide RNA candidate is selected by a module configured to analyze the one or more criteria and select the guide RNA candidate based on the one or more criteria.
- [0342] 170. The computer-implemented system of any one of embodiments 117-169, wherein the guide RNA candidate is a clinical candidate.
- [0343] 171. The computer-implemented system of any one of embodiments 117-170, wherein the guide RNA candidate is encoded by a sequence according to any one of SEQ ID NOS: 6-549.
- [0344] 172. The computer-implemented system of any one of embodiments 117-170, wherein the target sequence comprises at least about 90% sequence identity to any one of SEQ ID NOS: 2-5.
- [0345] 173. The computer-implemented system of embodiment 172, wherein the target sequence comprises at least 15 nucleotides.
- [0346] 174. The computer-implemented system of embodiment 172, wherein the target sequence comprises at least 20 nucleotides.
- [0347] 175. The computer-implemented system of embodiment 172, wherein the target sequence comprises at least 30 nucleotides.
- [0348] 176. The computer-implemented system of embodiment 172, wherein the target sequence comprises about 20 nucleotides.
- [0349] 177. A method of selecting, evaluating, or prioritizing a guide RNA candidate, comprising:
- [0350] a. providing a target sequence (e.g., consensus sequence);
- [0351] b. identifying one or more targeting sites in the target sequence;
- [0352] c. identifying one or more guide target sequences in proximity to the one or more targeting sites;
- [0353] d. calculating one or more criteria based on the one or more guide target sequences or a guide RNA corresponding to at least one of the one or more guide target sequence; and
- [0354] e. selecting the guide RNA candidate based on the one or more criteria of step (d).
- [0355] 178. The method of embodiment 177, wherein the one or more targeting sites are protospacer adjacent motifs (PAMs).
- [0356] 179. The method of embodiment 177, wherein the target sequence is a reference sequence.
- [0357] 180. The method of embodiment 177, wherein the target sequence is a single natural or computed sequence.
- [0358] 181. The method of embodiment 177, wherein the target sequence is a single natural sequence.
- [0359] 182. The method of embodiment 177, wherein the target sequence is a single computed sequence.
- [0360] 183. The method of embodiment 177, wherein the target sequence is generated by aligning a plurality of sequences.
- [0361] 184. The method of embodiment 183, wherein the target sequence is a consensus sequence is determined by aligning the plurality of sequences.
- [0362] 185. The method of embodiment 184, wherein the consensus is determined by aligning sequences with common geographies, pathologies, or combinations thereof.
- [0363] 186. The method of embodiment 185, wherein the consensus sequence is determined by comparing nucleotides at each position of the plurality of sequences; and selecting a nucleotide at each position that appears at a frequency higher than other nucleotides.
- [0364] 187. The method of any one of embodiments 183-186, wherein the plurality of sequences comprises at least 5 sequences.
- [0365] 188. The method of any one of embodiments 183-186, wherein the plurality of sequences comprises at least 50 sequences.
- [0366] 189. The method of any one of embodiments 183-186, wherein the plurality of sequences comprises at least 100 sequences.
- [0367] 190. The method of any one of embodiments 183-186, wherein the plurality of sequences comprises at least 500 sequences.
- [0368] 191. The method of any one of embodiments 183-186, wherein the plurality of sequences comprises at least 1000 sequences.

- [0369] 192. The method of any one of embodiments 183-191, wherein the guide RNA candidate is compared against at least one (e.g., a plurality) of the plurality of sequences.
- [0370] 193. The method of any one of embodiments 183-191, wherein the guide RNA candidate is compared against a sequence of a viral strain different from the plurality of sequences.
- [0371] 194. The method of any one of embodiments 183-191, the sequence of a viral strain different from the plurality of sequences is a viral sequence reference.
- [0372] 195. The method of embodiment 196, the sequence of a viral strain different from the plurality of sequences is derived from multiple genome sequences (e.g., multiple genome sequences from a library of viral genome, e.g., Virus Pathogen Database and Analysis Resource (ViPR) and/or LANL Research Library Database).
- [0373] 196. The method of any one of embodiments 183-191, wherein the guide RNA candidate is compared against a sequence of a human genome different from the plurality of sequences.
- [0374] 197. The method of embodiment 196, wherein the sequence of a human genome is a human reference sequence.
- [0375] 198. The method of embodiment 196, wherein the sequence of a human genome is derived from multiple genome sequences (e.g., multiple genome sequences from a library of human genome, e.g., from The 100,000 Genomes Project).
- [0376] 199. The method of embodiment 196, wherein the sequence of a human genome comprises one or more single nucleotide polymorphisms (SNPs).
- [0377] 200. The method of any one of embodiments 183-199, wherein the plurality of sequences are a plurality of viral sequences.
- [0378] 201. The method of embodiment 200, wherein the plurality of viral sequences are sequences from one virus.
- [0379] 202. The method of embodiment 200, wherein the plurality of viral sequences are sequences from different viruses.
- [0380] 203. The method of embodiment 200, wherein the plurality of viral sequences are sequences within a same genotype of a virus.
- [0381] 204. The method of embodiment 200, wherein the plurality of viral sequences are sequences within different genotypes of a virus.
- [0382] 205. The method of embodiment 200, wherein the plurality of viral sequences are sequences within different subclades of a virus.
- [0383] 206. The method of embodiment 200, wherein the plurality of viral sequences are sequences within a same subclade of a virus.
- [0384] 207. The method of any one of embodiments 200-206, wherein the virus is Hepatitis B virus (HBV), Human Immunodeficiency virus (HIV), JC virus (JCV), herpes simplex virus (HSV), or SARS-CoV-2.
- [0385] 208. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and a genotype is HBV-A.
- [0386] 209. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and a genotype is HBV-B.
- [0387] 210. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and genotype is HBV-C.
- [0388] 211. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and different genotypes comprise HBV-A, HBV-B, HBV-C, or combinations thereof.
- [0389] 212. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and different genotypes comprise HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof.
- [0390] 213. The method of embodiment 207, wherein the virus is Hepatitis B virus (HBV) and various subclades within HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, HBV-F, HBV-G, HBV-H, or combinations thereof.
- [0391] 214. The method of embodiment 213, wherein the subclade within HBV-A comprises HBV-A1, HBV-A2, HBV-QS-A3, HBV-A4, or combinations thereof.
- [0392] 215. The method of embodiment 213, wherein the subclade within HBV-B comprises HBV-B1, HBV-B2, HBV-QS-B3, HBV-B4, HBV-B5, or combinations thereof.
- [0393] 216. The method of embodiment 213, wherein the subclade within HBV-C comprises HBV-C1, HBV-QS-C2, HBV-C3, HBV-C4, HBV-C5, HBV-C6-C15, or combinations thereof.
- [0394] 217. The method of embodiment 213, wherein the subclade within HBV-D comprises HBV-D1, HBV-D2, HBV-D3, HBV-D4, HBV-D5, HBV-D6, or combinations thereof.
- [0395] 218. The method of embodiment 213, wherein the subclade within HBV-F comprises HBV-F1, HBV-F2, HBV-F3, HBV-F4, or combinations thereof.
- [0396] 219. The method of any one of embodiments 177-211, wherein the one or more criteria are user-supplied criteria.
- [0397] 220. The method of any one of embodiments 177-211, wherein the one or more criteria are based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a target site (e.g., a PAM), or combinations thereof.
- [0398] 221. The method of embodiment 220, wherein the knockout score is an on-target knockout score.
- [0399] 222. The method of embodiment 221, wherein the on-target knockout score is determined by efficiency of cleavage.
- [0400] 223. The method of embodiment 221, wherein the on-target knockout score is determined using an algorithm (e.g., Azimuth 2.0).
- [0401] 224. The method of embodiment 220, wherein the knockout score is an off-target knockout score.
- [0402] 225. The method of embodiment 224, wherein the off-target knockout score or off-target cutting potential is determined using an algorithm (e.g., COSMID, python script, Cas-OFFinder).
- [0403] 226. The method of any one of embodiments 177-225, wherein the guide RNA candidate is a clinical candidate.

- [0404] 227. The method of any one of embodiments 177-226, wherein the guide RNA candidate is encoded by a sequence according to any one of SEQ ID NOs: 6-549.
- [0405] 228. The method of any one of embodiments 177-226, wherein the target sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.
- [0406] 229. The method of embodiment 228, wherein the target sequence comprises at least 15 nucleotides.
- [0407] 230. The method of embodiment 228, wherein the target sequence comprises at least 20 nucleotides.
- [0408] 231. The method of embodiment 228, wherein the target sequence comprises at least 30 nucleotides.
- [0409] 232. The method of embodiment 228, wherein the target sequence comprises about 20 nucleotides.
- [0410] 233. A computer-implemented system to select, evaluate, or prioritize a targeting site, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising:
- [0411] a. a data storage system comprising a target sequence (e.g., consensus sequence) comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5;
 - [0412] b. a criteria analysis module configured to calculate one or more criteria of the targeting site; and
 - [0413] c. a target identifier for selecting the target site based on the one or more criteria of step (b).

- [0414] 234. The computer-implemented system of embodiment 233, wherein the one or more criteria is based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a targeting site (e.g., a PAM), or combinations thereof.
- [0415] 235. A computer-implemented system to select, evaluate, or prioritize a targeting site, the system comprising: at least one processor, a memory, and instructions executable by the at least one processor comprising:
- [0416] a. a data storage system comprising a target sequence (e.g., consensus sequence); and
 - [0417] b. a criteria analysis module configured to calculate one or more criteria of the targeting site, wherein the one or more criteria is based on positional entropy, conservation, a knockout score, an overlapping reading frame, a gene location, a coding region, a non-coding region, predicted cutting rate or efficiency, efficacy, a frequency of a targeting site (e.g., a PAM), or combinations thereof; and
 - [0418] c. a target identifier for selecting the target site based on the one or more criteria of step (b).
- [0419] 236. The computer-implemented system of any one of embodiments 233-235, wherein the targeting site is recognized by a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a CRISPR-associated protein (e.g., Cas).

SEQUENCE LISTING

```

Sequence total quantity: 549
SEQ ID NO: 1      moltype = DNA  length = 3182
FEATURE          Location/Qualifiers
source           1..3182
                 mol_type = other DNA
                 organism = synthetic construct

SEQUENCE: 1
aattccacaa ccttccacca aactctgcaa gatcccagag tgagaggcct gtattccct 60
gctgggtgcg ccagttcagg aacagtaaac cctgttctga ctactgcctc tccttatcg 120
tcaatcttcg cgaggattgg ggaccctcgct ctgaacatgg agaacatcac atcaggattc 180
ctaggaccgg ttctcggtt acaggcgggg tttttcttgt tgacaagaat cctcacaata 240
ccgcagagtc tagactcggt gtggactttt ctcaattttc tggtggaaac taccgtgtgt 300
cttggccaaa attccggcgtt cccaaacctcc aatcactcac caaccttctt tcctccaact 360
tgtccctgggt atcgttggat gtgtctgggg cgttttatca tcttccttcatcgtgt 420
ctatgcctca tcttttttgcg ggttcttctgc gactatcaag gtatgttgcg cgttttgctt 480
ctaattcccg gatccctcaacc aaccaggcgg ggaccatggcat gactactgt 540
caaggaaacct ctatgtatcc ctccgttgc tgtaaaaaac ctccggacgg aaatggcacc 600
tgtattccca tccccatcatc ctggggcttgc ggaaaattcc tatgggagtg ggcttcagcc 660
cgttttccctt ggcttcagggt actagtggca tttgttcaagt gggttcgttgg gctttccccc 720
actgtttggc tttaggttattt atggatgtatc tggttattttgggg ggcggaaatgtt gtacagcatc 780
tttagtgcctt ttttaccgtt gttaccatc ttctttttgtt ttgggttata catttaaacc 840
ctaacaaaac aaagagatgg gggtactctc taaaatttttgggttatgtc attggatgtt 900
atgggtccctt gccacaagaac cacatcatac aaaaaatcaa agaaatgtttt agaaaacttcc 960
ctatthaacacg gcctatgtat gttggaaatgt gtcaacaaat tttgggtttttt ttgggtttttg 1020
ctggcccttt tacacaatgtt ggttacatcg eggttgcgttcc ttgttatgcg tgatcaat 1080
ctaaaggcggc ttcaacttcc tcgcacaaatc acaaggcgtt tctgtgtaaa caataacctga 1140
accccttaccc cggtggccgg caacggccag gtctgtgcac agtgtttgtt gacggcaaccc 1200
ccactggctg ggggttgggtt atggggccatc agcgcatgcg tggaacacctt tcggctcc 1260
tgccgatccca tactcggttgc ctccatcgcc ttgtttttgc tcgcacggg tctggagca 1320
acattatcggt gactgtataac tctgttgcac tateccgcac atatacatcg tttccatggc 1380
tgcttaggtctg tgctgcacaa tggatccgcg gggggacgtc ctttgtttac gtcggcgttgg 1440
cgctgaatcc tcgcggacac cttcttcggg tgctgttttttgcg ecctctcc 1500
gtctgcgtt ccggaccgacc acggggccgcg cttcttttgcg cggccactcc cggctgtgc 1560
cttctcatct ggccggaccgt gtgcacttgc ctteacatct gcacgtgcg tggagaccac 1620
cgtgaacgcgc caccaaatat tgcccaaggt cttacataag aggactcttg gactctcagc 1680
aatgtcaacg accgacccctt aggcataactt caaagactgt ttgtttaaag actggggagga 1740
gttggggag gagatgttggat taaaggttgc ttgtacttagga ggctgttagc ataattttgtt 1800

```

-continued

ctgcgcacca	gcaccatgca	acttttca	ctctgcctaa	tcatctcttg	ttcatgtcct	1860
actgttcaag	cctccaagt	gtgcattggg	tggotttggg	gcatggacat	cgacccttat	1920
aaagaatttg	gagctactgt	ggagttactc	tcgttttgc	cttctgacct	cttccttc	1980
gtacgagatc	ttctagatac	cgcctcagct	ctgtatcggg	aagccttaga	gtctctgg	2040
cattgttcc	ctcaccatac	tgcactcagg	caagcaattc	tttgcgtggg	ggaactaatg	2100
actctagota	ctgggttggg	tgttaatttg	gaagatccag	egtctagaga	cctagtatgc	2160
agttatgtca	acaactaatat	gggcctaagg	ttcaggcAAC	tcttgcgtt	tcacatttct	2220
tgtctcaactt	tttggaaagaga	aacagtata	gagtatttgg	tgtcttccg	agtgtggatt	2280
cgcactctc	cagttatag	accaccaa	atccctatcc	tatcaact	tccggagact	2340
actgttgc	tacgcacggg	caggcccc	agaagaqaaa	ctccctcggc	tcgcagacga	2400
aggtctcaat	ggccgcgtcg	cagaagatc	caatctcggg	aatctcaatg	tttagtattcc	2460
ttggactcat	aagggtggg	actttactgg	gctttattct	tctactgtac	ctgtctttaa	2520
tectcattgg	aaaacaccat	cttttctaa	tatacattt	caccaagaca	tttcaaaaa	2580
atgtgaacag	tttgcggcc	cactcacgt	taatgagaaa	agaagatgc	aattgattat	2640
gcctgcagg	ttttatccaa	aggttacca	atatttacca	ttggataagg	gtattaaacc	2700
tttattatcca	gaacatctag	ttaatcatta	cttccaaact	agacattact	tacacactt	2760
atgaaaggcg	ggtatattat	ataagagaga	aacaacacat	agcgcctcat	tttgcgttgc	2820
accatattct	ttgggaaacaag	atctacagca	tggggcgaaa	tcttccccc	agcaatctc	2880
tgggattctt	tcccgatcc	cagttggatc	cagccttcag	agcaacacc	gcaaatccag	2940
atgggactt	caatcccaac	aaggacactt	ggccagacgc	caacaaggta	ggagctggag	3000
cattcggtt	gggttccacc	ccaccgcacg	gaggccttt	gggggtggagc	cctcaggctc	3060
agggcatact	acaaactttg	ccagcaatc	cgcctccctc	ctccaccaat	cgcgcgtc	3120
gaaggcagcc	taccccgctg	tctccaccc	tgagaaacac	tcatctcag	gccatgcgt	3180
gg						3182

SEQ ID NO: 2	moltype = DNA	length = 3221
FEATURE	Location/Qualifiers	
source	1..3221	
	mol_type = other DNA	
	organism = synthetic construct	

SEQUENCE: 2						
ttccactgcc	ttccaccaag	ctctgcgaga	tcccagagt	aggggtctgt	atttccctgc	60
tggtgtcc	agttcaggaa	cagtaaaccc	tgtccgaat	attgccttc	acatctcg	120
aatctcccg	aggactgggg	accctgtac	gaacatggg	aacatcacat	caggattcct	180
aggaccctct	ctcgctgtac	aggggggtt	tttcttgcgtt	acaagaatcc	tcacaatacc	240
gcagagtca	gactcgctgt	ggacttctc	caatttctca	gggggatcac	ccgtgtgt	300
tggccaaat	tcgcgcgtcc	caaccccaa	tcactcaca	acccctctgc	ctccaaattt	360
tcctggat	cgctggatgt	gtctcgccg	ttttatcata	ttccctttca	tcctgtgtct	420
atgcctatc	ttcttgcattt	ttcttctca	ttatcaagg	atgttgccg	tttgcctt	480
aattccagga	tcaacaacaa	ccagtagggg	accatgcgg	acctgcacga	ctccctgtca	540
aggcaactct	atgtttccct	catgtgcgt	tacaaaact	acggatggaa	attgcactg	600
tattcccatc	ccatctgtcc	ggggttccgc	aaaataccta	ttggagttgg	cctcagtcgg	660
tttctcttgg	ctcagtttac	tagtgcatt	tggttcgttgc	ttcgttagggc	tttcccccac	720
tgttgggtt	tcagctattt	ggatgtatgc	gtattgggg	ccaagttgt	acagcatcgt	780
gagtccctt	ataccgtgt	taccaattt	cttttgtctc	tgggtataca	tttaaccc	840
aacaaaacaa	aaagatgggg	ttattcccta	aacttcatgg	tttacataat	ttggagttgg	900
ggaaacattgc	cacaggatca	tattttacaa	aaagatcaaa	actgttttag	aaaacttcc	960
gttaacacggc	ctattgttg	gaaagtatgc	caaagaattt	tttttttttt	gggttttgt	1020
gtccatttta	cacaatgtgg	atatctgc	ttatgtcc	tgtatgc	tatataagct	1080
aaacaggctt	tcactttctc	gcacacttac	aaggccttc	taagtaaaca	gtatcatgaa	1140
cttaccctcc	ttgtcgccaa	acggcctgt	ctgtgc	ttttgcgt	cgcaaccc	1200
actggctgg	gtttggccat	aggccatcg	cgcacgtcg	gaacctttgt	ggctccctcg	1260
cgcattccata	ctgcggcaact	cctacgcgt	ttttttgtc	cgacgcggc	ttggacaaag	1320
ctcatcgaa	ctgacaattt	tgttgttctc	tcgggaaat	atacatcg	tccatggct	1380
ctaggcgtta	ctgcgcact	gatcttgc	ggggacgtc	ttttttacgt	cccggtcg	1440
ctgaatcccg	cgggacgacc	ctctggggc	cggttgggg	tetctcg	ccttctcg	1500
ctggcggtcc	acccggccac	ggggccacc	tctcttacg	cggttccccc	gtctgtgc	1560
tctcatctgc	cggtccgtgt	gcacttgc	tcaccc	acgttgc	gagaccac	1620
tgaacgcaca	tcagatctgt	cccaagggt	tacataag	gacttgc	ctcccgacaa	1680
tgtcaacacg	cgacccctg	gcctactca	aaagactgt	ttttaggg	ttgggggg	1740
tggggggaggaa	gatgttttgc	tttttttttt	tatttaggg	tttgcgttgc	aaatgggt	1800
gcgcaccaggc	accatgcac	tttttccac	ctgccttac	atcttgc	catgtcc	1860
tgttcaaggcc	tccaaatgt	gccttgggt	gttttggggc	atggacattt	acccttataa	1920
agaatatttgg	gtactgtgg	tttttttttt	tctgtactt	ttcccttc	cggttttgt	1980
cagagatctc	ctagacaccc	cctcactgt	gtatcg	tttttttttt	tttttttttt	2040
ttgtctcacct	caccatact	cactcaggca	agccatttctc	tttttttttt	tttttttttt	2100
tctagctacc	ttgggtgggt	ataatttgg	agatccagca	ttccaggatc	tttttttttt	2160
ttatgttaat	actaacatgg	tttttttttt	caggcaactt	tttttttttt	tttttttttt	2220
ccttactttt	ggaaggagaga	ctgtacttgc	tttttttttt	tttttttttt	tttttttttt	2280
cactcctcca	gcctatagac	caccaatgc	ccctatcttca	tcaacactc	tttttttttt	2340
tgttgcgttgc	cgacggggacc	ggggcgggtc	cccttgc	tttttttttt	tttttttttt	2400
acgcagatct	caatgcgc	gtcgcagaag	atctcaatc	tttttttttt	tttttttttt	2460
ttccctggac	tcataagggt	ggggatctt	ctgggctt	ttcccttaca	tttttttttt	2520
ttaatcttgc	atggcaaaact	ccttcc	ctaaaggatca	tttttttttt	tttttttttt	2580
atagggtgtca	acaatttgc	ggcccttc	ctgttaat	tttttttttt	tttttttttt	2640
ttatgcctgc	tagattctat	cataacc	ctaaatattt	tttttttttt	tttttttttt	2700

-continued

aaccttatta	tccagatcag	gtagttatac	attacttcca	aaccagacat	tatttacata	2760
ctctttggaa	ggctgttatt	ctatataaga	gggaaacccac	acgttagcga	tcattttgcg	2820
ggtcaccaata	ttcttggaa	caagactac	agcatgggg	gttgggtcata	aaaacctcg	2880
aaaggcatgg	ggacgaatct	ttctgttccc	aaccctctgg	gattcttcc	cgatcatcag	2940
ttggaccctg	cattcggagc	caactcaa	aatccagatt	gggacttcaa	ccccatcaag	3000
gaccactggc	cagcagccaa	ccaggttaga	gtggggagcat	tcggggcagg	gttcaccct	3060
ccacacggcg	gtgtttggg	gtggggccat	caggctcagg	gcatgttgc	cacagtgtca	3120
acaattcctc	ccctctgc	cacaatcgg	cagtccggaa	ggcagcctac	tcccatct	3180
ccacctctaa	gagacagtca	tcctcaggcc	atgcagtgg	a		3221

SEQ ID NO: 3	moltype = DNA	length = 3215				
FEATURE	Location/Qualifiers					
source	1..3215					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 3						
ctccaccact	ttccaccaa	ctcttcaaga	tcccagagtc	agggccctgt	actttctgc	60
tggtgttcc	agttcaggaa	cagtggatccc	tgctcagata	actgtctctg	ccatatctgc	120
aatcttatcg	aaagactgggg	accctgtacc	gaacatggaa	aacatcgat	caggactct	180
aggacccctg	ctcgttac	aggcgggg	tttctgttgc	acaaaaatcc	tcacaatacc	240
acagagtcta	gactcgtgg	ggacttctct	caatttctca	ggggggacac	ccgtgtgtct	300
tggccaaat	tccgactccc	aaatctccag	tcactcacca	acctgttgc	ctccaaatttgc	360
tcctgttgc	cgctggatgt	gtctgggg	tttctatcata	ttctgttgc	tcctgtgtct	420
atgcctcatc	ttcttgggg	ctatcaagg	atgttgc	cccg	tttgcctct	480
aattccagga	tcatcaacaa	ccagoacccg	accatgc	acactgcacaa	ctccgtctca	540
aggaaacctt	atgtttccct	catgtgtgc	tacaaaacct	acggacggaa	actgcac	600
tattccatc	ccatcatctt	ggggccatccc	aaaatcacca	tgggagtgg	ccctcagtc	660
tttcttggg	ctcagttac	tagtgcatt	tgttcagtgg	ttcgttagggc	tttccccccac	720
tgtctggctt	tca	ggatgtgt	gttttgggg	ccaa	gttgcgtt	780
gagtccctt	atgcgcgt	taccaat	ttttgtctt	tgggtatata	tttaaaccc	840
cacaaaacaa	aaagatgggg	atattccctt	aacttcatgg	gatgtat	ttgggagtgg	900
ggcacatcgc	cacaggaa	tatgtacaa	aaaatcaaa	tgtgtttag	gaaacttcc	960
gtaaacacgg	ctattgttt	gaaatgtgt	caacgaattt	tgggttctt	gggggttgc	1020
gccccttca	cgcaatgtgg	atatcctgt	ttaatgcctt	tatgtgc	tatacaagca	1080
aaacacggat	ttacttctc	gcacaa	aaaggcccttc	taagtaaca	gtatctgaa	1140
ctttaccccg	ttgtcggca	acggcgttgc	ctgtgcca	tggttgc	cgcaacccc	1200
actgggtggg	gottggccat	aggccatcag	cgcacgtgt	gaaac	tttgc	1260
ccgatccata	ctgcggaa	cctagecgt	tgtttgtc	gcagcagg	ttggggcaaaa	1320
ctcatcg	ctgcaatc	tgctgtc	tcccgca	aatacat	ttccatggct	1380
ctaggctgt	ctgcaact	gatctgtc	ttgttgc	cccg	tcg	1440
ctgaatcccg	cgacgaccc	ctccgggg	cgatggggc	tctacc	ccccc	1500
ctgttgtacc	gaccgaccac	gggggc	tc	atgttgc	cc	1560
tccatctgc	ggggccgt	gcac	tcac	tc	atgttgc	1620
tgaacacggca	ccggaa	cccaagg	tgc	atgttgc	tttttgc	1680
tgtcaacgc	cgacc	cgatctca	aaactgtgt	tgttactg	gg	1740
tggggggagg	gattaggtt	aagg	tcttgc	tactaggagg	ttgttgc	1800
gttcaccagg	accatgcac	tttttac	ctg	cttgc	atctcat	1860
tgttcaaggc	tca	gggttgggt	gttgc	atggacat	tttgc	1920
agaat	tttgc	tttttgc	tttgc	tttgc	tttgc	1980
tcgagatctc	ctcgacacc	cctctgt	gtatcgg	gcctt	atgttgc	2040
ttgttca	caccatc	cactcagg	agetatttgc	tttttgc	tttttgc	2100
tctagccacc	ttgggggg	gtat	tttttgc	tttttgc	tttttgc	2160
ctatgtcaac	gttaat	tttttgc	tttttgc	tttttgc	tttttgc	2220
tcttacttt	gggagagaaa	ctgttcttgc	atatttgc	tcttttgc	tgttgc	2280
cactcctct	ctat	tttttgc	tttttgc	tttttgc	tttttgc	2340
tgttgc	ttaga	ccat	tttttgc	tttttgc	tttttgc	2400
gttcaatcg	ccgcgtcg	gaat	tttttgc	tttttgc	tttttgc	2460
ggacacataa	ggtggaa	tttac	tttttgc	tttttgc	tttttgc	2520
ctaaatggca	aactcttct	tttctg	tttgc	tttgc	tttgc	2580
gtaagcaatt	tgttgc	tttgc	tttgc	tttgc	tttgc	2640
ctgtctgtt	ttat	tttgc	tttgc	tttgc	tttgc	2700
attatccaga	gtatgt	tttgc	tttgc	tttgc	tttgc	2760
gaaaggccgg	tat	tttgc	tttgc	tttgc	tttgc	2820
catattcttgc	gaaacaaat	ctac	tttgc	tttgc	tttgc	2880
atggggacaa	atcttcttgc	cccaat	tttgc	tttgc	tttgc	2940
cctgcattca	aagcaact	aaaaatcc	tttgc	tttgc	tttgc	3000
tggccggacg	ccaacaagg	gggat	tttgc	tttgc	tttgc	3060
ggggggactgt	ttgggtgg	ccctcagg	tttgc	tttgc	tttgc	3120
cctccctct	cttccacaa	tcggc	tttgc	tttgc	tttgc	3180
ctaaggacac	ctcatctca	ggccat	tttgc	tttgc	tttgc	3215

SEQ ID NO: 4	moltype = DNA	length = 3223
FEATURE	Location/Qualifiers	
source	1..3223	
	mol_type = other DNA	
	organism = synthetic construct	

-continued

SEQUENCE: 4

```

ctccaccaaca ttccaccaag ctctgctaga tcccagagtg agggcctat acttcctgc 60
tggggctcc agttccggaa cagtaaaccc tggccact actgcctac ccatacgctc 120
aatcttcctcg aggactgggg accctgcacc gaacatggag aacacaacat caggattcct 180
aggacccctg ctctgttac aggccccgggtt ttcttggatg acaagaatcc tcacaatacc 240
acagagtcta gactcggtgt ggacttctt caatttctta gggggagcac ccacgtgtcc 300
tggccaaaat tcgcagttcc caacctccaa tcaactccca acctcttgc ctccaatttg 360
tctctggatc cgctggatgt gtctgggg ttttatata tcctcttca tcctgtgtct 420
atgcctcata ttcttggatgt ttcttcttga ctaccaaggat atgttgcggg tttgtctct 480
acttccaggaa acatcaacta ccacgcacggg accatgcacga acctgcacga ttccgtctca 540
aggaacacctt atgtttccctt ctgttgcgt taaaaacccctt cgggacggaa actgcacttg 600
tattcccatc ccatcatccctt ggggttccgaa aagatctta tgggagtgccc cctcagttccg 660
tttctctggg ctcaagtttac tagtgcctt tggtcagtggg ttctgtgggccc tttcccccac 720
tggttgggtt tcagttatata ggtatgtgt gtatgggggg ccaagtctgt acaacatctt 780
gagtccttta ttaccttata tccaattttt cttttgtctt tgggtataaca ttgaacccct 840
aataaaacca aacgtggggg ctactccctt aacttcatgg gatatgtataat tggaaagtgg 900
ggtaatccatc cacaggaaaca tattgtacta aaaatcaaggc aatgttttcg aaaaactgcct 960
gttaatagac ctattgttgg gaaagtatgt caaaagaatttggggttgggttgggttgc 1020
gcccccttta ctcaatgtgg ctatgcctt ttaatgcctt tatatgcatg tatacaatct 1080
aagcaggott tcaacttctc gccaacttac aaggcccttc tggtaaaca atatgttgcac 1140
ctttaaccggc ttggccggca acgggttgcgt ctctgccaag tgggtgtca cgcaaccggc 1200
actggatggg gtttggccat aggccatcggtt cgcattgcgtt gaaacctttgtt ggcttctctg 1260
ccgatccata ctgcggaaactt ccttagcgtt tggttgcgtt gggccgggtt tggagcgaaa 1320
ctttagccaa cggacaaactt tgggttgcctt tccctggaaat acacccctt tccatggctg 1380
ctagggtgtg ctggcaactt gatcctgcgtt gggacgttctt ttgtcttgcgtt cccgtgggg 1440
ctgaatcccg cggacgaccc gtttgggggg cgtttggggac ttttgcgttcc cttttttcat 1500
ctggccgttcc gggccggaccac gggggggccat ttttttttgcgtt cgggttccccc gtctgtgcct 1560
ttccatctgc cggaccgtgt gcacttcgtt tcacccctgc acgtcgcgtt gagaccacccg 1620
tgaacgccttcc caagggttgc ttttttttgcgtt ctttttttgcgtt ctttttttgcgtt 1680
ctcagcaatgt tcaacgaccg accttttttttgcgtt atacttcaaa gactgtttgtt ttaaagactg 1740
ggaggagttt gggggggggg ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 1800
atttggctgtt tcacccatc catgcacattt ttttccatctt gccttcatat ctcatgttca 1860
tgccctacttgc ttcaagccctc caagtttttttgcgtt ctttttttgcgtt ttttttttgcgtt 1920
ccgtataaag aatttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 1980
ccttcttgc ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2040
ccggaaattt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2100
tttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2160
gttagtcaatgt taatatggggc ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2220
atttccctgtc ttttttttgcgtt aagagaaaatgt ttttttttgcgtt ttttttttgcgtt 2280
tggttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2340
gaaactactt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2400
agacgaagggt tcaatcgcc gctgtcgacatc agatctcaat ttttttttgcgtt ttttttttgcgtt 2460
tattccctgg actcataagg ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2520
ctttaatcttgc ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2580
taatagatgtt caacaatatgt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2640
aattatgtctt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2700
taaaccctttt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2760
tactctgtgg aaggctggca ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2820
tgggttccatc ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2880
gacaaggcat gggggggggg ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 2940
agtggaccctt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 3000
aggatcaatgtt gggggggggg ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 3060
caccacacggc cgggttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 3120
cagcagcacc ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 3180
cttccacccatctt aagagacatgt ttttttttgcgtt ttttttttgcgtt ttttttttgcgtt 3223

```

SEQ ID NO: 5 moltype = DNA length = 3219
 FEATURE Location/Qualifiers
 source 1..3219
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 5

```

ctccaccaaca ttccaccaag ctctgctaga tcccagagtg agggcctat acttcctgc 60
tggggctcc agttccggaa cagtaaaccc tggccact actgccttc ccatacgctc 120
aatcttcctcg aggactgggg accctgcacc gaacatggag aacacaacat caggattcct 180
aggacccctg ctctgttac aggccccgggtt ttcttggatg acaagaatcc tcacaatacc 240
acagagtcta gactcggtgt ggacttctt caatttctta gggggagcac ccacgtgtcc 300
tggccaaaat tcgcagttcc caacctccaa tcaactccca acctcttgc tcctcaatttg 360
tctctggatc cgctggatgt gtctgggg ttttatata tcctcttca tcctgtgtct 420
atgcctcata ttcttggatgt ttcttcttga ctaccaaggat atgttgcggg tttgtctct 480
acttccaggaa acatcaacac ccacgcacggg accatgcacga acctgcacga ttccgtctca 540
aggaacacctt atgtttccctt ctgttgcgtt taaaaacccctt cgggacggaa actgcacttg 600
tattcccatc ccacatcatctt ggggttccgaa aagatccata tgggagtgccc cctcagttccg 660
tttctctggg ctcaagtttac tagtgcctt tggtcagtggg ttcccccac 720
tggttgggtt tcagttatata ggtatgtgtt gtatgggggg ccaagtctgt acaacatctt 780
gagtccttta ttaccttata tccaattttt cttttgtctt tgggtataaca tttaaaccctt 840

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 10		
ccaaatggc ctgggttatcg		20
SEQ ID NO: 11	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 11		
gccccgttgc cctctaattc		20
SEQ ID NO: 12	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 12		
ggctttcgca aaataacat		20
SEQ ID NO: 13	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 13		
actgtctggc tttcagttat		20
SEQ ID NO: 14	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 14		
ggccaagtct gtacaacatc		20
SEQ ID NO: 15	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 15		
ttaccaattt tcttttgtct		20
SEQ ID NO: 16	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 16		
ccctcacaaa aaaaaagat		20
SEQ ID NO: 17	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 17		
gggatattcc cttaacttca		20
SEQ ID NO: 18	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 18		
acttcatggg atatgtattt		20
SEQ ID NO: 19	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 19		
attgatttgg aagtatgtca		20

-continued

```

SEQ ID NO: 20      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 20
gaaaaatgtc tcaacgaatt                                20

SEQ ID NO: 21      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 21
tcaacgaatt gtgggtcttt                                20

SEQ ID NO: 22      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 22
tgccgcgcct ttcacgcaat                                20

SEQ ID NO: 23      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 23
ctgcttaggct gtgctgccaa                                20

SEQ ID NO: 24      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 24
ttgtttacgt cccgtcgccg                                20

SEQ ID NO: 25      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 25
cttcaaagac tgtgtgttta                                20

SEQ ID NO: 26      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 26
ctgtgtgttt actgagtggg                                20

SEQ ID NO: 27      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 27
tcaaggctcc aagctgtgcc                                20

SEQ ID NO: 28      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 28
taaagaattt ggagcttctg                                20

SEQ ID NO: 29      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 29		
tgctctgtat cgggaggcct		20
SEQ ID NO: 30	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 30		
tcaaggcaagc tattctgtgt		20
SEQ ID NO: 31	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 31		
ttcttgttgc ggggtgagttg		20
SEQ ID NO: 32	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 32		
gagttgatga atcttagccac		20
SEQ ID NO: 33	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 33		
tttggaaat ccagcatcca		20
SEQ ID NO: 34	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 34		
ttttggaga gaaactgttc		20
SEQ ID NO: 35	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 35		
cttgaatatt tggtgtcttt		20
SEQ ID NO: 36	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 36		
tattttgggt cttttggagt		20
SEQ ID NO: 37	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 37		
aaatatattgc ccttagataa		20
SEQ ID NO: 38	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 38		
atttacacac tctttggaaag		20

-continued

```

SEQ ID NO: 39      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 39
ggcggttataaaaaa                                         20

SEQ ID NO: 40      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 40
cacacgtac gcctcatttt                                         20

SEQ ID NO: 41      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 41
tctttctgtc cccaaatcccc                                         20

SEQ ID NO: 42      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 42
tgcccgacg ccaacaagg                                         20

SEQ ID NO: 43      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 43
gggagtgaaa gcattcgggc                                         20

SEQ ID NO: 44      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 44
ccctccccat gggggactgt                                         20

SEQ ID NO: 45      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 45
gccctgactc tgggatcttg                                         20

SEQ ID NO: 46      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 46
aaagtacagg gccctgactc                                         20

SEQ ID NO: 47      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 47
gatgttctcc atgttcggta                                         20

SEQ ID NO: 48      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

SEQUENCE: 48	mol_type = other DNA organism = synthetic construct	
gtaacacgag caggggtcct		20
SEQ ID NO: 49	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 49		
accccgctg taacacgagc		20
SEQ ID NO: 50	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 50		
tcttagactct gtggatttgt		20
SEQ ID NO: 51	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 51		
aaaattgaga gaagtccacc		20
SEQ ID NO: 52	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 52		
gcgaattttg gccaaagacac		20
SEQ ID NO: 53	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 53		
gtgactggag atttggact		20
SEQ ID NO: 54	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 54		
aattggagga caacaggttg		20
SEQ ID NO: 55	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 55		
aagaagatga ggcatacgag		20
SEQ ID NO: 56	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 56		
gtgctgggtg ttgatgtcc		20
SEQ ID NO: 57	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 57		
aacatagagg ttccttgagc		20

-continued

```

SEQ ID NO: 58      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 58
aaagcccaag atgatggat                                     20

SEQ ID NO: 59      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 59
tttgcgaag cccaagatga                                     20

SEQ ID NO: 60      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 60
tccccatctt tttgtttgt                                     20

SEQ ID NO: 61      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 61
tacatatccc atgaagttaa                                     20

SEQ ID NO: 62      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 62
tgcataaaaa ggcattaaag                                     20

SEQ ID NO: 63      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 63
accaggccgt tgccgagcaa                                     20

SEQ ID NO: 64      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 64
atggccaagc cccaaaccagt                                     20

SEQ ID NO: 65      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 65
gcggcttagga gttccgcagt                                     20

SEQ ID NO: 66      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 66
tgcgagcaaa acaagcggtc                                     20

SEQ ID NO: 67      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 67		
cgacagaatt gtcagtcggc		20
SEQ ID NO: 68	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 68		
atacttgcgg gagagcacga		20
SEQ ID NO: 69	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 69		
taaacaaagg acgtcccgcg		20
SEQ ID NO: 70	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 70		
gccccgggag gggtcgatccg		20
SEQ ID NO: 71	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 71		
gagcccaag cggcccccggg		20
SEQ ID NO: 72	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 72		
cagatgagaa ggcacagacg		20
SEQ ID NO: 73	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 73		
gttgacattt ctgaaagtcc		20
SEQ ID NO: 74	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 74		
agaagctcca aattctttat		20
SEQ ID NO: 75	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 75		
gaggcggtgt cgaggagatc		20
SEQ ID NO: 76	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 76		
cccaacacag aatagcttgc		20

-continued

```

SEQ ID NO: 77      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 77
ttccatcaact caccccaaca                                         20

SEQ ID NO: 78      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 78
gactactaat tccctggatg                                         20

SEQ ID NO: 79      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 79
catagctgac tactaattcc                                         20

SEQ ID NO: 80      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 80
ggcttatatg caggaggagt                                         20

SEQ ID NO: 81      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 81
tttggtgttc tatatgcagg                                         20

SEQ ID NO: 82      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 82
gaccttcgtc tgcgaggcga                                         20

SEQ ID NO: 83      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 83
tttcccacct tatgtgtcca                                         20

SEQ ID NO: 84      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 84
attaagcaa ggtaccgtag                                         20

SEQ ID NO: 85      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 85
aaaagaagga gtttgccatt                                         20

SEQ ID NO: 86      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 86	
aatatgaatgt caggaaaaga	20
SEQ ID NO: 87	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 87	
tcaacaatgt cctcctgcaa	20
SEQ ID NO: 88	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 88	
gggcaaataat ttagtaacat	20
SEQ ID NO: 89	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 89	
gtaatgatta actacatgct	20
SEQ ID NO: 90	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 90	
tataagatac ccgccttcca	20
SEQ ID NO: 91	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 91	
atgctgtaga tcttgttccc	20
SEQ ID NO: 92	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 92	
atgatcgaaaa aagaatccca	20
SEQ ID NO: 93	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 93	
ggtcactg atgatcgaaaa	20
SEQ ID NO: 94	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 94	
ttctgagttg gctttgaatg	20
SEQ ID NO: 95	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 95	
ctggatttc tgagttggct	20

-continued

```

SEQ ID NO: 96      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 96
gagggtcccaa tctggatttt                                         20

SEQ ID NO: 97      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 97
gtgcgggtt aggtcccaa                                         20

SEQ ID NO: 98      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 98
gtccggccag ttgtccttgt                                         20

SEQ ID NO: 99      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 99
ggggaggggt gaaccctggc                                         20

SEQ ID NO: 100     moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 100
cccaacagtc ccccatgggg                                         20

SEQ ID NO: 101     moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 101
gaggagctgc tggcacagtt                                         20

SEQ ID NO: 102     moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 102
tcccttagag gtggagataa                                         20

SEQ ID NO: 103     moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 103
caccaagctc tgctagatcc                                         20

SEQ ID NO: 104     moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 104
gaacatggag aacacaacat                                         20

SEQ ID NO: 105     moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 105		
gccccgttt tcttgttgcac		20
SEQ ID NO: 106	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 106		
caagaatcct cacaataccaa		20
SEQ ID NO: 107	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 107		
ccaaatttgc ctggctatcg		20
SEQ ID NO: 108	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 108		
aacctcgaca aggcatgggg		20
SEQ ID NO: 109	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 109		
ggcttcgca agattcctat		20
SEQ ID NO: 110	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 110		
actgtttggc tttcagttat		20
SEQ ID NO: 111	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 111		
gggctactcc cttaacttca		20
SEQ ID NO: 112	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 112		
tgggatatgt aatttggaaagt		20
SEQ ID NO: 113	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 113		
ggaaaggatg tcaaagaatt		20
SEQ ID NO: 114	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 114		
gttgctgac gcaaccccca		20

-continued

```

SEQ ID NO: 115      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 115
caccccttt ccatggctgc                                         20

SEQ ID NO: 116      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 116
ctgtcttaggtt gtgctgcaaa                                         20

SEQ ID NO: 117      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 117
tttgtctacgtt cccgtcgccg                                         20

SEQ ID NO: 118      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 118
ctgtttgttt aaagactggg                                         20

SEQ ID NO: 119      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 119
catggacatt gaccgtata                                         20

SEQ ID NO: 120      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 120
gagttgtatga atctggccac                                         20

SEQ ID NO: 121      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 121
tttggaaagac ccagcatcca                                         20

SEQ ID NO: 122      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 122
ttttggaaaga gaaactgttc                                         20

SEQ ID NO: 123      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 123
cttgagtatt tggtgtcttt                                         20

SEQ ID NO: 124      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 124		
tcgcagaaga tctcaatctc		20
SEQ ID NO: 125	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 125		
tactgtaccc gtctttaatc		20
SEQ ID NO: 126	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 126		
tacacgcgcg gcctcatttt		20
SEQ ID NO: 127	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 127		
tctttctgtt cccaaatccctc		20
SEQ ID NO: 128	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 128		
attggggactt caaccccaac		20
SEQ ID NO: 129	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 129		
aggagcgggga gcattcgggc		20
SEQ ID NO: 130	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 130		
tgggatctag cagagcttgg		20
SEQ ID NO: 131	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 131		
aaagtataagg cccctcactc		20
SEQ ID NO: 132	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 132		
gggtgaggca gtagtcggaa		20
SEQ ID NO: 133	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 133		
tcctcgagaa gattgacgat		20

-continued

SEQ ID NO: 134	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 134	
tgtgttctcc atgttcggtg	20
SEQ ID NO: 135	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 135	
gcgaatttg gccaggacac	20
SEQ ID NO: 136	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 136	
gtgattggag gttggggact	20
SEQ ID NO: 137	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 137	
aattggagga caagagggtt	20
SEQ ID NO: 138	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 138	
ggcatagcag caggatgaag	20
SEQ ID NO: 139	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 139	
aaagcccagg atgatggat	20
SEQ ID NO: 140	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 140	
cttgcgaaag cccaggatga	20
SEQ ID NO: 141	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 141	
atagaaatct tgcgaaagcc	20
SEQ ID NO: 142	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 142	
ggactgaggc ccactcccat	20
SEQ ID NO: 143	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 143		
gccccaacgt ttggtttat		20
SEQ ID NO: 144	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 144		
tgcataaaaa ggcattaagg		20
SEQ ID NO: 145	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 145		
acctgaccgt tgccggcaa		20
SEQ ID NO: 146	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 146		
atggccaagc cccatccagt		20
SEQ ID NO: 147	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 147		
gctgcttagga gttccgcagt		20
SEQ ID NO: 148	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 148		
tgcgagcaaa acaagctgct		20
SEQ ID NO: 149	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 149		
gtatttccga gagaggacaa		20
SEQ ID NO: 150	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 150		
tagacaaaagg acgtcccgcg		20
SEQ ID NO: 151	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 151		
gccccgagac gggtcgtccg		20
SEQ ID NO: 152	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 152		
gagtccaaa cggccccgag		20

-continued

SEQ ID NO: 153	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 153	
gcagatgaag aaggggacgg	20
SEQ ID NO: 154	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 154	
gttgacattg ctgagagttc	20
SEQ ID NO: 155	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 155	
ggtcggtcgt tgacattgtc	20
SEQ ID NO: 156	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 156	
ggtctgttaag cgggaggagt	20
SEQ ID NO: 157	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 157	
tttgggtggtc tgtaagcgaa	20
SEQ ID NO: 158	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 158	
gtttgagttg gtcggaaacg	20
SEQ ID NO: 159	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 159	
tttcccacct tatgagtcca	20
SEQ ID NO: 160	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 160	
ccagtaaagt ttccccacctt	20
SEQ ID NO: 161	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 161	
attnaagaca ggtacagtag	20
SEQ ID NO: 162	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20

-continued

SEQUENCE: 162 aaaggaggga gtttgcact	mol_type = other DNA organism = synthetic construct	
		20
SEQ ID NO: 163 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 163 aatatgtt gagaaagga		20
SEQ ID NO: 164 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 164 ttaataatgtt ctcctgtaa		20
SEQ ID NO: 165 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 165 gggcaaatat ttggtaaggt		20
SEQ ID NO: 166 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 166 gtaatgattt actgcatttt		20
SEQ ID NO: 167 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 167 tatagaatgc cagccttcca		20
SEQ ID NO: 168 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 168 cgtagttt ctctttata		20
SEQ ID NO: 169 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 169 atgcgttgc tcttgttccc		20
SEQ ID NO: 170 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 170 gtgatcgaaa aagaatccca		20
SEQ ID NO: 171 FEATURE source	moltype = DNA length = 20 Location/Qualifiers 1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 171 ggtccaaactg gtgatcgaaa		20

-continued

SEQ ID NO: 172	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 172	
gaagtcccaa tctggattgt	20
SEQ ID NO: 173	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 173	
gttggggttg aagtccaaat	20
SEQ ID NO: 174	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 174	
ctctggccag tgatccttgt	20
SEQ ID NO: 175	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 175	
tggtgtgggtt gaaccctggc	20
SEQ ID NO: 176	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 176	
tctcttagag gtggagagat	20
SEQ ID NO: 177	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 177	
ctgccttcca ccaagctctg	20
SEQ ID NO: 178	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 178	
caccaagtc tgaggatcc	20
SEQ ID NO: 179	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 179	
ctctgcagga tccccagatc	20
SEQ ID NO: 180	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 180	
cagggaaacagt aaaccctgct	20
SEQ ID NO: 181	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 181		
gaacatggag aacatcacat		20
SEQ ID NO: 182	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 182		
gaagttgggg aacattgcca		20
SEQ ID NO: 183	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 183		
caagaatcct cacaataccg		20
SEQ ID NO: 184	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 184		
gacttctctc aattttctag		20
SEQ ID NO: 185	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 185		
tcatcttctt attgggttctt		20
SEQ ID NO: 186	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 186		
aacctcgcaa aggcatgggg		20
SEQ ID NO: 187	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 187		
catgttgctg tacaaaacct		20
SEQ ID NO: 188	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 188		
actgtttggc tttcagctat		20
SEQ ID NO: 189	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 189		
ggccaagtct gtacagcata		20
SEQ ID NO: 190	moltype = DNA length = 20 Location/Qualifiers	
FEATURE	1..20	
source	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 190		
accctaacaa aacaaaaaga		20

-continued

SEQ ID NO: 191	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 191	
gggggttattc cctaaacttc	20
SEQ ID NO: 192	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 192	
tgttgctcca tttacacaat	20
SEQ ID NO: 193	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 193	
ctgcttaggct gtactgccaa	20
SEQ ID NO: 194	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 194	
catggacatt gacccttata	20
SEQ ID NO: 195	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 195	
taaagaattt ggagctactg	20
SEQ ID NO: 196	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 196	
agctctgtat cgggaaggct	20
SEQ ID NO: 197	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 197	
gcaagccatt ctctgctggg	20
SEQ ID NO: 198	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 198	
gaattgtga ctctagctac	20
SEQ ID NO: 199	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 199	
atttggaaaga tccagcatcc	20
SEQ ID NO: 200	moltype = DNA length = 20
FEATURE	Location/Qualifiers
source	1..20

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 200		20
tcaattatgt taatactaac		
SEQ ID NO: 201	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 201		20
tttggaaaga gagactgtac		
SEQ ID NO: 202	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 202		20
cttgaatatt tggctctttt		
SEQ ID NO: 203	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 203		20
tattttggct ctttcggagt		
SEQ ID NO: 204	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 204		20
tacagtagct atcttaatc		
SEQ ID NO: 205	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 205		20
aaatatattgc ccttagacaa		
SEQ ID NO: 206	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 206		20
cacacgttagc gcatcatttt		
SEQ ID NO: 207	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 207		20
tctttctgtt cccaaaccctc		
SEQ ID NO: 208	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 208		20
tggccagcag ccaaccagggt		
SEQ ID NO: 209	moltype = DNA length = 20 Location/Qualifiers	
FEATURE		
source	1..20	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 209		20
aggagtggga gcattcgccc		

-continued

```

SEQ ID NO: 210      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 210
ccctccacac ggcgggttt                                         20

SEQ ID NO: 211      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 211
aaatacaga cccctgactc                                         20

SEQ ID NO: 212      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 212
gtgagaggca atattcgag                                         20

SEQ ID NO: 213      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 213
gatgttcc atgttcgtca                                         20

SEQ ID NO: 214      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 214
tctagactct gcggatttgt                                         20

SEQ ID NO: 215      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 215
aattggagga caggaggttg                                         20

SEQ ID NO: 216      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 216
gtactggttg ttgttgatcc                                         20

SEQ ID NO: 217      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 217
aacatagagt tgccttgagc                                         20

SEQ ID NO: 218      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 218
acagcaacat gagggaaaca                                         20

SEQ ID NO: 219      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 219		
gtttgagttg gtcggaaatg		20
SEQ ID NO: 220	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 220		
aaagcccaagg acgatgggat		20
SEQ ID NO: 221	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 221		
tttgcgaaag cccaggacga		20
SEQ ID NO: 222	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 222		
accccatctt tttgttttgt		20
SEQ ID NO: 223	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 223		
tatgtAACCC atgaagtta		20
SEQ ID NO: 224	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 224		
tgcatacAAA ggcattaagg		20
SEQ ID NO: 225	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 225		
atggccaAGC CCCAGCCAGT		20
SEQ ID NO: 226	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 226		
atatttccgc gagaggacga		20
SEQ ID NO: 227	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 227		
cccccgagAG gggTCGTCCG		20
SEQ ID NO: 228	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 228		
gagtcccaAG CGGCCCCGAG		20

-continued

```

SEQ ID NO: 229      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 229
gcagacggag aaggggacga                                20

SEQ ID NO: 230      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 230
tctaaggcca aatatttagt                                20

SEQ ID NO: 231      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 231
cttcttatgtta agacaccttggg                                20

SEQ ID NO: 232      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 232
gttgacattt ctgggagttcc                                20

SEQ ID NO: 233      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 233
agttagctcca aattctttat                                20

SEQ ID NO: 234      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 234
agaagtcaaaa aggcaaaaac                                20

SEQ ID NO: 235      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 235
cccagcagag aatggcttgc                                20

SEQ ID NO: 236      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 236
gtcatcaatt ccccccaagca                                20

SEQ ID NO: 237      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 237
ttattaccca cccaggttagc                                20

SEQ ID NO: 238      moltype = DNA  length = 20
FEATURE
source
1..20

```

-continued

SEQUENCE: 238	mol_type = other DNA organism = synthetic construct	
gactactaga tccctggatg		20
SEQ ID NO: 239	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 239		
cataattgac tactagatcc		20
SEQ ID NO: 240	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 240		
ggtctatagg ctggaggagt		20
SEQ ID NO: 241	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 241		
tttggtggtc tataggctgg		20
SEQ ID NO: 242	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 242		
gatctgcgtc tgcgaggcga		20
SEQ ID NO: 243	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 243		
attnaaagata ggtactgttag		20
SEQ ID NO: 244	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 244		
aaaggaagga gtttgccatt		20
SEQ ID NO: 245	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 245		
aatatgaatct taggaaagga		20
SEQ ID NO: 246	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 246		
ttaataatgt cctcttgtaa		20
SEQ ID NO: 247	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 247		
aatatattgt gtgggttaga		20

-continued

```

SEQ ID NO: 248      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 248
gtaatgatttttactacgtat                                     20

SEQ ID NO: 249      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 249
tatagaataccggccttcca                                     20

SEQ ID NO: 250      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 250
cggtgtggtttcccttata                                     20

SEQ ID NO: 251      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 251
atgatcgaaa aagaatccca                                     20

SEQ ID NO: 252      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 252
ggtccaaactg atgatcgaaa                                     20

SEQ ID NO: 253      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 253
ctggattttt tgagttggct                                     20

SEQ ID NO: 254      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 254
gatggggttt aagtcccaat                                     20

SEQ ID NO: 255      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 255
tgctggccat tggtccttga                                     20

SEQ ID NO: 256      moltype = DNA length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 256
gtggagggggtt gaaccctggc                                     20

SEQ ID NO: 257      moltype = DNA length = 20
FEATURE
source
1..20

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 257		
ccccaaaacac cgccgtgtgg		20
SEQ ID NO: 258	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 258		
cgatttgttgg aggcaaggagg		20
SEQ ID NO: 259	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 259		
gaacatggag aacaccacat		20
SEQ ID NO: 260	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 260		
ctgtgtgttt aatgactggg		20
SEQ ID NO: 261	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 261		
tggccagagg caaaccaggt		20
SEQ ID NO: 262	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 262		
gggagaggca gtagtcggaa		20
SEQ ID NO: 263	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 263		
ggtgttctcc atgttcggtg		20
SEQ ID NO: 264	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 264		
cttgcgaaag cccaagatga		20
SEQ ID NO: 265	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 265		
acctgaccgt tgcccgagcaa		20
SEQ ID NO: 266	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 266		
gagccccaaa cggcccccag		20

-continued

```

SEQ ID NO: 267      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 267
ggtctgtaa caggaggagt                                20

SEQ ID NO: 268      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 268
tttgtgtc tgtaagcagg                                20

SEQ ID NO: 269      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 269
aaaagaggga gtttgccact                                20

SEQ ID NO: 270      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 270
aatgaatgt gagaaaaaga                                20

SEQ ID NO: 271      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 271
ttaataatgt ctcctgc当地                                20

SEQ ID NO: 272      moltype = DNA  length = 20
FEATURE
source
1..20
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 272
tataaaatgc ccgccttcca                                20

SEQ ID NO: 273      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 273
cctctgcacg tcgcatggag ac                                22

SEQ ID NO: 274      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 274
cccaactgtct ggctttcagt ta                                22

SEQ ID NO: 275      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 275
gagttggcgt tgaatgcagg gt                                22

SEQ ID NO: 276      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 276		
ccatgttcgg tacagggtcc cc		22
SEQ ID NO: 277	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 277		
gatactgttt acttagaaag gc		22
SEQ ID NO: 278	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 278		
catttcctgt cttaacttttgc gg		22
SEQ ID NO: 279	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 279		
tgttgacaaa aatcctcaca at		22
SEQ ID NO: 280	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 280		
catctgccgg accgtgtgca ct		22
SEQ ID NO: 281	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 281		
tctggactat caaggtatgt tg		22
SEQ ID NO: 282	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 282		
catcccatca tcttgggctt tc		22
SEQ ID NO: 283	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 283		
gcaatgtcaa cgaccgacct tg		22
SEQ ID NO: 284	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 284		
gcagtatgga tcggcagagg ag		22
SEQ ID NO: 285	moltype = DNA length = 22 Location/Qualifiers	
FEATURE		
source	1..22	
	mol_type = other DNA organism = synthetic construct	
SEQUENCE: 285		
tgtggcaatg tgccccaaact cc		22

-continued

```

SEQ ID NO: 286      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 286
cagtcccaa tctccagtc ct                                22

SEQ ID NO: 287      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 287
cactccctc gcatatagac ca                                22

SEQ ID NO: 288      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 288
tgttggttct tctggactat ca                                22

SEQ ID NO: 289      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 289
caccttatgt gtccaaaggaa ta                                22

SEQ ID NO: 290      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 290
tctgcgaggc gagggagttc tt                                22

SEQ ID NO: 291      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 291
gcgccgacgg gacgtaaaca aa                                22

SEQ ID NO: 292      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 292
cacccaggtg gctagattca tc                                22

SEQ ID NO: 293      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 293
tctgcatcct gctgctatgc ct                                22

SEQ ID NO: 294      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 294
tctacggtagt cttgctttaa tc                                22

SEQ ID NO: 295      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

```
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 295
caaaaatacct atggggagtgg gc                                22
SEQ ID NO: 296      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 296
attcggagatc tcctcgacac cg                                22
SEQ ID NO: 297      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 297
ggaacagtga gcccctgctca ga                                22
SEQ ID NO: 298      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 298
gcgcacgcggc gatttagagacc tt                                22
SEQ ID NO: 299      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 299
tgtcttactt ttggggagaga aa                                22
SEQ ID NO: 300      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 300
ccccctcccca tgggggactg tt                                22
SEQ ID NO: 301      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 301
ccctagaaaa ttgagagaag tc                                22
SEQ ID NO: 302      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 302
cttaacttca tgggatatgt aa                                22
SEQ ID NO: 303      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 303
cttcacacct gcacgtcgca tg                                22
SEQ ID NO: 304      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 304
tgctggggc tccagttcag ga                                22
```

-continued

```

SEQ ID NO: 305      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 305
ctcccaaag taagacagga aa                                22

SEQ ID NO: 306      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 306
cttcatgtgc tgtacaaaac ct                                22

SEQ ID NO: 307      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 307
cttggcttag tttactatgtc cc                                22

SEQ ID NO: 308      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 308
ctcaatttc tagggggAAC ac                                22

SEQ ID NO: 309      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 309
tgactgcccga ttgggtggagg ca                                22

SEQ ID NO: 310      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 310
cggtggtttc catgcgcacgt gc                                22

SEQ ID NO: 311      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 311
tgggaacaag atctacagca tg                                22

SEQ ID NO: 312      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 312
tttgtcttt ggtatacatt ta                                22

SEQ ID NO: 313      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 313
cgccaactta caaggccttt ct                                22

SEQ ID NO: 314      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 314	
cgcgaatgtgg atatcctgct tt	22
SEQ ID NO: 315	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 315	
tggggatatgt aattggggagt tg	22
SEQ ID NO: 316	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 316	
tgcacattcat ttgcaggagg ac	22
SEQ ID NO: 317	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 317	
tgttaaacagg cctatttgatt gg	22
SEQ ID NO: 318	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 318	
cgagatttag atcttctgct ac	22
SEQ ID NO: 319	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 319	
tgaatattttg gtgtcttttg ga	22
SEQ ID NO: 320	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 320	
tgaactggag ccaccaggcag ga	22
SEQ ID NO: 321	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 321	
gacttcttgc cttcttattcg ag	22
SEQ ID NO: 322	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 322	
tcaactcacc ccaacacaga at	22
SEQ ID NO: 323	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 323	
cctcaccata cggcactcag gc	22

-continued

```
SEQ ID NO: 324      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 324
gagcagggt cactgttccct ga                                22

SEQ ID NO: 325      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 325
tgtcctactg ttcaaggcctc ca                                22

SEQ ID NO: 326      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 326
ccgcctgttg taccgaccga cc                                22

SEQ ID NO: 327      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 327
atggctgtcta ggctgtgtcg cc                                22

SEQ ID NO: 328      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 328
ggaagtgttg ataagatagg gg                                22

SEQ ID NO: 329      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 329
caagaatatg gtgacccgca aa                                22

SEQ ID NO: 330      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 330
gtccgttaggt tttgtacagc aa                                22

SEQ ID NO: 331      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 331
acgcatgcgc tcatggccta tg                                22

SEQ ID NO: 332      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 332
ttggacacat aaggtgggaa ac                                22

SEQ ID NO: 333      moltype = DNA  length = 22
FEATURE
source
1..22
```

-continued

	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 333	
gtccccaaatc ccctgggatt ct	22
SEQ ID NO: 334	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 334	
ggagactcta aggccctcccg at	22
SEQ ID NO: 335	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 335	
accaaactct tcaagatccc ag	22
SEQ ID NO: 336	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 336	
gtcgtgctc cccgcaagta ta	22
SEQ ID NO: 337	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 337	
gtggttcgta gggctttccc cc	22
SEQ ID NO: 338	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 338	
gtgttgggt gagttgatga at	22
SEQ ID NO: 339	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 339	
aatcaatagg cctgtttaca gg	22
SEQ ID NO: 340	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 340	
aagtaaacag tatctgaacc tt	22
SEQ ID NO: 341	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 341	
gtacagggtc cccagtcttc ga	22
SEQ ID NO: 342	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 342	
gttatatatgga tgatgtggtt tt	22

-continued

```
SEQ ID NO: 343      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 343
tccccgatca tcagttggac cc                                22

SEQ ID NO: 344      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 344
aaagactgtgt gtttactgag tg                                22

SEQ ID NO: 345      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 345
tttactgtaa gggggcccac aa                                22

SEQ ID NO: 346      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 346
tttcctgaca ttcatttgca gg                                22

SEQ ID NO: 347      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 347
aaatttacttc ccacccaggt gg                                22

SEQ ID NO: 348      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 348
aaagagtgtg taaataatgt ct                                22

SEQ ID NO: 349      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 349
tttgcaggag gacattgttgc at                                22

SEQ ID NO: 350      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 350
taaaacacat ttgattttt tg                                22

SEQ ID NO: 351      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 351
aacacctcgaa aaggcatggg ga                                22

SEQ ID NO: 352      moltype = DNA  length = 22
FEATURE
source
1..22
```

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 352
tagggcttc ccccaactgtc tg                                22

SEQ ID NO: 353      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 353
aagccaactc agaaaatcca ga                                22

SEQ ID NO: 354      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 354
actgcatggc ctgaggatga gt                                22

SEQ ID NO: 355      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 355
ctggatgctg gatcttccaa at                                22

SEQ ID NO: 356      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 356
aggtttgaa gaccaacctc cc                                22

SEQ ID NO: 357      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 357
tctaacaaca gtagttccg ga                                22

SEQ ID NO: 358      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 358
ttccttctat tcgagatctc ct                                22

SEQ ID NO: 359      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 359
ttgacatact ttccaatcaa ta                                22

SEQ ID NO: 360      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 360
agcctccaag ctgtgccttg gg                                22

SEQ ID NO: 361      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 361
ttctattcga gatctcctcg ac                                22

```

-continued

```

SEQ ID NO: 362      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 362
ggtgggcgtt cacgggtgtc tc                                22

SEQ ID NO: 363      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 363
aggatcatca acaaccagca cc                                22

SEQ ID NO: 364      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 364
ttgagcagga gttgtgcagg tt                                22

SEQ ID NO: 365      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 365
agatctcctc gacaccgcct ct                                22

SEQ ID NO: 366      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 366
agatcccaga gtcagggccc tg                                22

SEQ ID NO: 367      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 367
ataagattga cgatatggca ga                                22

SEQ ID NO: 368      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 368
agacgagaca ttatttacac ac                                22

SEQ ID NO: 369      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 369
agaacagttt ctctcccaa ag                                22

SEQ ID NO: 370      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 370
ggccagggtt caccctcccc ca                                22

SEQ ID NO: 371      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 371
agggggaaaca cccgtgtgtc tt                                22

SEQ ID NO: 372      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 372
ggaacagtaa accctgttcc ga                                22

SEQ ID NO: 373      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 373
taggaccctt gtcgtgtta ca                                22

SEQ ID NO: 374      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 374
cttccaaaag taagacagga aa                                22

SEQ ID NO: 375      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 375
ggccagggtt caccccacca ca                                22

SEQ ID NO: 376      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 376
ggataataag gttaatgcc tt                                22

SEQ ID NO: 377      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 377
tagggcttcc cccactgtt tg                                22

SEQ ID NO: 378      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 378
tgagtatttg gtgtcttttg ga                                22

SEQ ID NO: 379      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 379
tccccatgcc ttgtcgaggt tt                                22

SEQ ID NO: 380      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 380
tatgggagtg ggcctcagtc cg                                22

```

-continued

SEQ ID NO: 381 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 381
tcatctgcgc ttccggccga cc 22

SEQ ID NO: 382 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 382
ctttctcgcc aacttacaag gc 22

SEQ ID NO: 383 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 383
ctggatgctg ggtcttccaa at 22

SEQ ID NO: 384 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 384
gatattgttt acacagaaaag gc 22

SEQ ID NO: 385 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 385
tctaactgtac ctgtctttaa tc 22

SEQ ID NO: 386 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 386
tcctgctgct atgcctcata tt 22

SEQ ID NO: 387 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 387
gataagttc gctccagacc gg 22

SEQ ID NO: 388 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 388
gtccgaagg tttgtacagc aa 22

SEQ ID NO: 389 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 389
gagccaactc aaacaatcca ga 22

SEQ ID NO: 390 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 390
tcttcatcct gctgctatgc ct                                22

SEQ ID NO: 391      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 391
gtgcagggtc cccagtcctc ga                                22

SEQ ID NO: 392      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 392
gttcccaatc ctctggatt ct                                22

SEQ ID NO: 393      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 393
tctggactac caaggtatgt tg                                22

SEQ ID NO: 394      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 394
gagagaggac aacagagttg tc                                22

SEQ ID NO: 395      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 395
gttatatgga ttagtggtta tt                                22

SEQ ID NO: 396      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 396
ggccgaccac ggggcccacc tc                                22

SEQ ID NO: 397      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 397
gactactgcc tcacccatat cg                                22

SEQ ID NO: 398      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 398
gcgcgcgacgg gacgtagaca aa                                22

SEQ ID NO: 399      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 399
gacggaaaact gcacttgtat tc                                22

```

-continued

```

SEQ ID NO: 400      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 400
gtgtaaacaa tatctgaacc tt                                22

SEQ ID NO: 401      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 401
ggaactggag ccaccaggcag ga                                22

SEQ ID NO: 402      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 402
tttgtcttg ggtatacatt tg                                22

SEQ ID NO: 403      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 403
ctttagttgc tgtacaaaac ct                                22

SEQ ID NO: 404      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 404
caatccctcg ggatttttc cc                                22

SEQ ID NO: 405      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 405
caagattct atgggagtgg gc                                22

SEQ ID NO: 406      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 406
caagaatatg gtgaccacaca aa                                22

SEQ ID NO: 407      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 407
tgctcaagga acctctatgt tt                                22

SEQ ID NO: 408      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 408
ttatacgggt caatgtccat gc                                22

SEQ ID NO: 409      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

```
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 409
ttcccgatca ccagttggac cc                                22
SEQ ID NO: 410      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 410
atcctaacct taccaaatat tt                                22
SEQ ID NO: 411      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 411
atataagaga gaaactacac gc                                22
SEQ ID NO: 412      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 412
agggggagca cccacgtgtc ct                                22
SEQ ID NO: 413      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 413
ttgagcagga atcgtgcagg tc                                22
SEQ ID NO: 414      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 414
actgcatggc ctgaggatga ct                                22
SEQ ID NO: 415      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 415
acgcatgcgc cgatggccta tg                                22
SEQ ID NO: 416      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 416
accccaacaa ggatcaactgg cc                                22
SEQ ID NO: 417      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 417
accaagctt gcttagatccc ag                                22
SEQ ID NO: 418      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 418
acagagtatg taaataatgc ct                                22
```

-continued

```

SEQ ID NO: 419      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 419
aattacatat cccatgaagt ta                                22

SEQ ID NO: 420      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 420
aatgtataacc caaagacaaa ag                                22

SEQ ID NO: 421      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 421
aatcaatagg tctatattaca gg                                22

SEQ ID NO: 422      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 422
tttacaggag gacatttatta at                                22

SEQ ID NO: 423      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 423
aagactgttt gtttaaagac tg                                22

SEQ ID NO: 424      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 424
aaacttaggca ttatttacat ac                                22

SEQ ID NO: 425      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 425
aacacctcgac aaggcatggg ga                                22

SEQ ID NO: 426      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 426
aaaaagttaaga cagggaaatgt ga                                22

SEQ ID NO: 427      moltype = DNA  length = 22
FEATURE
source
1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 427
aaaactgcct gttaatagac ct                                22

SEQ ID NO: 428      moltype = DNA  length = 22
FEATURE
source
1..22

```

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 428
aaaacattgc ttgattttta gt                                22

SEQ ID NO: 429      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 429
caccagggt gccagattca tc                                22

SEQ ID NO: 430      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 430
ttaactgtaa gagggccccac at                                22

SEQ ID NO: 431      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 431
atggctgcta gggtgtgctg cc                                22

SEQ ID NO: 432      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 432
cactcctccc gcttacagac ca                                22

SEQ ID NO: 433      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 433
ctcttatata gaatgccagc ct                                22

SEQ ID NO: 434      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 434
tgctggtggc tccagttccg ga                                22

SEQ ID NO: 435      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 435
ctccagaccc gctgcgagca aa                                22

SEQ ID NO: 436      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 436
tggaagtaga ggacaaacgg gc                                22

SEQ ID NO: 437      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 437
ctcaatttc tagggggagc ac                                22

```

-continued

SEQ ID NO: 438 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 438 tgggaacaag agctacagca tg 22

SEQ ID NO: 439 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 439 tggatatatgt aatttggaaatgt tg 22

SEQ ID NO: 440 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 440 cgatcaccagg ttggaccctg cg 22

SEQ ID NO: 441 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 441 cgaggactgg ggacccttgca cc 22

SEQ ID NO: 442 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 442 cctggcttagt tttactatgt cc 22

SEQ ID NO: 443 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 443 caccttatga gtccaaaggga ta 22

SEQ ID NO: 444 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 444 cctctgccta atcatctcat gt 22

SEQ ID NO: 445 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 445 tgtcaacaag aaaaaccccg cc 22

SEQ ID NO: 446 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 446 cctcaccata cagcacatcg gc 22

SEQ ID NO: 447 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

```
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 447
tgtcttactt ttggaagaga aa                                22
SEQ ID NO: 448      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 448
tcacattcat ttacaggagg ac                                22
SEQ ID NO: 449      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 449
tgttggttct tctggactac ca                                22
SEQ ID NO: 450      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 450
cagtccccaa cctccaatca ct                                22
SEQ ID NO: 451      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 451
catcccatca tcctgggctt tc                                22
SEQ ID NO: 452      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 452
tgtggtaaag tacccaaact tc                                22
SEQ ID NO: 453      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 453
tgttgacaag aatcctcaca at                                22
SEQ ID NO: 454      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 454
ccatgttcgg tgcaagggtcc cc                                22
SEQ ID NO: 455      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 455
cccactgttt ggctttcagt ta                                22
SEQ ID NO: 456      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 456
catttcctgt cttaacttttg ga                                22
```

-continued

SEQ ID NO: 457 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 457
tctggattat caaggatgt tg 22

SEQ ID NO: 458 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 458
tttgtctctg ggtatacatt ta 22

SEQ ID NO: 459 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 459
tttgtctaag ggcaaataatt ta 22

SEQ ID NO: 460 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 460
tccccatgcc tttgcgaggt tt 22

SEQ ID NO: 461 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 461
ttataagggt caatgtccat gc 22

SEQ ID NO: 462 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 462
tttcctaaga ttcatttaca ag 22

SEQ ID NO: 463 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 463
tttacagtga gagggcccac aa 22

SEQ ID NO: 464 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 464
tgggttacat aattgaaagt tg 22

SEQ ID NO: 465 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 465
ttcccgatca tcagttggac cc 22

SEQ ID NO: 466 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

```
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 466
tttacaagag gacattatta at                                22
SEQ ID NO: 467      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 467
tcctccgtcc tccaccaatc gg                                22
SEQ ID NO: 468      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 468
ttggactcat aagggtggaa ac                                22
SEQ ID NO: 469      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 469
tctacagtagt ctagtttaa tc                                22
SEQ ID NO: 470      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 470
ttccgtcaga gatctccctag ac                                22
SEQ ID NO: 471      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 471
ttccctccgt cagagatctc ct                                22
SEQ ID NO: 472      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 472
tgttaacagg cctattgatt gg                                22
SEQ ID NO: 473      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 473
tgtactgttt acttagaaag gc                                22
SEQ ID NO: 474      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 474
aaaacagtgt ttgatcttt gt                                22
SEQ ID NO: 475      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 475
ccgtctgcgg ttccagccga cc                                22
```

-continued

SEQ ID NO: 476 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 476
aagactgtgt gtttaaggac tg 22

SEQ ID NO: 477 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 477
cctctgccta atcatcttctt gt 22

SEQ ID NO: 478 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 478
cctctgcacg ttgcatggag ac 22

SEQ ID NO: 479 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 479
tcacagggtc cccagtcctc gc 22

SEQ ID NO: 480 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 480
ccccctccaca cggcggttgtt tt 22

SEQ ID NO: 481 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 481
ccccagcaga gaatggcttg cc 22

SEQ ID NO: 482 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 482
cccaactgttt ggctttcagc ta 22

SEQ ID NO: 483 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 483
ccatgttcgt cacagggtcc cc 22

SEQ ID NO: 484 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 484
ccaacttcca attatgtaac cc 22

SEQ ID NO: 485 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

```
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 485
catctgcccc tccgtgtgca ct                                22
SEQ ID NO: 486      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 486
catccccatcg tcctgggctt tc                                22
SEQ ID NO: 487      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 487
cactcctcca gcctataagac ca                                22
SEQ ID NO: 488      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 488
caccttatga gtccaaaggaa ta                                22
SEQ ID NO: 489      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 489
caaccctctg ggatttttc cc                                22
SEQ ID NO: 490      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 490
atggctgtcta ggctgtactg cc                                22
SEQ ID NO: 491      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 491
atcttctttt ttcatttaca gt                                22
SEQ ID NO: 492      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 492
atcctaccca cactaaatat tt                                22
SEQ ID NO: 493      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 493
atccgttaggt tttgtacagc aa                                22
SEQ ID NO: 494      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 494
atataagagg gaaaccacac gt                                22
```

-continued

SEQ ID NO: 495 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 495
agtacagtct ctcttccaaa ag 22

SEQ ID NO: 496 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 496
agggggatca cccgtgtgtc tt 22

SEQ ID NO: 497 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 497
aggatcaaca acaaccagta cg 22

SEQ ID NO: 498 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 498
agccgaccac ggggcgcacc tc 22

SEQ ID NO: 499 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 499
aagtaaacag tacatgaacc tt 22

SEQ ID NO: 500 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 500
actgccttcc accaagctct gc 22

SEQ ID NO: 501 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 501
accccatcaa ggaccactgg cc 22

SEQ ID NO: 502 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 502
accaagctct gcaggatccc ag 22

SEQ ID NO: 503 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 503
cgatacagag ctgaggcggt gt 22

SEQ ID NO: 504 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 504	
aatcaatagg cctgttaaca gg	22
SEQ ID NO: 505	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 505	
aaatttattac ccacccaggt ag	22
SEQ ID NO: 506	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 506	
cgggacgtcc ttgtttacg tc	22
SEQ ID NO: 507	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 507	
tattggttct tctggattat ca	22
SEQ ID NO: 508	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 508	
tatatacttgc cttaacttttga	22
SEQ ID NO: 509	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 509	
taagatttcat ttacaagagg ac	22
SEQ ID NO: 510	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 510	
gttcccaacc ctctgggatt ct	22
SEQ ID NO: 511	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 511	
gtcgtcctct cgcgaaata ta	22
SEQ ID NO: 512	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 512	
gtcagagatc tccttagacac cg	22
SEQ ID NO: 513	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 513	
aaaaagtaagg caagatataat ga	22

-continued

SEQ ID NO: 514 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 514
ggccagggtt caccctcca ca 22

SEQ ID NO: 515 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 515
ggattaaaga taggtactgt ag 22

SEQ ID NO: 516 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 516
ggaacagtaa accctgtcc ga 22

SEQ ID NO: 517 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 517
gaaactact gttgttagac ga 22

SEQ ID NO: 518 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 518
gctatatgga tcatgtggta tt 22

SEQ ID NO: 519 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 519
gcgagaggac gacagaattt tc 22

SEQ ID NO: 520 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 520
gcatcgccgc gatttagatc tg 22

SEQ ID NO: 521 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 521
gatgagctt gtcaggacc gg 22

SEQ ID NO: 522 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 522
gagtgtggat tcgcactcct cc 22

SEQ ID NO: 523 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 523	
gagcagggtt tactgttcct ga	22
SEQ ID NO: 524	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 524	
gacttcttc ctccgtcag ag	22
SEQ ID NO: 525	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 525	
aaaccagaca ttatttacat ac	22
SEQ ID NO: 526	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 526	
aaagagtatg taaaataatgt ct	22
SEQ ID NO: 527	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 527	
cttttcattt acagtgagag gg	22
SEQ ID NO: 528	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 528	
cttcacacct gcacgttgca tg	22
SEQ ID NO: 529	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 529	
ctgctggggg gaattgtatga ct	22
SEQ ID NO: 530	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 530	
ctcttatata gaataccagc ct	22
SEQ ID NO: 531	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 531	
ctcaatttc tagggggatc ac	22
SEQ ID NO: 532	moltype = DNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 532	
ctaaacttca tgggttacat aa	22

-continued

SEQ ID NO: 533 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 533
cggtggtctc catgcaacgt gc 22

SEQ ID NO: 534 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 534
cgcatcatcg ttggaccctg ca 22

SEQ ID NO: 535 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 535
aattatgtaa cccatgaagt tt 22

SEQ ID NO: 536 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 536
aagactgtgt gtttaatgac tg 22

SEQ ID NO: 537 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 537
tttgcaggag gacattatta at 22

SEQ ID NO: 538 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 538
tcacattcat ttgcaggagg ac 22

SEQ ID NO: 539 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 539
ttgagcagga gtcgtgcagg tc 22

SEQ ID NO: 540 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 540
cactccctcct gcttacagac ca 22

SEQ ID NO: 541 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 541
tgtaaataga cctattgatt gg 22

SEQ ID NO: 542 moltype = DNA length = 22
FEATURE Location/Qualifiers
source 1..22

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 542
cgatcaccag ttggaccctg ca 22

SEQ ID NO: 543      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 543
cttcttatata aaatgccgc ct 22

SEQ ID NO: 544      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 544
gaaaccttcct gtaaaatagac ct 22

SEQ ID NO: 545      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 545
gactactgcc tctcccatat cg 22

SEQ ID NO: 546      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 546
tcgtctgccc ttccggccga cc 22

SEQ ID NO: 547      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 547
ttgtactagg aggctgttagg ca 22

SEQ ID NO: 548      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 548
gaaaacatttg ttgtatttt tg 22

SEQ ID NO: 549      moltype = DNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 549
cctctgcacg tcgcatggag ac 22

```

1. A composition comprising:

- (a) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease; and
- (b) one or more guide RNAs (gRNAs) or a nucleic acid sequence encoding the one or more gRNAs, the one or

more gRNA hybridizes or is complementary to a target nucleic acid sequence within a Hepatitis B Virus (HBV) genome, the HBV genome comprising at least about 90% sequence identity to any one of SEQ ID NOs: 2-5.

2-22. (canceled)

* * * * *